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ABSTRACT OF THE DISSERTATION
Mechanistic characterization of resistome and microbiome
dynamics across diverse microbial habitats
by
Andrew J. Gasparrini
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2018
Professor Gautam Dantas, Chair

Increasing antibiotic resistance in pathogens is a serious public health challenge, with
over two million antibiotic resistant infections in the United States leading to at least 23,000
deaths and an estimated $55 billion in excess healthcare and societal costs. Antibiotic resistance
has risen steadily in both pathogenic and benign bacteria since antibiotics’ introduction to
agriculture and medicine 70 years ago. A dramatic reduction in the number of antibiotics
approved for human use has accompanied this rise in antibiotic resistance, leading to the
alarming prospect of a post-antibiotic era. Understanding the evolutionary origins, genetic
contexts, and molecular mechanisms of antibiotic resistance in diverse environments is crucial to
anticipating and mitigating the spread of antibiotic resistance. It is similarly critical to understand
the effect of antibiotic exposure on the microbial communities, such as the human gut
microbiota, which serve as reservoirs for antibiotic resistance genes available for horizontal
transfer to pathogenic organisms. In this work, I take a multipronged biochemical, microbiologic,
and genomic approach to surveil existing and emerging antibiotic resistance threats in

xiii

environmental and human-associated microbial habitats, and understand the effects of antibiotic
perturbation on microbial community and resistome dynamics.
To understand the effect of antibiotic perturbation on microbial community and resistome
dynamics, I examined a population of very and extremely preterm infants who received
extensive antibiotic exposure during their hospitalization in the neonatal intensive care unit. I use
complementary sequencing and culture-based methods to analyze 448 stools collected
longitudinally over the first 20 months of life from 41 preterm infants, as well as 17 antibioticnaïve near term infants that served as developmental controls. Using random forests, I define a
program of healthy microbiota assembly in antibiotic naïve infants, and demonstrate acute but
transient deviations from this program in antibiotic treated preterm infants. With a combination
of sequencing isolates cultured from infant stool and functional metagenomics, I show that a
consequence of early life antibiotic treatment in preterm infants is prolonged carriage of
multidrug resistant Enterobacteriaceae and an enriched gut resident resistome.
I address the emergence of antibiotic resistance from environmental and commensal
reservoirs to pathogens through the lens the tetracycline destructases, a family of flavoenzymes
capable of inactivating diverse tetracycline substrates. I conduct a bioinformatic survey of
functionally selected metagenomes to show that these enzymes are widespread in diverse
microbial communities, and characterize their spectrum of activity and mechanism of action to
confirm that these enzymes are functionally and biochemically novel and illuminate sequencefunction relationships underlying the family. I identify an inhibitor of these enzymes that
prevents tetracycline degradation in vitro and rescues tetracycline activity against resistant
bacteria, and show that this inhibitor works by both competing for substrate binding and
sterically restricting critical FAD cofactor dynamics. Lastly, I identify a Pseudomonas
xiv

aeruginosa clinical isolate from a cystic fibrosis patient that encodes a functional tetracycline
inactivator with 100% nucleotide identity to one previously identified in our bioinformatic
survey, signaling the clinical arrival of this family of enzymes.
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Chapter 1: Introduction
1.1 Next-generation approaches to understand and combat
the antibiotic resistome
Antibiotic resistance is a natural feature of diverse microbial ecosystems. Although recent
studies of the antibiotic resistome have highlighted barriers to horizontal transfer of antibiotic
resistance genes between habitats, the rapid global spread of resistance genes to carbapenem,
colistin, and quinolone illustrates the dire clinical and societal consequences of such events. Over
time, the study of antibiotic resistance has grown from a focus on single pathogenic organisms in
axenic culture to a study of antibiotic resistance in pathogenic, commensal, and environmental
bacteria at the level of microbial communities. As the study of antibiotic resistance advances, it
is important to incorporate this comprehensive approach to inform global antibiotic resistance
surveillance and antibiotic development. It is increasingly becoming apparent that although not
all resistance genes are risks for geographic and phylogenetic dissemination, the threat presented
by those that are is serious and warrants an interdisciplinary research focus. Here, I highlight
seminal work in the resistome field, discuss recent advances in the studies of resistomes, and
propose a resistome paradigm that can pave the way for improved proactive identification and
mitigation of emerging antibiotic resistance threats.

1.1.1 The promise of antibiotics and the threat of resistance
Antibiotics have revolutionized modern medicine and have saved millions of lives since
their discovery at the beginning of the 20th century. These crucial drugs are invaluable owing to
their ability to kill or inhibit the growth of bacteria without damaging host cells and tissues 2,9.
1

Aside from directly curing deadly infectious diseases, antibiotics have enabled physicians to
pursue new treatments such as surgery, organ transplantation, and cancer chemotherapy that
were previously infeasible or unsafe owing to the high collateral risk of infection10. Antibiotics
remain one of the most commonly prescribed classes of drugs, with over 70 billion clinical doses
given globally in 2010, which represents a 36% increase in antibiotic consumption compared to
200011. Although the first antibiotics were synthetic compounds, most antibiotics are natural
products or derivatives thereof12. Many antibiotics were recovered from cultured soil
microorganisms, particularly those belonging to the Streptomyces genus10. As might be expected
given their origins as natural products of bacterial secondary metabolism, many antibiotics can
be detected at low levels in pristine environmental samples and have been found in samples
predating human antibiotic use13,14.
Because of the ubiquity of antibiotic production by environmental microorganisms,
defense mechanisms against these antibiotics and thus resistance also appear to be ancient.
Sequencing of ancient environmental DNA preserved in 30,000 year old permafrost sediments
has detected genes that confer resistance to several classes of antibiotics15, and direct screening
of bacteria cultured from a cave that had no anthropogenic contact for the past four million years
revealed extensive resistance against fourteen antibiotics16. Similarly, the host-associated
microbiome of previously uncontacted indigenous people in South America was found to encode
several antibiotic resistance genes17. This indicates that resistance to antibiotics far predates
appropriation of these small molecules for human use.
The collection of resistance genes in a given environment, which is termed the
‘resistome’18,19, encompasses both intrinsic and acquired resistance genes, as well as protoresistance genes and silent or cryptic resistance genes. It is thought that many clinically relevant
2

antibiotic resistance genes have their evolutionary origins in environmental microorganisms,
which we define for the purposes of this article to be composed of microorganisms not generally
associated with humans. This hypothesis was pioneered by Benveniste and Davies, who in 1973
noted

biochemically

identical

resistance-conferring

kanamycin

acetyltransferases

in

environmental Streptomyces and in clinical isolates of pathogenic Escherichia coli20. Further
evidence was provided by a recent functional screen of soil metagenomes, which revealed the
presence of environmental antibiotic resistance genes with >99% nucleotide identity to resistance
genes in pathogenic isolates4. Synteny of these genes with other resistance genes and mobility
elements suggests that they are likely candidates for past or future dissemination by horizontal
gene transfer (Fig. 1.1b).
The ancient origin of antibiotics and antibiotic resistance makes it unsurprising that largescale clinical and agricultural use of these compounds has selected for increasing resistance
across the bacterial domain of life. Robust evidence for mounting environmental resistance exists
in decades old soil samples, in which increasing levels of antibiotic resistance genes correlate
with industrial scale production and use of these drugs21. The resulting deterioration of the
efficacy of our antibacterial armamentarium has come with substantial costs that are expected to
rise over the next decades. Worldwide, it has been estimated that at least 700,000 people die
annually due to resistant infections, a figure that is predicted to increase to 10 million annual
deaths by the year 2050 if the current trajectory is not altered. Over the next decades, the
cumulative global cost of antibiotic resistance is predicted to exceed 100 trillion US dollars22.
The recent spread of mcr-1, kpc, blaNDM-1, qnr and other plasmid-borne resistance
determinants underscores two themes. The first is that in the antibiotic arms race against bacteria,
humanity is rarely ahead. This was illustrated with the first widely used antibiotics, the sulfa
3

drugs, against which resistance was observed only six years following their mass introduction1.
More recently, resistance to tigecycline was identified even before its approval for human use, let
alone its introduction into the clinic23. It is therefore either a sign of hubris or a lack of
understanding of evolutionary principles when new antibiotics are advertised as being resistanceproof. The second theme has been our relatively myopic (albeit understandable) focus on
resistance in human pathogens. It is a tautology that antibiotics are most effective at treating
human pathogens. They would not be antibiotics if they failed to effectively treat pathogens, but
our emphasis on a few pathogen ‘trees’ initially resulted in the field of antibiotics being blind to
the ‘forest’ of environmental bacteria. The targets of most antibiotics are both highly conserved
and essential across bacterial taxa, and have therefore made excellent subjects of intra-kingdom
communication and competition among prokaryotes throughout biological history24. When our
view is expanded to include the vast diversity of non-pathogenic bacteria it is not surprising to
see that all genera of the prokaryotic kingdom have evolved resistance mechanisms that protect
these vital processes.
Here, I will examine these themes across three eras of antibiotic resistance research. The
first era, which coincides with the golden age of antibiotics, is characterized by a focus on
resistance in pathogens in the clinic and by the ready supply of new antibiotics and diverse
antibiotic mechanisms of action. In this era, drawing inspiration from Koch, the research priority
was on single resistance genes and enzymes primarily from pathogenic organisms in axenic
culture. In the second era of antibiotic resistance studies, we slipped the restrictive bonds of
Koch’s postulates and shifted our attention to resistomes. Antibiotic resistance of both benign
and pathogenic bacteria was studied at the microbial community level, and metagenomic
approaches were incorporated to discover resistance determinants from diverse habitats. As we
4

enter the next era of antibiotic resistance research, we should acknowledge the ubiquity of
antibiotic resistance and take steps to improve development of new antibiotic therapies and
surveillance of emerging resistance threats, focusing on resistance genes that are the most likely
candidates for horizontal transfer to pathogens. In the remainder of this introduction, I will
provide brief overviews of the previous eras of resistome studies, and outline how distinct
philosophies from each of these generations could be integrated to improve the translational
impact of resistome research going forward.

1.1.2 Common mechanisms of antibiotic action and antibiotic resistance
Antibiotic targets are generally conserved across the bacterial domain of life and are
absent from or sufficiently different in eukaryotes. Although hundreds of such targets exist in
theory, our current antibiotic arsenal generally attacks the bacterial ribosome (inhibiting protein
synthesis, for example, aminoglycosides), cell wall synthesis and lipid membrane integrity
(compromising membrane integrity or lysing bacterial cells, for example, β-lactams), singlecarbon metabolic pathways (inducing metabolic disruption, for example, sulfa drugs), and DNA
maintenance (interfering with bacterial replication and genomic integrity, for example,
quinolones)1,9,25 (see Fig. 1.1, top).
Bacteria typically resort to one of a few common strategies to resist antibiotics26 (see Fig
1.1, bottom). One resistance mechanism involves inactivation of the antibiotic through enzymatic
degradation or modification of the antibiotic scaffold, which renders it ineffective. Examples of
this mechanism include chloramphenicol acetyltransferases27, tetracycline inactivating enzymes
such as Tet(X)28,29, and, most notably, the widespread β-lactamases30,31. A second strategy for
resistance is protection, alteration, or overexpression of the antibiotic target. This approach is
used by vancomycin resistant enterococci (VRE), which enzymatically modify peptidoglycan,
5

Figure 1.1: Common mechanisms of antibiotic action and resistance.
Antibiotics generally function by one of a few common mechanisms (top). These
include inhibition of protein synthesis, inhibition of cell wall or membrane
synthesis or integrity, disruption of single-carbon metabolism, or disruption of
DNA replication and integrity. Likewise, bacteria resort to one of several strategies
to resist antibiotics (bottom). These strategies include enzymatic degradation or
modification of the antibiotic, alteration or occlusion of the antibiotic target, active
efflux of the antibiotic, or reduced permeability of the bacterial cell to antibiotic
influx.
thus decreasing the affinity of vancomycin for its target32, and by methicillin resistant
Staphylococcus aureus (MRSA), which expresses a redundant, methicillin-insensitive variant of
the native penicillin-binding protein33. Two additional resistance mechanisms rely on keeping the
antibiotic out of the bacterial cell, either through efflux or altering cell membrane permeability.
By expressing either a generalist multidrug efflux pump34-37 or an antibiotic-specific exporter
such as the tetracycline efflux pumps38, bacteria keep the intracellular concentration of the
antibiotic below inhibitory levels. Alternatively, some bacteria reduce cell membrane or cell wall
permeability to prevent antibiotics from entering the cell by decreasing porin expression or
expressing a more selective porin variant39,40. In some cases, bacteria will use several
6

complementary mechanisms to achieve high-levels of resistance. For example, high level
carbapenem resistance in clinical isolates of Enterobacter cloacae that lack any known
carbapenemase can be achieved through a combination of porin mutations to decrease
carbapenem uptake and increased expression of a chromosomal non-carbapenemase βlactamase41.

1.1.3 The golden age of antibiotics
Both Sir Alexander Fleming and Gerhard Domagk, the discoverers respectively of
penicillin and prontosil, warned of the danger of bacterial resistance developing following
improper use of their antibiotics42,43. One of the first reports of antibiotic resistance was the
finding that a cell-free extract from a coliform bacterium that was impervious to penicillin was
able to inactivate penicillin, which indicated enzymatic degradation of the drug44. In the
following decades, extensive use of penicillin in hospitals led to widespread resistance in
Staphylococcus aureus and resulted in the 1953 penicillin-resistant S. aureus phage-type 80/81
pandemic, which represented the world’s first superbug until the release of methicillin ended the
threat45. Soon after, the emergence of multi-drug resistant strains of Shigella spp. following
apparent horizontal gene transfer from fecal E. coli strains was reported. Remarkably, there was
evidence for such transfers occurring in hospitalized patients during the course of their antibiotic
treatment 46.
The first era of resistance studies was concomitant with the golden age of antibiotics.
During this period, all modern major classes of antibiotic were discovered. Within years, many
were rendered obsolete in at least some organisms through the acquisition and spread of
resistance1. For a period, novel or previously known mechanisms of resistance that arose in new
pathogens were commonly dealt with through the development and release of a new antibiotic.
7

Figure 1.2: Next-generation sequencing and functional metagenomic
selection accelerate cataloging of known and novel resistance genes. (a) The
catalog of resistance genes has increased exponentially in the second era of
antibiotic resistome studies owing to improvements in next-generation
sequencing. This trend is exemplified by the tetracycline efflux pump tetA, the βlactamase family of enzymes (bla), and by chloramphenicol acetyl transferase
(CAT). Data from the UniProt database5 were accessed October 12, 2016 based
on searches using E.C. numbers (bla 3.5.2.6, CAT 2.3.1.28) or by family name
(tetA major facilitator superfamily tcr tet family). Data for sequencing costs from
National Human Genome Research Institute webpage6. (b) Functional
metagenomics is a powerful tool for ascribing antibiotic resistance function to
known gene products. Antibiotic resistance proteins identified by functional
metagenomic selection of the preterm infant gut microbiome have high amino
acid identity to proteins in NCBI, but low amino acid identity to proteins in
antibiotic resistance databases. (c) Additionally, functional metagenomics can
reveal entirely sequence-novel resistance determinants. β-lactamases that were
identified by functional metagenomic selection of two human gut resistomes (red
squares) encompassed greater phylogenetic diversity than all previously identified
classes of β-lactamases (blue squares). Part b adapted from Gibson et al. 20167,
part c adapted from Sommer et al. 20098.
Indeed, resistant bacteria were even welcomed by Domagk as an opportunity to increase
antibiotic market share42. During this era, resistance genes and bacteria were largely identified
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one gene and one strain at a time using culture-based methods. This low-throughput approach,
combined with incompletely exhausted reserves of natural antibiotics, disguised the otherwise
apparent threat that antibiotic resistant bacteria were destined to become.

1.1.3 High-throughput resistance discovery
The second era of resistome studies has been characterized by a broader ecological view
of resistance, which was enabled by several breakthrough technologies. In the past decades, the
new ecological resistome philosophy that recognized the environment as the plausible original
source of resistance genes and as the reservoir of resistance gene diversity has been driven by the
technical advances in molecular biology and nucleic acid sequencing.
Sequencing-based resistance discovery.
The development of genomic techniques that allow the culture-independent study of
diverse environmental microbial communities has been a critical driver of the paradigm shift in
resistome studies6,47-49. This is illustrated by the growth of the catalog of known resistance genes,
concomitant with the steep drop in sequencing costs. A survey of resistance proteins in the
UniProt database5 demonstrates that since 1986 there has been an exponential increase in the
number of hypothetical resistance determinants classified as β-lactamases, chloramphenicol
acetyltransferases, or tetracycline efflux pumps (Fig. 1.2a). The surfeit of sequencing data
exemplifies the second era of resistance studies although, in many cases, the lack of functional
validation of these genes calls into question whether all are resistance determinants. Similarly,
the sequence diversity that is captured using cutting-edge techniques may not translate into
functional diversity. One technique that has proven useful in discovery of resistance
determinants that are novel, diverse, and validated is functional metagenomics (Fig. 1.3), which
is a technique developed to mine metagenomes for a variety of phenotypes without a need for
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Figure 1.3: Functional metagenomic approaches for characterizing resistomes. A graphical
overview of the functional metagenomic experimental and computational workflow.
Metagenomic DNA is shotgun cloned into an expression system, selected for antibiotic
resistance, and resistant transformants are sequenced, assembled, and annotated in high
throughput to identify resistance determinants in a sequence- and culture-unbiased manner.
culturing50. Functional metagenomics has proven essential for characterizing antibiotic
resistomes. Briefly, this technique consists of cloning metagenomic DNA into expression vectors
and screening for a phenotype of interest (for example, antibiotic resistance) in a facile host
organism. This bypasses the bottleneck that is imposed by difficult to culture bacteria and
explicitly selects for genes that are a threat for horizontal transfer, as only phenotypes
transferable to a heterologous host are detected. However, resistance to antibiotics that results
from mutation of the antibiotic target, an important contributor to resistance in many organisms
such as M. tuberculosis51,52, may not be always be detected in functional metagenomic screens as
a single wild-type copy of these genes in the expression host often confer a dominant susceptible
phenotype. This is the case for quinolone resistance resulting from mutations in the DNA gyrase
enzyme51, although analysis of evolutionary patterns in such genes may allow for antibiotic
resistance risk estimates to be made53-55. Furthermore, the artificial action of extracting and
cloning DNA can lead to the transfer of genes that otherwise might not be mobilizable, which
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possibly raises concerns over the spread of resistance in cases where actual risk may be low, but
may also result in the underestimation of sequences related to mobility elements, which are not
explicitly selected for in screens for antibiotic resistance.
Functional metagenomics is a powerful culture- and sequence-unbiased tool.56 A
metagenomic library is created by extracting total metagenomic DNA from a microbial
community, shearing the DNA to a target size distribution, and cloning these fragments en masse
into a screening vector. The metagenomic library is then transformed into a heterologous host
and selected for a phenotype of interest, for example by culturing with antibiotics at a
concentration that is lethal to the wild-type host49,57 (Fig. 1.3). Pairing functional metagenomic
selection with next-generation sequencing and better sequence assembly and annotation
algorithms4 has simultaneously decreased the cost and increased the throughput of functional
metagenomic experiments, which facilitated the characterization of resistomes from diverse
habitats3,7,17,23,58. Importantly, there is no need to culture members of the target microbial
community and novel resistance genes can be discovered. Furthermore, the genes discovered by
functional metagenomics are by definition threats for horizontal transfer, as they must be
functional in a heterologous host.
However, there are several limitations. For a gene to be identified in a functional
metagenomic screen, it must be functional in a heterologous host. Common hosts such as E. coli
likely present a poor system for discovery of resistance genes that originated from Gram-positive
organisms. Indeed, poor overlap has been reported between clones recovered from the same
functional metagenomic library subjected to the same screen but in different hosts59,60. In
addition, it is generally difficult to screen Gram-positive-specific antibiotics in E. coli or other
common Gram-negative platforms owing to their innate resistance, although in some cases this
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may be overcome61. Thus, there is a clear need to develop and screen functional libraries in
phylogenetically diverse heterologous hosts56,62. Furthermore, functional metagenomic
experiments may oversample resistomes, as the method struggles to distinguish resistance genes
that pose clinical threats from those that are unlikely to spread beyond their current environment.
Genes that confer antibiotic resistance when overexpressed in a heterologous host similarly may
not be genuine resistance genes in their native contexts55. To reduce the risk of false positives, it
is important that ‘novel’ resistance genes are validated using complementary microbiological and
biochemical methods and crosschecked against existing databases. Finally, removal of an
antibiotic resistance gene from its genomic context often also removes positional information
that is pertinent to assessing its risk dissemination. This can be overcome, in part, by altering
insert size, as larger inserts may contain informative regions flanking resistance genes, including
mobility elements or plasmid sequences that might indicate risk for spread (that is, the
mobilome)3,58,63.
The coupling of functional metagenomic selections with high throughput sequencing and
computational methods has facilitated an increase in our ability to catalog resistomes from
diverse habitats. Importantly, functional metagenomics can both ascribe resistance function to
known genes that were not previously identified as resistance determinants and uncover
resistance genes with novel sequences. For example, a recent analysis of functionally discovered
resistance genes found that, whereas many of the gene products had high amino acid identity to
known enzymes, most had low identity to known resistance determinants7 (Fig. 1.2b). Similarly,
the utility of functional metagenomics in uncovering entirely new resistance functions is
highlighted by its recent application to discover novel rifamycin phosphorylases64, dihydrofolate
reductases65, and tetracycline-inactivating enzymes29.
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The resistomes of different habitats.
Functional metagenomics was first described in 2000 as a method for accessing the
diverse biochemical activities encoded in the uncultured soil metagenome50. In an early
application of functional metagenomics for the explicit purpose of screening for antibiotic
resistance genes, a library, which contained 5.4 Gb of metagenomic DNA from a remnant oak
savannah site, was selected against a panel of aminoglycoside antibiotics, as well as tetracycline
and nalidixic acid66. Ten resistant clones were sequenced, and all but one were found to contain
novel resistance determinants. Since these initial studies, functional metagenomics has been
widely used to screen a diverse array of soil metagenomes, including remote arctic soils67-69,
apple orchard soils70, alluvial soils71,72, wetland soils73, agricultural soils58,65, and urban soils74,
and has identified novel antibiotic resistance genes to diverse classes of antibiotics. Agricultural
resistomes are of particular interest because the selective pressure of heavy antibiotic use and
extensive anthropogenic interaction make this a high-risk habitat for antibiotic resistance
selection and dissemination. Indeed, the mcr-1 plasmid-mediated colistin resistance determinant
was first discovered on a Chinese pig farm75, although it has since been detected in new and
banked clinical and environmental samples across the globe76-84.
Global spread of plasmid-borne resistance.
In the past several decades, a variety of new antibiotic resistance threats have emerged
and spread worldwide. In particular, the emergence and spread of plasmid-borne resistance genes
(Fig. 1.5), which pose serious threats for horizontal gene transfer, have jeopardized many last
line antibiotic therapies, including the cephalosporin and carbapenem families of β-lactam
antibiotics, quinolones such as ciprofloxacin, and an antibiotic of last resort, colistin12.
Cephalosporins have been compromised by resistance owing to extended spectrum β-lactamases
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Figure 1.4: Recent global dissemination of plasmid-borne resistance. Resistance
genes encoded on plasmids represent particular threats for broad dissemination. In recent
years, resistance genes to quinolones, carbapenems, and polymixins have been observed
in clinical isolates worldwide not long after their first identification. Location of first
report is indicated as a square, and locations of subsequent identifications are indicated as
circles.
(ESBLs), which were first reported in 197985 and subsequently spread phylogenetically across
the Enterobacteriaceae and geographically across the globe86. As a result, many infections that
were previously treated by drugs such as cefotaxime must now be treated with the carbapenem
class of antibiotics. However, the spread of carbapenemases87, particularly the New Delhi
metallo-β-lactamase-1 (NDM-1)88-90 and Klebsiella pneumoniae carbapenemases (KPC)91 since
their respective discoveries in 2006 and 2001, have similarly rendered these antibiotics
vulnerable92.
A similar development has been observed with the quinolones, which were originally
touted to be at low risk of the type of transferable resistance that has beleaguered the β-lactam
antibiotics. Indeed, whereas chromosomal resistance can readily develop to this class of
antibiotic through DNA gyrase mutations, transferable resistance was slow to develop following
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clinical introduction of these antibiotics in the 1960s. Nonetheless, plasmid-mediated resistance
through the Qnr proteins, first described in 1998, has emerged from quinolone overuse and
subsequently spread worldwide. In searching for the origins of Qnr resistance determinants, a
PCR screen of Gram-negative organisms found homologs in the aquatic bacterium Shewanella
algae with almost 99% amino acid identity93. Shewanella species that lack these homologs were
found to have 4- to 8-fold greater sensitivity to quinolone antibiotics, which indicates the ability
of the qnr-related genes to confer some antibiotic resistance even in their native contexts in
which they likely function to bind DNA for some other purpose9,93. The hypothesized horizontal
transfer of qnr homologs from environmental to pathogenic bacteria corroborates hypotheses that
many resistance genes may have been coopted by pathogens from the environmental
resistome4,20,93,94. Quinolone efficacy has been further reduced by the emergence in Shanghai in
2003 of the plasmid-borne bi-functional aminoglycoside and quinolone resistance gene aac(6’)Ib-cr95. This gene, which differs from a classical aminoglycoside transferase by only two basepairs, is notable in its ability to modify fluoroquinolones as well as aminoglycosides through
acetylation. Alarmingly, aac(6’)-Ib-cr is often colocalized with other resistance genes such as
ESBLs96 on multi-drug resistance plasmids.
The spread of the aforementioned resistance mechanisms leave only a few classes of
antibiotics approved for the treatment of infection by carbapenem-resistant Enterobacteriaceae.
One of these, the polymyxin class of peptide antibiotics, was first used in the 1960s, but was
abandoned in favor of other antibiotics owing to its toxicity. Recently, the polymyxin colistin has
been revived owing to its efficacy against several multidrug resistant Gram-negative pathogens97.
However, transferable resistance has now begun to threaten colistin. In 2015, an E. coli isolate
from a pig farm in Shanghai with colistin resistance was found to contain mcr-1 — a plasmid15

born gene that encodes a phosphoethanolamine transferase75. This finding, and the subsequent
discovery of mcr-1 on plasmids worldwide76-84, foreshadows the fall of colistin as the final
antibiotic of last resort without transferable plasmid-encoded resistance. With high levels of
antibiotic prescription in medicine and unregulated use in agriculture around the world it is likely
only a matter of time before completely pan-resistant plasmids are found that combine the above
resistance mechanisms. Indeed, the coexistence of NDM-1 and MCR-1 in Enterobacteriaceae has
already been observed80,98, and a recent report documented the co-transfer of mcr-1 and ndm-5
on a mobile hybrid IncX3-X4 plasmid99.
In addition to soil habitats, human-associated resistomes have been a recent focus of
functional metagenomic investigations. The first human-associated microbial community to be
queried for antibiotic resistance by functional metagenomic selection was the oral microbiome.
Screening of a small functional library constructed from dental plaque and saliva samples against
tetracycline resulted in the discovery of tet(37), a gene encoding a tetracycline-inactivating
enzyme with low sequence identity to any previously described tetracycline resistance
determinant, as well as other resistance genes100. A larger follow-up study revealed resistance
against tetracycline, gentamicin and amoxicillin in the oral microbiota101. The first report of a
functional metagenomic interrogation of the human gut resistome screened metagenomic DNA
from the saliva and stool of two healthy humans against a panel of 13 antibiotics. Ninety-five
unique inserts, which together conferred resistance to all 13 antibiotics screened, were sequenced
and found to be largely dissimilar from the closest known resistance genes. For example, ten
novel β-lactamases were identified in just two gut microbiomes, indicating that these
microbiomes encompassed greater phylogenetic β-lactamase diversity than all previously
described β-lactamases (Fig. 1.2c)8. Additional studies have examined the gut microbiomes of
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diverse human populations, including healthy adults102, healthy twins and their mothers23,103,104,
preterm infants7, uncontacted antibiotic-naïve Amerindians17, and families, as well as livestock
and pets, from developing countries in Latin America3. Importantly, these studies have made it
clear that although the resident human-associated resistome is enriched after antibiotic therapy7,
the gut harbors an extensive resistome even in the absence of anthropogenic antibiotic use3,17.
Limitations of resistome studies.
Although these studies are extremely valuable in cataloging the genetic diversity of the
global resistome, they have been largely descriptive or philatelic exercises with substantial
requirements for downstream mechanistic validation. It is important to emphasize that just
because a gene confers resistance when it is overexpressed in a heterologous host, it may not be a
bona fide resistance gene in the original host. Indeed, nuanced definitions of antibiotic resistance
should consider the function of resistance determinants in their native contexts and risk for
transmission between bacterial species55. There is extensive evidence that resistome composition
is strongly correlated with the phylogenetic structure of a microbial community, and that synteny
of antibiotic resistance genes with mobility elements is observed less frequently in environmental
metagenomes (for example, from soil) than in sequenced pathogen genomes58,105 (Fig. 1.5b).
Nonetheless, the discovery of identical resistance genes in multiple genomic and environmental
contexts suggests historical transfer and/or dissemination events. For example, a recent
functional metagenomic study uncovered an identical TEM-1 β-lactamase in 25 different habitats
and genetic backgrounds3 (Fig. 1.5a). This research, when viewed in light of recent emerging
resistance threats, underscores that, although not all resistance genes are threats for widespread
dissemination, we should pay close attention to the ones that are. A focus of future studies on
antibiotic resistomes should be a quantification of risk for horizontal gene transfer to pathogens
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based on ‘metadata’ associated with a given resistance gene (for example, synteny with mobility
elements, plasmid-borne or chromosomal, in a close relative of human pathogen) to model the
risk for transmission54,55.

Figure 1.5: Synteny of antibiotic resistance genes provide historical context and
foreshadow future threats. The genetic context of antibiotic resistance genes can provide
important evidence of the likelihood of past or future horizontal gene transfer. (a) A single βlactamase (TEM-1) was found in 25 different genetic contexts in a recent cross-habitat resistome
study, which provided a historical record of past mobility. Five contexts are shown here. Habitats
in which gene was discovered are indicated on the left (human: human-associated microbial
community, animal: animal-associated microbial community, WWTP: wastewater treatment
plant, latrines: composting latrine). (b) Four resistance determinants that were discovered in
functional selections of soil metagenomic libraries (bottom) have high identity with resistance
genes from clinical pathogenic isolates. Shading indicates >99% nucleotide identity, which
suggests recent horizontal transfer. Resistance genes in pathogens are syntenic with mobility
elements and other resistance genes, which suggests that they may be present on a mobile
multidrug resistance cassette and pose a threat for horizontal gene transfer. Part a adapted from
Pehrsson et al 20163 and part b from Forsberg et al 20124.
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1.1.4 Next-generation approaches to resistance
Strategies to combat antibiotic resistance will require substantial changes to both the
antibiotic pipeline and stewardship practices and antibiotic resistance surveillance. The ubiquity
of antibiotic resistance suggests that the drug development pipeline must include proactive
screens for existing environmental resistance threats to new drugs and should explore alternative
strategies for combating resistance outside of the traditional antibiotic pipeline. Additionally, it is
the responsibility of the wider medical and scientific communities to apply the fruits of the first
two eras of resistome studies towards efforts to surveil potential antibiotic resistance hotspots for
emerging resistance threats before they spread.
Next-generation therapeutics.
A key aspect for the next-generation of antibiotic resistance studies is the proactive
development of therapeutic strategies to counteract emerging antibiotic resistance. One side of
this approach involves improved development of new antibiotics with a greater focus on
resistance potential. Current antibiotic discovery and development pipelines only take into
account resistance mechanisms that are already prevalent in the clinic. In retrospect, we know
that this strategy is doomed to fail, as resistance has been observed for every antibiotic that has
been implemented for human use1. Going forward, we should improve on the current reactive
strategies by screening promising lead compounds for resistance against diverse functional
metagenomic libraries. This will illuminate existing mechanisms of resistance that are likely to
disseminate to the clinical setting upon the introduction of the antibiotic for clinical use (Fig.
1.6).
In the near future, our understanding of the resistome will be sufficiently mature to
enable the development of strategies that actively combat resistance mechanisms themselves in
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contrast to current strategies that side-step resistance through the expensive development of new
antibiotics that immediately select for new mechanisms of resistance. This approach, in our
opinion, provides a higher likelihood of success than searching for a fabled ‘silver bullet’
antibiotic to which resistance is unlikely to develop. One such strategy is the repurposing of
existing antibiotics in synergistic combinations. Consider, for example, the triple β-lactam
combination of meropenem, piperacillin, and tazobactam, which was found to synergistically kill
methicillin-resistant Staphylococcus aureus (MRSA) N315 in vitro and in a mouse infection
model. The combination of these three antibiotics was collaterally sensitive and thus suppressed
the evolution of further resistance106. Treatment regimens that induce collateral sensitivity not
only enable the elimination of resistant bacteria, but also subject resistant bacteria to selective
pressure to discard their resistance gene107. Inverting the selective advantage of antibiotic
resistance is a promising approach for slowing the rate at which resistance evolves in a
population. A recent highlight in the search for selection-inverting compounds involved a screen
of nearly 20,000 small molecules for compounds that select against the tetracycline efflux pump
TetA. This screen identified two candidates that successfully selected for loss of the tetA gene108.
Perhaps more important are drugs under development and in early phase testing that target AcrAAcrB-TolC type efflux complexes in Gram-negative bacteria. Unlike TetA proteins, which are
tetracycline-specific, AcrA-AcrB-TolC pumps have broad substrate tolerance and can confer
multi-drug resistance, in particular in Gram-negative bacteria109.
A final strategy that has already proven effective in opposing widespread resistance is the
inhibition of antibiotic resistance enzymes110. Small molecules that lack antibiotic activity but
enhance the efficacy of antibiotic therapy are broadly termed antibiotic adjuvants111. β-lactamase
inhibitors and Tet(A) efflux selection inversion108,110,112 fall in this category, as do promising
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examples from recent studies that paired antibiotics with repurposed drugs already on the market
for other indications such as the opioid-receptor agonist loperamide which facilitates tetracycline
uptake and the ADP receptor antagonist ticlopidine which inhibits teichoic acid
biosynthesis10,111,113,114. Continued discovery of antibiotic adjuvants is facilitated and informed
by resistome studies that comprehensively describe the universe of possible resistance genes.
Consider, for example, the recently described E. coli-hosted array of >40 mechanistically distinct
and functionally validated resistance genes. This platform, which represented resistance to 16
classes of antibiotics, was used to screen a limited small molecule library for compounds that
could enhance the antibiotic activity of gentamicin. Of the 27 compounds that exhibited this
activity, eight were found to block aminoglycoside-2″-O-nucleotidyltransferase (ANT(2″)-Ia)
mediated resistance. Two compounds selected for further validation exhibited poor antibiotic
activity alone and were confirmed to inhibit ANT(2″)-Ia in vitro. By screening drug
combinations against a phenotypic resistome array, the authors were able to identify inhibitors of
antibiotic resistance genes, demonstrating the utility of leveraging resistome data to discover
adjuvants that can prolong the efficacy of existing antibiotics115.
Next-generation surveillance.
Lastly, it is important to prioritize continued and increased surveillance of the antibiotic
resistome, in particular, ‘hotspots’ in which there is a high likelihood of resistance gene
evolution and transfer between organisms (Fig. 1.6). These hotspots include, but are not limited
to, agricultural settings in which large quantities of antibiotics and human pathogens as well as
environmental microorganisms intermingle and potentially exchange DNA75, hospitals in which
selective pressure is omnipresent due to extensive use of antibiotics and antimicrobials, which
may co-select for antibiotic resistance46, and waste-water and sewage systems in which the
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human gut microbiota is directly exposed to many pharmaceutical residues3. Surveillance
requires regular testing of pathogens, commensals, and microbial communities for resistance to a
broad panel of antibiotics. This can occur using culture-dependent or genomic approaches, and
necessarily entails the continued development of technologies that will facilitate identification of
antibiotic resistance determinants.
Recent computational and bioinformatic advancements have offered substantial
improvements in our ability to identify antibiotic resistance genes from PCR amplicons and
whole-genome sequencing (WGS)49. These databases contain nucleotide or protein sequences for
known antibiotic resistance determinants, and can be queried (by BLAST116, for example) to
identify the antibiotic resistance genes that are present in a given genome or metagenome.

Figure 1.6: Integration of next-generation sequencing and screening
technologies with drug development and resistance surveillance.
The wide application of functional metagenomic selections and next
generation sequencing will steadily increase our knowledge of
functionally annotated antibiotic resistance genes and their genetic
context. This will allow for more intelligent antibiotic resistance
surveillance and drug design by accounting for specific mechanisms of
resistance and risk of resistance spread.
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However, these functional predictions are explicitly based only on sequence data and are
vulnerable to false positive predictions, particularly when functional assignments are based on
annotations that are themselves removed from direct biochemical or phenotypic validation. A
key component of our ability to annotate and predict antibiotic resistance genes from genomic
data is the continued improvement of antibiotic resistance gene databases through functional
validation117-122. In addition, improved probabilistic annotation algorithms such as profile hidden
Markov models (HMMs) have been shown to perform substantially better than pairwise
sequence alignment in terms of precision and recall123,124. For example, Resfams, a curated
database of 166 profile HMMs that were constructed from functionally validated resistance
protein families correctly predicted 45% more β-lactamases in functionally selected
metagenomic contigs compared to BLAST alignment to antibiotic resistance databases122. In
another case, nucleotide sequences from metagenomic datasets were used to computationally
predict qnr genes that might confer quinolone resistance. Although qnr genes display low
similarity to other resistance determinants and relatively high in-family diversity, the authors
were able to discover and functionally verify several novel variants125,126. As a result of these
tools, we are now able to more confidently identify both transferable and intrinsic resistance
determinants from genomes and metagenomes. Going forward, it is important that these
databases are regularly updated with the nucleotide and amino acid sequences of functionally
validated, emerging resistance determinants (Fig. 1.6).
Despite these advancements, the prediction of resistance phenotype based on genotype
remains a challenge. WGS-based methods present a promising approach to improve the speed
and accuracy of diagnostics127-129. An additional advantage of WGS-based diagnostics is the
possibility for improved identification of antibiotic resistance by target modification, which is
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often not feasible by existing PCR-based or microarray-based methods129-131. A current highlight
of sequencing based diagnostics is the Mykrobe predictor, which identified antibiotic
susceptibility profiles for twelve antibiotics from raw, unassembled Illumina sequencing data
from Staphylococcus aureus and Mycobacterium tuberculosis isolates as well as from in silico
simulated heterogeneous populations with high sensitivity and specificity132. A recently
described alternative approach uses draft genome assemblies as input and a machine learning
approach to accurately predict resistance profiles for multi-drug resistant Enterobacteriaceae
isolates124. Although it is currently cost and time prohibitive to use WGS as a clinical diagnostic
tool, continued reductions in sequencing costs and improvements in computational algorithms
may soon make this approach feasible. Faster and more accurate diagnostics will importantly
reduce empiric and unsuitable antibiotic prescriptions, limiting further selection for resistance
(Fig. 1.6).
Two recent examples from the literature highlight the important of surveillance efforts as
we attempt to arrest the spread of antibiotic resistance. These examples pertain to the current
antibiotics of last resort against carbapenem-resistant Enterobacteriaceae — colistin and
tigecycline. The first is the emergence of the mcr-1 gene as a transmissible threat to colistin use.
The seminal example of a plasmid-borne colistin resistance gene was found through an active
surveillance programme in China monitoring antimicrobial resistance in food animals75. Soon
after its discovery, several retrospective studies demonstrated that plasmid-borne mcr-1 had
already spread worldwide and into the clinic133 (Box 2). In this case, surveillance provided
crucial early detection. The second example of the importance of surveillance relates to
tigecycline, a semi-synthetic tetracycline antibiotic134. Due to its increased affinity for the
bacterial ribosome compared to other tetracyclines, and the presence of a glycyl tail, tigecycline
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is subject to reduced resistance through ribosomal protection or drug efflux 135. However,
tigecycline is vulnerable to the tetracycline-inactivating protein Tet(X)136. Although this protein
was originally discovered in Bacteroides fragilis — a traditionally non-pathogenic human gut
commensal, several clinical isolates have recently tested positive for tet(X)137,138, and tetracycline
inactivation has been discovered to be more widespread in environmental metagenomes than
previously thought29. Continued surveillance of this apparent emerging resistance mechanism is
prudent, as tigecycline and other next-generation tetracycline derivatives are being designed to
exclusively evade resistance through ribosomal protection and efflux 139,140. Increased use of next
generation tetracyclines imposes a strong selective pressure for the acquisition and spread of
tetracycline-inactivating enzymes from the environmental resistome. Foresight of this event
should enable the proactive development of next-generation therapeutic strategies before the
widespread dissemination of a resistance threat.

1.1.5 Conclusions
Extensive study of the antibiotic resistome over the past decades has allowed us to begin
to understand and address existing antibiotic resistance threats. However, it is evident that
antibiotic resistance will continue to evolve and spread in spite of our best efforts to develop new
antibacterial agents. Unless current practice is changed, it will be increasingly difficult to
establish and maintain even a transient lead over bacteria in this arms race. As research into
antibiotic resistance expands, it is important to adopt an explicitly proactive approach to
antibiotic resistance identification and surveillance, as well as antibiotic therapy development.
This proactive approach involves using a combination of functional metagenomics, nextgeneration sequencing, and cutting-edge computational methods to monitor evolution and
dissemination of resistance before a given resistance determinant emerges in a pathogen or in the
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clinical setting, as well as proactively developing next-generation therapies that target these
resistance determinants. The spread of plasmid-borne carbapenem, quinolone, and polymyxin
resistance in recent years is a sobering reminder of our need to catch up to existing threats, and to
anticipate emerging resistance mechanisms before they circulate widely in the clinical setting if
we wish to alter the current grim antibiotic resistance trajectory. Recent advances in the field
highlight the promise that the next-generation of resistome studies holds for characterizing and
countering emerging resistance threats.
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1.2 Genomic and functional techniques to mine the
microbiome for novel antimicrobials and antimicrobial
resistance genes:
Microbial communities contain diverse bacteria that play important functional roles in
every environment. Advances in sequencing and computational methodologies over the past
decades have illuminated the phylogenetic and functional diversity of microbial communities
from diverse habitats. Among the functions encoded in microbiomes are the abilities to
synthesize and resist small molecules, yielding antimicrobial activity. These functions are of
particular interest when viewed in light of the public health emergency posed by the increase in
clinical antimicrobial resistance and the dwindling antimicrobial discovery and approval
pipeline, and given the intimate ecological and evolutionary relationship between antimicrobial
biosynthesis and resistance. Herein, I review genomic and functional methods that have been
developed for accessing the antimicrobial biosynthesis and resistance capacity of microbiomes
and highlight outstanding examples of their applications.

1.2.1 Introduction
Nobel Laureate Joshua Lederberg was the first to propose the term “microbiome”, which
he defined as “the ecological community of commensal, symbiotic, and pathogenic
microorganisms that literally share our body space.”141 While Lederberg coined the term in
reference to the microorganisms that inhabit human body sites, microbial communities can be
associated with any environmental, clinical, or engineered habitat. Concurrent with the
expansion in sequencing capacity and the widespread adoption of “omics” technologies, the term
microbiome was redefined as the collective genetic material of a microbial community, while
“microbiota” is generally used to refer to the microorganisms themselves.142 Initial studies of
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microbial communities attempted to characterize the phylogenetic and functional diversity by
culturing the organisms and performing targeted functional assays. However, culture-based
assays are inherently biased, as a large fraction of microbes from most habitats are not readily
cultured using standard methods.94 Fortunately, metagenomic sequencing of microbial
communities, facilitated by the revolution in genomics over the past several decades, has enabled
increased investigation and appreciation of the breadth and depth of functions encoded in diverse
microbiomes.
The study of antimicrobial resistance and biosynthesis in microbial communities is
motivated by the ubiquity and diversity of microbes in wide-ranging habitats, the evolutionary
and ecological origins of antimicrobial resistance, and the global health crisis posed by
increasing antimicrobial resistance. The human commensal microbiota, harbors approximately
10trillion microbes,143,144 while the diversity of the soil microbiota has been estimated to be as
high as 10,000 unique species per gram.145 Both culture-based and culture-independent analyses
of these and other microbial communities have revealed biosynthetic pathways for small
molecules with antimicrobial activity146,147 as well as abundant and diverse antimicrobial
resistance genes.148-150 The collection of resistance genes in a given microbiome, known as the
antimicrobial “resistome”, consists of acquired, intrinsic, proto, and silent resistance genes.19,151
It is important to characterize resistomes and biosynthetic pathways from varied microbial
communities in order to better understand and combat the rise of clinical antimicrobial
resistance.149 This is ideally achieved by pairing functional and sequence-based genomic
technologies with traditional culture-based analyses.
This review is intended to provide an overview of functional and sequence-based
methods that have been developed for discovery of antimicrobial biosynthesis pathways and
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resistance genes from microbial communities. We will critically evaluate these methods and
highlight outstanding examples of their applications, with a specific focus on the advantages and
disadvantages that each method provides.

1.2.2 Rise in Antimicrobial Resistance and Decline in Antimicrobial Discovery
The World Health Organization has described antimicrobial resistance as the single
greatest challenge in infectious disease today, posing a serious public health threat on a global
scale.152 Clinical and environmental antimicrobial resistance have been increasing since the
widespread anthropogenic deployment of antimicrobials. Indeed, clinical resistance is now
frequently observed within a year of deployment of a new antimicrobial.1,2 (Fig. 1.7)
Furthermore, PCR based surveys of archived soils have revealed that the prevalence of
environmental antimicrobial resistance genes has been on the rise since 1940.21,94 In the USA
alone, 2 million people currently acquire serious infections that are resistant to the antimicrobials
designed to treat those infections, resulting in an estimated 23,000 deaths.153 Incidences of
multidrug resistance in human pathogens are also increasing.153 The proportion of clinical
isolates that are resistant to antimicrobials, including deadly MRSA (methicillin-resistant
Staphylococcus

aureus),

VRE

(vancomycin-resistant

Enterococcus),

and

FQRP

(fluoroquinolone-resistant Pseudomonas aeruginosa) strains has been steadily increasing since
the 1980s.154 The economic burden of antimicrobial resistance is also tremendous, with an
estimated 8 million additional hospital days resulting in $20 billion in direct healthcare costs and
$35 billion in lost productivity in the US alone.153,155 If the current trajectory is not altered, it is
estimated that worldwide deaths from antimicrobial resistance could climb to 10 million each
year by 2050.22
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Compounding the problem posed by antimicrobial resistance, the “golden age” of
antimicrobial discovery (ca. 1940-1960) was followed by a substantial innovation gap spanning
1962-2000, in which no new classes of antimicrobials were introduced (Fig. 1.7).2,156 Only three
new antimicrobials were approved for human use during the first decade of the 21st century.157
The decrease in antimicrobial discovery can be partially attributed to low incentives for research
and development of new drug classes.152 While most antimicrobial products currently in the
pipeline are active against at least some of the pathogens identified by the FDA as posing a
‘serious threat to public health’, barely a third (16 drugs) show significant activity against
multidrug resistant Gram-negative species.152 The issue is complicated by the collateral damage
from excessive antimicrobial use: when an antimicrobial is administered clinically or
agriculturally, it provides selective pressure for increased antimicrobial resistance in all microbes
in those habitats, not simply the targeted pathogen(s), and thus has a negative societal impact.158
To counter the withdrawal of pharmaceutical companies from the antimicrobial market, the US
Congress is considering legislation to create a streamlined antimicrobial approval pathway. This
would approve drugs to treat life-threatening infections based on smaller (and hence faster)
clinical trials, provided that they meet the same Phase I safety and efficacy standards as other
drugs.159 While these measures are being considered, it is imperative that we continue to better
understand the ecological and evolutionary dimensions of antimicrobial production and
resistance, to support the improved stewardship of both our current and future arsenals of
antimicrobial compounds.

1.2.3 Brief History of Antimicrobials
Antimicrobials are defined as chemicals that either kill (bacteriocidal) or inhibit the
growth of (bacteriostatic) bacteria at defined concentrations, and function by targeting systems
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critical to bacterial physiology. The five major modes of antimicrobial action are: (i) inhibition
of cell wall synthesis; (ii) inhibition of protein synthesis via the bacterial ribosome; (iii)
inhibition of DNA or RNA synthesis; (iv) inhibition of the folic acid pathway of nucleic acid
synthesis; and (v) disruption of cell membrane integrity.2,26,160-162
Antimicrobials have likely been naturally produced by environmental microbes as a
means for communication and defense for billions of years.163-165 Residues of antimicrobials
were discovered in human skeletal remains dating from 350-550 CE, suggesting that humans
have been exposed to antimicrobials for thousands of years.9,166,167 However, it was not until the
20th century that natural-product antimicrobials were deliberately repurposed for human use,
revolutionizing our treatment of infectious diseases. Up to the 1920s, infectious diseases were
the leading cause of death, with pneumonia, influenza, gastrointestinal infections, and
tuberculosis accounting for a combined 540 deaths per 100,000 deaths in the US during the first
decade of the 20th century.168 Ehrlich’s discovery of arsphenamine, an organoarsenic drug, a
compound that could cure syphilis-infected rabbits9,169 and Fleming’s subsequent serendipitous
discovery of penicillin, a β-lactam,170 signaled the advent of the antimicrobial era. The “golden
age” of antimicrobial discovery began in the 1940s and lasted through the 1960s, fueled by
Selman Waksman’s rapid antimicrobial discovery platform.1,171 Waksman was awarded the
Nobel Prize for the development of this method,172 and the drugs developed during the golden
age of antimicrobial discovery substantially improved the treatment of infectious disease.
Many natural-product antimicrobials were found to have pharmacological or
toxicological drawbacks, or eventually became obsolete due to evolution and spread of
resistance.10 Synthetically altering natural product antimicrobials to improve pharmacology or
evade resistance launched a new era of medicinal chemistry. Many antimicrobials were
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synthesized by modifying molecular scaffolds of antimicrobials previously discovered during the
golden era. As a result, amphenicol, tetracycline, aminoglycoside, macrolide, glycopeptide, and
quinolone classes were introduced or expanded, further improving our treatment of infectious
diseases.1,9,156,173,174

1.2.4 Brief History of Antimicrobial Resistance
The introduction of antimicrobials to the clinic resulted in a precipitous drop in mortality
worldwide from infectious disease.175 However, the selective pressure placed on bacterial
systems targeted by antimicrobials due to the extensive use of antimicrobials in clinical and
agricultural settings soon led to the steady evolution and increase of antimicrobial resistance,
systematically compromising each of the antimicrobials in our arsenal (Fig. 1.7).13,25,26,176
The strategies that bacteria use to resist antimicrobials can be divided into four general
categories: (i) drug efflux, (ii) reducing permeability of cell wall or membrane, (iii) target
overexpression, modification or protection, and (iv) enzymatic inactivation of the drug.26,177 In
the first resistance mechanism of drug efflux, bacteria pump out the antimicrobial, keeping the
intracellular concentration low and preventing the drug from reaching inhibitory concentrations.
This mechanism encompasses efflux pumps that are both specific to single antimicrobials or
classes, such as the tetracycline efflux pumps,38 as well as nonspecific, multidrug resistance
efflux pumps.34-37 The second resistance strategy, thematically related to the first, involves
reducing the permeability of the cell wall or cell membrane to the antimicrobial, thereby
preventing it from reaching its target. This can occur via reducing porin expression or expressing
a more selective porin variant.39,40 The third resistance strategy is overexpression, modification,
or protection of the drug target in the bacterium, enabling survival. This mechanism is used by
methicillin resistant Staphylococcus aureus (MRSA) which expresses PBP2a, a redundant and
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methicillin-insensitive version of the native PBP2 penicillin-binding protein, encoded by the
mecA gene.33 The final (fourth) resistance strategy involves enzymatic inactivation of the drug,
by either degrading or modifying the antimicrobial compound such that it no longer has activity.
Examples of this mechanism include β-lactamases, which degrade β-lactam antimicrobials,30,31
tetracycline destructases such as Tet(X),28,29 and chloramphenicol acetyltransferases.27
While we primarily evaluate antimicrobial resistance in terms of its effects on clinical use
of antimicrobials, the capacity to resist such compounds is in fact a natural and ancient feature of
all microbial communities.15,16 It is important to consider that the genes that we refer to as
“resistance genes” may have had functions unrelated to clinical antimicrobial resistance in their
original context, but could be repurposed for resisting antimicrobials when they are encountered
in a new context. The original functions of such genes may include cell wall biosynthesis (e.g. βlactamases), export of signaling molecules, metabolic intermediates, or plant produced
compounds (e.g. multidrug efflux pumps), or detoxifying the original host from the antimicrobial

Figure 1.7: Timeline of antibiotic deployment and resistance observation. The introduction
of an antimicrobial to the clinic (green) is rapidly followed by the first observation of resistance
to that antimicrobial (red).1,2
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that it is producing (e.g. tetracycline efflux pump induced just-in-time by its biosynthetic
precursor anhydrotetracycline112).178 The discovery of β-lactam, tetracycline, and vancomycin
resistance genes in 30,000 year-old Beringian permafrost sediments confirms that genes that
confer resistance to antimicrobials preceded the clinical use of antimicrobials by several
thousand years.15 Furthermore, while the first enzymatic degradation of penicillin was described
in 1940 when researchers noted that extracts of certain bacterial cells were capable of
inactivating penicillin,44 it is estimated that environmental β-lactamases have existed for over 2
billion years.179,180 Intensive human use of antimicrobials in clinical, agricultural, and industrial
settings over the past 80 years have led to the fairly recent exaptation of such genes with
resistance-conferring potential for surviving in the presence of antimicrobials.181,182
Since the introduction of antimicrobials to the clinic, the study of antimicrobial resistance
has been largely focused on isolates of human pathogens, and has relied on information gathered
from culturing these organisms.8 However, it is thought that most clinical antimicrobial
resistance has its evolutionary origins in the aforementioned genes with resistance-conferring
potential encoded by benign environmental and human-associated bacteria. Furthermore, a recent
study identified numerous resistance genes from benign soil bacteria with 100% nucleotide
identity to resistance genes that were present in diverse human pathogens, suggesting the
relatively recent sharing of resistance genes via horizontal gene transfer.4 This finding highlights
the need to study antimicrobial resistance in benign as well as pathogenic bacteria and in the
context of microbial communities as well as isolates, as horizontal gene transfer is the
mechanism by which most pathogens become resistant to antimicrobials.183
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Figure 1.8: Function and sequence-based methods for mining microbiomes. DNA is
isolated from source material (center), which can then be mined for antimicrobial resistance
genes (left) or antimicrobial biosynthetic pathways (right). Functional metagenomic methods
(top) typically entail shotgun cloning metagenomic DNA into an expression vector, and
selecting for a desired phenotype (e.g. antimicrobial resistance or antimicrobial activity).
Sequence-based methods (bottom) customarily involve sequencing metagenomic DNA and
annotating sequences using general or function-specific databases.

1.2.5 Culture-based methods underestimate functional diversity of
microbiomes
Discovering novel antimicrobials and resistance from microbial communities through
culture-based methods is challenging and limited to the cultivable minority of bacteria.184
Genomic technologies offer the promise of substantial performance improvements for
characterizing the functional capacity of microbiota, which has implications in both the basic
science and translational realms.184,185 For example, characterizing antimicrobial resistance using
current culture-based methods can take approximately 1 – 3 weeks versus the proposed less than
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12 hours using genomic technologies.184 Whole genome sequencing has the potential to reduce
exposure to ineffective drugs and the evolution of resistance by reducing diagnosis to days
instead of weeks as seen in the case of drug resistant Mycobacterium tuberculosis. 185,186
Depending on the habitat, traditional culturing efforts may capture as little as 1% of a
microbial community.94 The other 99% includes species that are recalcitrant to culture by
standard methods.187 This severe undersampling has motivated considerable recent
advancements in culturing methods to enable improvements in the proportion of microbial
communities that can be cultured. However, these methods, which may leverage microfluidic
technologies,188,189 clever simulations of natural growth conditions,189,190 or exhaustive sampling
of culture conditions,191 can be technically challenging and are not yet part of standard culturing
workflows. Culture-based methods are further hindered by the possible unreliable identification
of the cultured organisms, which is dependent on the expertise of the researcher. Culture-based
methods are also riddled with irreproducibility on non-selective media.192 It is often difficult to
recapitulate the phenotype of resistance of a targeted bacterium from selective media to nonselective media.
Advancements in genomic and computational technologies and the concomitant dramatic
reductions in sequencing costs over the past decades have allowed for an explosion of microbial
genome and metagenome sequencing, illuminating the diversity of microbial communities and
the breadth and depth of functions encoded therein.6,184,193-198 Genomic technologies can
overcome culture-based limitations and facilitate the discovery of novel antimicrobials and
resistance determinants. The remaining review details the functional and sequencing-based
methods which can be employed to quantitatively interrogate microbiomes and resistomes (Fig.
1.8).
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1.2.6 Function based methods for resistance discovery
Hybridization/PCR-based Methods
In addition to functional metagenomics, a powerful method described in Section 1.1 (Fig.
1.3), hybridization and PCR based methods are promising approaches for functional
identification of resistance genes. One method that integrates culturing and sequencing for
resistance characterization is a new technology that utilizes molecular padlock probes.199 In this
method, which shows particular clinical promise in predicting the antimicrobial susceptibility
profile of patient samples, the microbial community is exposed to the antimicrobial of interest
for a short period of time, after which metagenomic DNA is extracted.199 The metagenomic
DNA is then mixed with complementary biotinylated oligonucleotides of targeted rRNA gene
sequences and streptavidin-coated magnetic beads. This is to ensure the capture of the relevant
rRNA gene sequences. The mixture is then hybridized and ligated to the designed padlock
probes, usually designed to detect certain positions in the 16S rRNA gene.199 The probes are then
amplified through rolling circle amplification.199 After amplification, the final product is
fluorescently labeled and DNA copy number is quantified using a high-performance
fluorescence detector.199 An antimicrobial susceptibility profile can be determined by using DNA
copy number of the sample without antimicrobials and comparing with the DNA copy number of
the sample after exposure to antimicrobials.199 If there is an increase in DNA copy number after
exposure to antimicrobials, this indicates resistance. If there is no significant growth after
exposure to antimicrobials, this indicates susceptibility.199 This method has been used to
characterize the antimicrobial susceptibility profile of uropathogens from complex urinary tract
infection samples.199 Researchers accurately predicted the antimicrobial susceptibility profile for
55 out of 56 samples, highlighting the clinical utility of this method.199 An advantage that the
37

padlock probe method presents is short turnaround time, leveraging high throughput to give
results in a matter of hours and help clinicians prescribe correct antimicrobials to patients with
bacterial infections. However, the probes that are used in the assays have to be designed for
individual bacterial species and antimicrobials that are targeted to be used in the assay, and
cannot characterize novel resistance genes.

1.2.7 Sequence-based methods for resistance discovery
While function-based methods have been valuable in identifying novel resistance
determinants from diverse microbiomes, they are limited in throughput and are ideally
complemented by sequence-based methods, which we will review here. The ability to analyze
bacterial communities through culture-independent shotgun metagenomic sequencing has
revolutionized our ability to characterize resistomes.3,200-202 These analyses have benefited from
databasing projects, including the 35,000+ public metagenomes which have been uploaded to the
Metagenomics Rapid Annotations using Subsystems Technology server (MG-RAST).203
Shotgun metagenomic sequencing involves extracting and sequencing total metagenomic DNA
from a microbial community. Once sequenced, a specific subset of informative marker genes
from the metagenome can be used to infer phylogeny and functions that are present in the
microbial community of interest.204 To predict antimicrobial resistance from shotgun sequencing,
most studies have relied on pair-wise comparisons (e.g. by Basic Local Alignment Search Tool
(BLAST)116) of sequences to databases of known or predicted resistance genes.205-209 Many
antimicrobial resistance databases are highly biased toward human-associated organisms;
therefore, environmental antimicrobial resistance is comparatively ignored.122 Prediction
algorithms based on hidden Markov models (HMMs) trained on functionally-validated resistance
genes from diverse environments have proven to be superior to traditional pair-wise annotators
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in both precision and accuracy of resistance gene annotation, since HMM profiles allows for the
discovery of highly diverse and understudied antimicrobial resistance genes.122
Antimicrobial Resistance Gene Databases
A number of databases that store nucleotide and protein sequence information for
antimicrobial resistance genes have been developed. Query sequences are aligned to sequences
of known antimicrobial resistance determinants in the databases by BLAST,116 which performs a
strict pairwise DNA or protein sequence alignment, to catalog the antimicrobial resistance gene
content of a genome or metagenome. These databases have dramatically advanced the field of
genomic and metagenomic analyses of antimicrobial resistance by allowing the sequence-based
identification of known resistance determinants.120
The Antibiotic Resistance Gene Database (ARDB) is a manually curated antimicrobial
resistance database.118 ARDB provides a comprehensive ontology which creates a resistance
profile by matching specific genes and mechanism of actions. It uses BLAST to identify and
annotate antimicrobial resistance genes. Many studies have used ARDB as their sole method to
identify antimicrobial resistance genes210-212 and have revealed that a majority of antimicrobial
resistance genes cluster based on ecology.205,211,213 Although this database was the first of its
kind, it has not been updated since 2009.
The Comprehensive Antibiotic Resistance Database (CARD) is a collection of known
resistance determinants and associated antimicrobials.119 It is designed to predict known
antimicrobial resistance from genome sequence data by using a BLAST-based pairwise sequence
alignment to known antimicrobial resistance genes in the database. The database is organized
based on ontologies, linking genes to their function. This is an ideal database to use if the
antimicrobial resistance mechanism of interest has been previously thoroughly researched.
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However, it is not suited for the detection of point mutations in chromosomal target genes known
to be associated with antimicrobial resistance genes.214 Many studies have annotated
antimicrobial resistance using CARD alone or in combination with ARDB.208,209,215,216 Unlike
ARDB, the CARD database is actively managed and periodically updated.
The Bush-Jacoby β-lactamase list is a curated database that matches β-lactamase gene
sequences to resistance to β-lactam antimicrobials. This database will soon be hosted on the
NCBI website. This database was originally focused heavily on TEM, SHV and OXA type βlactamases, only a subset of β-lactam antimicrobial resistance genes. Other β-lactamases that are
now included in the database are CTX-M, CMY, AmpC, CARB, IMP, VIM, KPC, GES, PER,
VEB.120
The Lactamase Engineering Database (LacED)217 is an extension of the Bush-Jacoby βlactamase list. This database includes a way to predict TEM, SHV, and class B enzymes by
merging the information from both NCBI peptide database and the TEM mutation table. LacED
builds protein families from these databases and integrates protein sequence and structure
information using DWARF.218
The Repository of Antibiotic Resistance Cassettes (RAC) takes advantage of the fact that
resistance genes are often syntenic with mobile genetic elements, forming resistance cassettes.
This database was the first to simultaneously automate identification of antimicrobial resistance
genes and place the genes in their broader genetic context.219
ResFinder121 combines the Bush-Jacoby β-lactamase list with ARDB and other published
antimicrobial resistance gene sequences. Similar to other resistance databases, query sequences
are matched to the sequences in the database via BLAST. The difference between ResFinder and
most other resistance gene databases is the ability for the user to tailor the identity and length
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coverage thresholds. This allows the user to specify settings that are suited for the depth and
quality of sequencing for each project. The current challenge with using ResFinder and
previously described databases is the inability to classify chromosomal mutations which can lead
to antimicrobial resistance or to classify novel resistance genes, and is thus limited to resistance
genes commonly acquired through horizontal gene transfer.214
The Antibiotic Resistance Gene-Annotation (ARG-ANNOT)

214

uses a BLAST-enabled

search on a curated antimicrobial resistance gene database compiled from Bush-Jacoby βlactamase list, Resfinder121, ARDB118 and others. A main difference between this program and
others is the ability to additionally predict resistance function based on chromosomal point
mutations. ARG-ANNOT contains a curated database focused on mutations found in many
chromosomal genes (i.e. rpoB, gyrA1, gyrA2, parC) that can confer resistance to antimicrobials.
It is difficult to identify novel resistance genes when using pairwise comparisons (e.g. by
BLAST) to resistance databases which are largely based on resistance genes from cultured
bacterial isolates, and are especially biased towards human associated pathogens. Resfams
implements an alternative method in order to identify known and novel resistance genes with
high precision and accuracy.122 Resfams is a curated database of profile HMMs built on
resistance proteins compiled from CARD119, LacED217, and Jacoby and Bush’s collection of
curated β-lactamases, based on the gene ontology from the CARD database. Additionally, the
Resfams profile HMMs incorporate antimicrobial resistance genes from environmental, human
commensal, and pathogenic bacteria which have been discovered through culture-independent
functional metagenomic selections. The HMM approach is superior to pairwise annotation
approaches in both precision and accuracy. Pairwise BLAST searches against resistance gene
databases were unable to identify over 60% of resistance genes identified by Resfams from a
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functionally-validated resistance gene test set.122 Perhaps more importantly, differences in
HMM-based versus BLAST-based pairwise resistome analyses of the same data can lead to
significantly different (and sometimes completely contradictory) biological conclusions. For
instance, comparison of resistome predictions from over 6,000 bacterial genomes by Resfams
versus predictions by pair-wise alignment of resistance gene databases revealed that pair-wise
methods are inaccurately biased in both their phylogenetic and ecological distributions towards
the relatively oversampled human-associated environments which they represent.122
These myriad resistance gene databases are clearly important tools for interrogating
microbiomes for antimicrobial resistance genes, but some challenges in their use and
opportunities for their improvement exist. An important limitation to both HMM- and BLASTbased searches is the implicit requirement for users to determine the accuracy of the predicted
resistance gene function, especially when the exact sequence being annotated has not been
previously functionally assayed. Additionally, many of these databases do not incorporate
information on the host-specific functionality of some antimicrobial resistance genes.220 For
example, most Gram-negative bacteria are intrinsically resistant to important classes of Grampositive specific drugs (e.g. vancomycin, linezolid, and macrolides) because they cannot cross
the Gram-negative outer membrane.177 Accordingly, it is likely inappropriate to annotate
homologs of genes which provide resistance to these antimicrobials in Gram-positive bacteria
when they are identified in Gram-negative bacteria. An important future goal in these databases
is a species-dependent risk estimator for horizontal gene transfer to quantify the likelihood of
resistance gene dissemination between species and habitats. Additionally, it is important that
environmental or “non-clinical” resistance genes which are currently underrepresented these
databases be included122. Because most clinical resistance originated in the environment, this will
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facilitate the surveillance of emerging resistance mechanisms as they disseminate beyond benign
organisms. Despite the inherent limitations in ascribing resistance function based on sequence
alone, antimicrobial resistance databases play a key role in curating sequences of known
resistance determinants. It is crucial that these databases are regularly updated and
simultaneously cross-validated to maintain accuracy and relevance. Continued maintenance and
improvement of these databases, including the ongoing incorporation of novel, functionally
validated resistance determinants and associated metadata from diverse habitats, will ensure that
they remain valuable resources for the antimicrobial resistance community for years to come.
It is likely that the selective pressure that drove the evolution of most antimicrobial
resistance genes is the incredible biosynthetic potential of microbial communities to synthesize
natural products with antimicrobial activity. This motivates the need to understand antimicrobial
resistance in microbial communities in the context of antimicrobial biosynthesis, and vice versa.
Paralleling recent improvements in methods to characterize resistomes, there have also been
significant advances in functional and sequence-based methods for discovering novel
antimicrobial biosynthesis machinery, which we will review below.

1.2.8 Function-based methods for antimicrobial discovery from microbiomes
Function-based methods for the discovery of antimicrobials from microbiomes present a
clear advantage over sequence-based methods in that no a priori knowledge of the sequence of a
natural product biosynthetic pathway is required. This facilitates the discovery of novel natural
products that are produced by biosynthetic pathways that are divergent from previously
characterized pathways and provides access to novel chemical diversity. This unbiased approach
has been successfully used for the discovery of natural products with antimicrobial activity.221,222
The method depends on shotgun cloning of metagenomic DNA from a given environment into
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an expression vector, heterologous expression of pathways encoded in the metagenomic DNA in
an appropriate host, and screening for production of bioactive natural products.223
Despite the advantages that this unbiased approach provides, there are several challenges
that have hindered the discovery of natural product antimicrobials using functional
metagenomics. The main disadvantage is construction and heterologous expression of large
insert libraries is technically challenging.224 Strategies to improve the heterologous expression of
biosynthetic pathways, including overexpression of alternative sigma factors in E. coli, have
proven successful for heterologous production of polyketides and hold promise for the
development of improved metagenomic screening hosts.225 Additionally, nontraditional
heterologous hosts such as Streptomyces lividans have demonstrated utility in the discovery of
bioactive natural products from metagenomic libraries.226 A final challenge inherent in functional
metagenomic antimicrobial discovery lies in the fact that antimicrobial production is a more
complicated phenotype to select for than antimicrobial resistance, for reasons which we will
detail below. This necessitates the use of clever screening strategies to identify and isolate clones
of interest.224
One screening strategy that successfully enables discovery of antimicrobial biosynthesis
from metagenomic libraries is to directly assay for antimicrobial activity against an indicator
strain using a double-agar layer method.227 In this method, the heterologous host of the
metagenomic library is allowed to grow on plates, after which top agar containing the indicator
strain is overlaid. This method was used to discover two clones from a 113,500 member fosmid
library representing 4 Gb constructed from a soil metagenome that were able to inhibit the
growth of Bacillus subtilis. The clones encoded a biosynthetic pathway that produced indigo and
indirubicin, pigments that were confirmed to be responsible for the observed antibacterial
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activity.221 Another application of this method resulted in the identification of 65 clones with
antibacterial activity from a 700,000 member soil library. A small molecule from the clone with
the highest apparent bioactivity was purified and identified as a long chain N-acyl amino acid.
This represented the first report of the antibacterial activity of long chain N-acyl amino acids, as
well as the first identification of genes involved in long chain N-acyl amino acid biosynthesis,
highlighting two key advantages of the functional metagenomic approach to antimicrobial
discovery.222
An alternative approach that extends traditional culturing methods uses the innovative
‘iChip’,

a multichannel, microfluidic diffusion growth chamber.189 This device was recently

used to discover a novel non-ribosomal peptide with antimicrobial activity from a soil microbial
community.228 The iChip requires that input microbial community samples are diluted such that
each channel receives approximately one bacterial cell. The device is sealed with a
semipermeable membrane and returned to the source so that nutrients and growth factors from
the natural environment of the source organisms can diffuse into the chamber, increasing the
likelihood of culturing fastidious organisms.189 This high-throughput method was used to culture
10,000 diverse isolates from a soil sample, which were predicted to be recalcitrant to culture
using traditional methods. Screening of extracts from these isolates for antimicrobial activity
revealed the presence of a non-ribosomal peptide, named teixobactin, synthesized by a
previously uncultured betaproteobacterial species. Teixobactin was isolated and characterized,
and found to have activity against multi-drug resistant Gram-positive pathogens in vitro, as well
as in animal models for MRSA and Streptococcus pneumoniae.228 Although this method relied
on classical antimicrobial screening platforms, innovative culture methods facilitated the
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discovery of a novel antimicrobial and revealed the biosynthetic potential of the uncultivable
fraction of microbial communities.

1.2.9 Sequence-based methods for antimicrobial discovery from microbiomes
Sequence-based methods for discovery of antimicrobial biosynthetic pathways from
microbiomes depend on homology between the query sequence and known biosynthetic
pathways. A clear advantage of this method is throughput. Advancements in annotation and
prediction algorithms coupled with the abundance of microbial genome and metagenome
sequences have made feasible the analysis of sequence data for identification of biosynthetic
gene clusters that may encode novel bioactive natural products. A disadvantage of this strategy is
that prediction of the structure of a small molecule from the sequence of a biosynthetic gene
cluster is nontrivial, as is prediction of a small molecule’s activity from its structure.
One of the first attempts to identify biosynthetic pathways from an uncultured community
relied on PCR amplification of ketosynthase genes from Streptomyces isolates as well as from
metagenomic DNA isolated from soil.229 The amplicons were purified, cloned into an expression
vector, and sequenced. Of 20 randomly selected transformants that were sequenced, only two
had similarity to any known ketosynthase gene products. Four of the novel ketosynthases were
shown to be functional when expressed in a Streptomyces lividans or Streptomyces glaucescens
host as part of a hybrid polyketide synthase pathway (that is, the native ketosynthase was
replaced with the newly discovered ketosynthase). The polyketide products of the hybrid
biosynthetic pathways were purified and characterized to be novel octaketide and decaketide
natural products. This highlights the utility of culture-free methods for identifying novel,
sequence-divergent genes involved in biosynthetic pathways to expand access to novel natural
products with diverse bioactivities, including potential antimicrobial activity.
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Tools for identifying genes involved in natural product biosynthesis from sequence data
represent a significant advancement over targeted PCR-based studies. One of the resources
developed for mining genomic data for biosynthetic gene clusters is antiSMASH.230 antiSMASH
makes use of the ClusterFinder algorithm,231 which is an HMM based algorithm for the
discovery of biosynthetic gene clusters from genomic data. The ClusterFinder algorithm consists
of a four-step prediction pipeline that can identify biosynthetic gene clusters in genomic data.
The use of an HMM-based, probabilistic algorithm allows identification of biosynthetic gene
clusters that lack high similarity in domain structure to any known biosynthetic gene clusters,
circumventing the problem that had previously been posed in identification of biosynthetic gene
clusters from sequence data. antiSMASH also includes an Active Site Finder module that
identifies conserved amino acid motifs in the active sites of key biosynthetic enzymes including
those involved in polyketide biosynthesis. A final, key feature of antiSMASH is an algorithm
that predicts the structure of a natural product synthesized by the annotated biosynthetic gene
cluster. Furthermore, the development of a web-based server has democratized the process of
identifying biosynthetic gene clusters, because it is available to those without access to high
throughput computing facilities.230
The ClusterFinder/antiSMASH workflow was successfully used to identify a natural
product with antimicrobial activity from metagenomic sequencing data generated as part of the
NIH Human Microbiome Project. 2,430 genomes of members of the human microbiota were
queried using ClusterFinder to identify over 14,000 putative biosynthetic gene clusters.
Metagenomic reads from 752 samples representing five body sites of healthy subjects were
mapped to the 14,000 predicted biosynthetic gene clusters. Among the natural products predicted
was a thiopeptide from the vaginal commensal Lactobacillus gasseri. The thiopeptide, named
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lactocillin, was purified and characterized. Lactocillin was found to have antimicrobial activity
against Gram positive bacteria including Enterococus faecalis, Gardnerella vaginalis,
Staphylococcus aureus, and Corynebacterium aurimucosum. The discovery and characterization
of the structure and bioactivity of lactocillin from human microbiome metagenomic sequencing
data demonstrates the potential that diverse metagenomes hold for encoding natural products
with antimicrobial activity.147
A current shortcoming of software available to identify biosynthetic gene clusters from
metagenomic sequencing data is that assembly of short read data into genomes or large contigs is
required. Although there have been recent advancements in metagenomic assemblies of this
type,232-234 it remains a challenge. One way to circumvent the requirement for metagenomic
assembly is the use of ShortBRED,235 which finds short, unique amino acid markers from
reference proteins of interest and maps metagenomic sequencing reads to these markers. This
tool has been successfully implemented for the identification of antimicrobial resistance genes 200
and has potential for the identification of genes involved in natural product biosynthesis directly
from short read metagenomic sequencing data.
An alternative method that can be used to access the biochemical diversity of
microbiomes without the necessity for metagenomic assembly uses short DNA sequences that
are conserved between biosynthetic gene clusters. PCR amplification of these conserved
biosynthetic motifs from a metagenomic source using degenerate primers followed by amplicon
sequencing can provide an overview of the biosynthetic capabilities of a given microbiome, and
highlight promising leads for heterologous expression and further characterization.236 A
bioinformatics platform for mapping short DNA sequence tags to known biosynthetic gene
clusters, termed Environmental Surveyor of Natural Product Diversity (eSNaPD), has been
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developed to facilitate analysis of amplicon sequencing data in the context of natural product
biosynthesis.237 This strategy has been successfully used in the identification of novel bioactive
small molecules, including some with antimicrobial activity.236,238
A final, promising method for sequence-based identification of biosynthetic gene clusters
from microbiomes involves assembly of complete or near-complete genomes using singlemolecule, real-time sequencing (SMRT),239 followed by annotation with antiSMASH or a similar
annotation pipeline. This approach was successfully applied in tandem with short-read data
reference-independent assembly of a high-quality Corynebacterium simulans genome de novo
from a skin microbiota sample. This previously uncharacterized genome was annotated with
antiSMASH, revealing predicted nonribosomal peptide synthetases, type I polyketide
synthetases, terpene synthases, and bacteriocin production genes.240 Interestingly, the bacteriocin
production locus was homologous to the locus for biosynthesis of lactococcin, a bacteriocin
which is known to be bactericidal.241 Although the natural products whose biosynthetic gene
clusters were identified in this study were not isolated or confirmed for bioactivity, the authors
demonstrate the power of metagenomic assembly in the identification of biosynthetic gene
clusters from microbiomes.

1.2.10 Future directions in antimicrobial and antimicrobial resistance
discovery
The increasing threat to human health from multi-drug resistant pathogens underscores
the need to develop tools to interrogate microbiomes for novel antimicrobials and to understand
and mitigate the evolution and transmission of resistance genes. A more complete understanding
of antimicrobial resistance in the context of microbial communities will advance our treatment of
antimicrobial-resistant infections and help us choose therapies that will reduce selection for
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resistance. Additionally, novel antimicrobials discovered within microbial communities will lay
the groundwork for narrow-spectrum, next generation antimicrobials that reduce collateral
microbiome damage. Given that most clinical antimicrobial resistance genes originated in
environmental microbes, and most antimicrobials are natural products or derivatives thereof, it is
critical that these two microbial functions be studied in tandem and in the context of microbial
communities in order to understand the dynamics governing the evolution and transmission of
antimicrobial resistance and biosynthetic capacities.
Advances in sequencing technology will facilitate discovery of complex functions from
metagenomes based on sequence alone. For example, long read sequencing technologies such as
the NanoPore Minion and the PacBio SMRT will help to overcome the challenges currently
posed by metagenomic assembly from short read data, providing greater information about
functions encoded in large operons, such as biosynthetic and multidrug resistance gene
clusters.233,242,243 Furthermore, cheaper sequencing will allow for deeper sequencing, improving
our ability to assemble metagenomes and profile antimicrobial resistance and biosynthetic
capacities.6 Single-molecule sequencing, particularly when combined with short-read shotgun
metagenomic data, may also improve metagenomic assembly and allow for better identification
of biosynthetic gene clusters.240 In addition to progress resulting from improvements to DNA
reading, advancements in DNA writing will likely benefit the field. Dramatic reductions in the
cost and efficiency of DNA synthesis may soon make synthesis and recoding of entire
biosynthetic gene clusters feasible, simplifying heterologous expression in genetically tractable
hosts and downstream characterization of bioactive natural products.244,245 An integration of
functional and genomic techniques, aided by these and other inevitable technical and
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computational developments, will help us better understand the delicate interplay between
antimicrobial biosynthesis and resistance in microbiomes.
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1.3: Antibiotics and the preterm infant gut microbiome and
resistome
1.3.1 Introduction
The infant gut microbiota is shaped by both prenatal and postnatal factors246,247.
Following birth, the infant gut microbiota undergoes a patterned maturation process248-250. This
process begins with a few taxa, but this population inexorably expands in content and
concentration until it approaches an adult-like microbial configuration dominated by
Bacteroidetes and Firmicutes248,251-253. Perturbation of the gut microbiota during this key
developmental window can have lasting effects on host physiology and disease risk254-259. One of
the most common perturbations during this period, antibiotic therapy258,260, can substantially alter
the gut microbiota and infant physiology255,261-266. Because preterm infants are at high risk for
infection, antibiotics are the most commonly prescribed medications in neonatal intensive care
units (NICUs) in the United States (Fig. 1.9)260,267,268 accounting for three of the top six
medications with the greatest relative increase in use in NICUs in the United States between
2005 and 2010269. Antibiotic-induced gut microbiota dysbioses in this population have been
linked to the pathogenesis of necrotizing enterocolitis270-272, late onset sepsis273,274, and other
adverse health outcomes275. While these correlations exist, the underlying etiologies remain
unclear, motivating the study of microbiota development in the context of antibiotic therapy in
this vulnerable population that accounts for nearly 10% of all births in the United States276.

1.3.2 Techniques for studying development of the infant gut microbiota and
the developing resistome
Microbial ecology studies, especially those focused on the gut microbiota, have
flourished because of widespread adoption of sequencing-based studies, either using the 16S
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Figure 1.9: Prescription data in the NICU. Data adapted from
Clark et al. Pediatrics 200623. Frequency defined as the number
of times a unique medication name was reported in the
medications table in 220 NICUs in the United States and Puerto
Rico between January 1996 and April 2005. Antibiotics are the
most prescribed medications in the neonatal intensive care unit.
rRNA gene or metagenomic shotgun sequencing, resulting in a deeper appreciation of
microbiome diversity249,265,272,277-279. Until recently, similar efforts to characterize the preterm
infant gut reservoir of antibiotic resistance genes (the resistome) have been largely culture or
PCR-based. While these methods can provide a high level overview of the resistome, they
underestimate diversity, are limited to previously known resistance genes, and are only semiquantitative. In contrast, deep sequencing of microbiomes paired with functional metagenomics
offers an unbiased method to identify functional resistance determinants in a stool, and can
provide quantitative information on microbiome and resistome architecture23,57. Gibson et al.
recently used this suite of techniques to develop a sequence-unbiased account of the effects of
antibiotic therapy on the preterm infant microbiota with respect to phylogeny and antibiotic
resistance gene distribution200.
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1.3.3 A longitudinal, sequencing based interrogation of the preterm infant gut
microbiota
To assess the effects of antibiotics on the dynamics of the preterm infant gut microbiota,
Gibson et al. assembled a cohort consisting of 84 preterm infants, of whom 82 received
antibiotics within the first 24 to 48 hours of life, as is common practice in the NICU. However,
39% received no further antibiotic therapies after the first week of life, allowing them to serve as
controls to study the effects of antibiotic treatment on preterm infants in the first weeks of life.
All infants in the cohort were low birthweight and born prematurely, with a median gestational
age of 27 weeks and a median birthweight of 865 grams. This sample set was complemented by
robust metadata including detailed histories of all antibiotic exposures, overall health indications
including infections, delivery mode, postmenstrual age, hospital environment, enteral feeding,
other medications, and maternal health.
A total of 401 stools from these infants, collected longitudinally during their stay in the
NICU and ranging from day 6 to day 158 of life, were interrogated by shotgun metagenomic
sequencing. In total, Gibson et al. sequenced and analyzed 551 gigabases (Gb) of preterm infant
gut metagenomes (1.37 +/- 1.17 Gb per sample) and a total of 107 Gb of functionally selected
preterm infant resistomes (5.1 +/- 3.6 Gb per sample). Unique clade-specific marker genes from
approximately 17,000 reference genomes were used to assess the phylogenetic composition
allowing both species-level resolution and accurate relative abundance estimations of bacterial
species composition of these communities, an advantage over traditional 16S rRNA marker gene
sequencing204,280. This represents the largest metagenomic sequencing-based study of the preterm
infant gut microbiota to date, providing the statistical power to address questions of microbiota
and resistome development in preterm infant populations subject to heavy antibiotic exposure.

54

1.3.4 Antibiotics disrupt the preterm gut microbiota richness and composition
Gut microbial species richness, defined as the number of species present in a microbiota,
is widely used as a measure of microbiome health. Decreased species richness in infancy has
been associated with a number of host pathologies and is widely used as a measure of
microbiome perturbation258,270,281,282. To identify factors that significantly contribute to species
richness, Gibson et al. developed a generalized linear mixed model with individual included as a
random effect, leveraging available metadata including infant health (e.g. CRIB II (Clinical Risk
Index for Babies) score, day of life, gestational age, birthweight, delivery mode, and presence of
positive culture), medications (e.g. antibiotics, caffeine, and iron), and maternal health (e.g.
preeclampsia and premature membrane rupture). While postmenstrual age and breast milk
significantly contribute to increased species richness, the opposite was true with high CRIB II
score, meropenem treatment, cefotaxime treatment, and ticarcillin-clavulanate treatment
significantly contributing to decreased species richness. Cumulative antibiotic exposure in
infants was associated with a significant reduction in species richness and, with the exception of
gentamicin, all antibiotics were associated with reduced species richness. This decrease in
species richness occurred over intervals during which the gut microbiota of age-matched,
antibiotic-naïve preterm infants was increasing in richness, and was accompanied by disruption
of microbiota composition (Fig. 1.10). For example, one individual had a ~25% decrease in
observed species following meropenem treatment, while over the same period a matched control
had a 20% increase (Fig. 1.10a). Similar age-matched comparisons can be made for combined
vancomycin and meropenem treatment (Fig. 1.10b) and for ticarcillin-clavulanate treatment (Fig.
1.10c). Antibiotic-induced perturbations of microbiota phylogenetic composition were observed
for these infants as well (Fig. 1.10a-c).
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Figure 1.10: Antibiotic treatment alters preterm infant gut microbiota development.
Preterm infant gut microbiota species richness (top) and composition (bottom) for the three
individuals with samples analyzed directly before and after depicted antibiotic treatments for
(A) meropenem, (B) vancomycin and meropenem, and (C) ticarcillin-clavulanate. Red bars
represent species richness for example individual. Black bars represent average species
richness for age matched preterm infants with no antibiotic treatment. Error bars depict one
standard deviation.

1.3.5 Antibiotic therapy enriches for antibiotic resistance genes and multidrug
resistant bacteria
For further insight into the effects of antibiotics on the resistome of the preterm infant gut
microbiota, Gibson et al. constructed functional metagenomic libraries from 21 representative
fecal samples. Functional metagenomics is a valuable technique for identifying functional
resistance determinants in microbiomes. Because functional metagenomics circumvents the bias
introduced by culture and the need for a priori knowledge of resistance function, the method
provides a high throughput, sequence-unbiased characterization of reservoirs of antibiotic
resistance genes in a given environment and can identify novel resistance genes57,66. These
libraries, representing a total of 107 Gb of bacterial DNA, were screened against 16 antibiotics,
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including those routinely used in NICUs. Of the 794 functionally identified antibiotic resistance
genes, 42% were encoded by E. coli, Enterobacter cloacae, and K. pneumoniae, taxa which
include many pathogenic strains implicated in nosocomial infections in preterm infants279,283.
Interestingly, the sequences of the majority of resistance determinants uncovered by the
functional metagenomics screens were already present in protein databases. However, they were
not found in antibiotic resistance specific databases, indicating that they had not previously been
ascribed a resistance function and highlighting a key advantage of using functional
metagenomics.
One third of the antibiotic resistance genes identified by functional selections conferred
resistance to multiple antibiotics, often across classes, or were co-selected with another antibiotic
resistance gene. For example, the loci selected by piperacillin also conferred resistance to other
-lactam antibiotics. In fact, many -lactamases identified in this study conferred resistance to
multiple classes of -lactam antibiotics. In addition to these genes, which may be extended
spectrum -lactamases (ESBLs), Gibson et. al. identified multiple Ambler class A -lactamases,
and -lactamases that conferred resistance to both penicillins and 2nd and 3rd generation
cephalosporins. ESBLs are of particular concern due to their increasing abundance in community
acquired infections and in clinical settings such as the NICU, often in Enterobacteriaceae family
members, including those that Gibson et. al. identified as dominant members of the preterm
infant gut microbiota284. In addition to cross resistance among -lactam antibiotics, Gibson et. al.
also observed contigs that conferred resistance across classes of antibiotic. For example, many
tetracycline resistance genes also conferred resistance to both chloramphenicol and cefoxitin.
Our findings suggests that many of these genes may be present in the context of a multidrug drug
resistance cassette and are threats for dissemination via horizontal gene transfer. Multidrug57

resistance is one of two key features associated with spread of antimicrobial resistance in the
preterm infant gut microbiota. The other feature is mobility, or the likelihood of horizontal gene
transfer. In order to investigate the potential mobility of resistance genes in the preterm infant gut
microbiome Gibson et al. assembled metagenomic contigs from shotgun reads, and found
widespread plasmid and chromosomally encoded multidrug resistance clusters. Alarmingly, the
authors identified plasmid-associated antibiotic resistance genes encoding resistance to more
than six antibiotic classes in 96% of preterm infant gut samples. Furthermore, the preterm infant
resistome was found to be highly resilient. Over the course of time represented by the
longitudinally sampled resistome, only about one fifth of the resistance gene classes showed
significant change, implying that early life antibiotic therapy may select for a lasting expansion
of the gut resistome.

1.3.6 The predictable response of the preterm infant gut microbiota to
antibiotic therapy
To quantify changes to the gut microbiota before and after antibiotic treatment Gibson et
al. utilized metagenomic shotgun sequencing to interrogate the phylogenetic architecture of the
bacterial community. While meropenem, cefotaxime, and ticarcillin-clavulanate each
significantly and immediately reduced species richness, gentamicin and vancomycin (two of the
most commonly used antibiotics in preterm infant populations, and which are often coadministered) resulted in variable species richness responses. Using random forests
classification, the direction of species richness response to vancomycin and gentamicin treatment
can be predicted based on the relative abundance of only two species (Staphylococcus aureus
and E. coli) and two antibiotic resistance genes (cpxR and cpxA) with an error rate of only 15%.
We hypothesize that this finding might be due to the innate vancomycin-resistance of Gram58

negative bacteria such as E. coli and the innate vancomycin-susceptibility of S. aureus, coupled
with the ability of cpxR and cpxA to confer gentamicin resistance to E. coli285. These analyses
reveal significant antibiotic-specific microbial and compositional responses of the preterm infant
gut microbiota. For a commonly prescribed antibiotic regimen, co-therapy with vancomycin and
gentamicin, Gibson et al. identified important species and antibiotic resistance gene biomarkers
that can predict with high accuracy the short-term species richness response and therefore
potential for disruption of the developing preterm infant gut microbiota.

1.3.7 Implications for future research
It is evident that use of specific antibiotics in the NICU, such as next generation -lactam
antibiotics, acutely (but perhaps not durably) perturb the gut microbiota while others, such as
gentamicin, are less disruptive. Going forward, it is important to understand the enduring effects
of antibiotics on the preterm infant gut microbiota and resistome. Recent studies have observed
that multidrug resistant clones present in preterm infants in the NICU are absent at two years of
age, suggesting that the preterm infant gut may recover following discharge to home286. On the
other hand, resistance genes persist for months or years after antibiotic therapy in adults287-289.
Sequence-based characterizations of gut microbiota composition and resistome of preterm
infants after they enter the community are needed to fully understand the longitudinal effects of
antibiotics on microbiota composition, multidrug resistant organism persistence, and resistance
gene carriage. Longitudinal studies also provide the opportunity to correlate dysbioses that
originate in the NICU with health outcomes that are manifest later in life. Additionally, it is
important to consider the effect of prenatal and intrapartum antibiotics, and prenatal exposure to
microbes, on the infant gut microbiota. This is of particular note in preterm infants, one in four of
whom are born to mothers with an intrauterine infection290, and in light of the increasing
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recognition that the uterus is a nonsterile environment. It is necessary to validate the results of
this study and others outside of the preterm human infant context. Murine models of antibiotic
use have been invaluable in informing microbiome research. Humanized gnotobiotic models in
particular have benefited the field greatly255,261,291, Development of a humanized infant mouse
model for preterm antibiotic therapy would allow for testing of clinical antibiotic protocols in a
controlled environment in order to discern their relative impacts on the developing gut
microbiota. Such analyses would build on the foundation laid by Gibson et al. to provide an
evidence-base supporting a personalized medicine approach to antibiotic treatment, wherein
antibiotic use in preterm infant populations will be tailored to limit collateral microbiota
disruptions and selection for resistance.

1.4 Scope of the thesis
Countering the public health crisis posed by antibiotic resistance requires, among other
aspects, a comprehensive understanding of the distribution of antibiotic resistance genes across
microbial communities, as well as a unified framework for comprehending the response of these
microbial communities to antibiotic perturbation. This entails identifying and characterizing
emerging resistance determinants that are not yet prevalent in the clinical setting anticipating
their ensuing dissemination under the strong selective pressure imposed by antibiotics. Such
early identification allows for proactive development of strategies to counter the eventual clinical
impact of pathogens bearing these resistance genes. An additional crucial component of
addressing antibiotic resistance in light of the pervasive use of antibiotics in the clinical,
agricultural, and industrial settings, is illuminating how microbial communities react to antibiotic
exposure. A particularly important microbial community is the human microbiota, which
mediates critical aspects of human health and disease144, is frequently exposed to therapeutic
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concentrations of antibiotics292, and is recognized as an important reservoir of resistance genes8.
Integration of these aims could advance our understanding of the factors governing the
emergence of antibiotic resistance through the lens of microbial ecology and evolution.
A crucial component of antibiotic resistance surveillance is the study of the resistome in
microbial communities across diverse habitats. A habitat that is particularly interesting is the
human gut, which houses a microbial community that is both critical to human health and
routinely exposed to antibiotics. Of particular interest is the gut microbiota of preterm infants,
who account for 12% of U.S. births and receive nearly universal and often extensive antibiotic
therapy. While the acute effects of antibiotics on the preterm infant gut microbiome are well
documented293, the long-term effects are not yet thoroughly understood. In Chapter 2, I seek
broadly to identify the long-term effects of antibiotic perturbation on microbial communities. To
this end, I conducted an integrative analysis of the gut microbiota of antibiotic treated extremely
and very premature infants over the first twenty months of life using a combination of shotgun
metagenomic sequencing, stool culturing and isolate sequencing, functional metagenomics, and
machine learning. In total, I sequenced nearly 1.2 Tb of metagenomic DNA from 444 stools
collected longitudinally from 58 infants to define a program of healthy microbiota assembly in
antibiotic naïve infants, and show acute but transient deviations from this program in antibiotic
treated preterm infants. By sequencing >500 isolates cultured, I demonstrate that antibiotic
treatment

selects

for

persistent

gastrointestinal

colonization

by

multidrug

resistant

Enterobacteriaceae in preterm infants. Likewise, I use functional metagenomics to reveal an
enriched gut antibiotic resistome and disrupted patterns of resistome development in preterm
infants compared to antibiotic naïve near term infants. Lastly, I develop a classifier which can
distinguish with high accuracy between antibiotic treated preterm infants and antibiotic naïve
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near term infants based on microbiota composition later in life, thus revealing a persistent and
possibly pathogenic metagenomic signature of early life antibiotic treatment in preterm infants.
A crucial component of addressing the growing clinical problem of antibiotic resistance
is the discovery and improved mechanistic understanding of novel antibiotic resistance
determinants in environmental bacteria at risk for acquisition by pathogens. In Chapters 3 and 4,
I explore an emerging mechanism of tetracycline inactivation using complementary
bioinformatic, microbiological, biochemical, and structural biology approaches. The work
described in these chapters will improve fundamental knowledge of the structure/mechanism
relationship of tetracycline inactivating enzymes with respect to catalysis and inhibition. Further,
this work addresses critical gaps in our understanding of the origins and evolution of an
emerging family of clinically-relevant tetracycline inactivating enzymes. While most tetracycline
resistance currently occurs by efflux or target (ribosomal) protection, we identified a family of
tetracycline inactivating enzymes through tetracycline and tigecycline selections of soil and gut
metagenomes29. I show that these genes are more widespread than previously thought in both gut
and environmental microbial communities. Using a combination of biochemistry and structural
biology, I characterize the mechanism of action of these enzymes, advancing our understanding
of tetracycline resistance by inactivation and flavoenzyme biology more broadly. I identify an
inhibitor of these enzymes that is sufficient to prevent tetracycline degradation and restore
antibiotic efficacy in the face of these resistance enzymes294. Lastly, I sequence and characterize
a Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Pakistan bearing a gene 100%
nucleotide identity to a gene first identified in our functional selections. I show that this gene is
responsible for tetracycline resistance in this isolate, thus signaling the clinical arrival of this
tetracycline resistance by inactivation in the clinical setting.
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This body of work contributes substantially to the fields of microbiology, antibiotics, and
resistance. The identification of enduring effects of antibiotics on the gut microbiota has promise
to inform antibiotic treatment regimens in vulnerable population such as preterm infants such
that infections are effectively treated while lasting collateral damage to the microbiota is
minimized. Additionally, consideration of adverse effects of antibiotics during infection
management will improve antibiotic stewardship in intensive care unit settings. My work on
emerging tetracycline resistance by inactivation has expanded our understanding of the
principles governing dissemination of antibiotic resistance from environmental to clinical
settings. Furthermore, the identification of environmental resistance genes prior to their clinical
emergence and proactive development of strategies (e.g. inhibitor coadministration) to counter
their eventual impact is a paradigm broadly applicable to the antimicrobial development space
that will enable sustainable development and deployment of our antibiotic arsenal.
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Chapter 2: Persistent metagenomic
signatures of early life antibiotic treatment in
the infant gut microbiota and resistome
2.1 Introduction
2.1.1 Abstract
Because hospitalized preterm infants are vulnerable to infection, they receive frequent
and often prolonged exposures to antibiotic therapy. It is not known if the short-term effects of
antibiotics on the preterm infant gut microbiota and resistome persist after discharge from
neonatal intensive care units. Here, we use complementary metagenomic, culture based, and
machine learning techniques to interrogate the gut microbiota and resistome of antibioticexposed preterm infants during, and after, hospitalization, and compare these readouts to
antibiotic-naïve healthy infants sampled synchronously. We find a persistently enriched
gastrointestinal

antibiotic

resistome,

prolonged

carriage

of

multidrug

resistant

Enterobacteriaceae, and distinct antibiotic-driven patterns of microbiota and resistome assembly
in extremely preterm infants who received early life antibiotics. Our results demonstrate lasting
collateral damage of early life antibiotic treatment and hospitalization in preterm infants and urge
alternative strategies for infection management in highly vulnerable neonatal populations.

2.1.2 Introduction
Gut microbes play important roles in host health and disease throughout life, and are
particularly important in infancy295. During this period, gut microbes exclude pathogens,
synthesize vitamins and amino acids, and promote immune system maturation295. Infant gut
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microbiota assembly accelerates in the first months of life, following inoculation by organisms
from mothers and the environment296, but stabilizes by approximately three years of age248.
Antibiotics

in

this

interval

may

disproportionately

damage

the

host-microbiota

ecosystem248,255,282. Indeed, emerging data suggest that early-life gut microbial alterations
correlate with a variety of chronic metabolic and immune disorders in childhood and later
life255,263-265,295,297-304,

including

allergies305,

psoriasis306,

adiposity307,

diabetes308

and

inflammatory bowel disease309-311. For most of these disorders, a causal link between antibioticmediated microbiota disruption and onset of pathology is lacking. However, antibiotics have
been linked to permanent immune alterations306,312 and inflammatory bowel disease in later
childhood311, highlighting the damaging long-term potential of early life antibiotic treatment.
Over 11% of live births worldwide occur preterm313, and preterm birth and its sequelae
are prominent causes of childhood morbidity and mortality worldwide314. Because bacterial
infections are serious and frequent complications of preterm birth315, nearly all infants in
neonatal intensive care units (NICUs) receive antibiotics269. We have shown that severe, acute
perturbation of the preterm infant gut microbiota immediately following antibiotic treatment is
characterized by decreased alpha diversity, increased abundance of Enterobacteriaceae, and
antibiotic-specific enrichment of antibiotic resistance genes (ARGs) and multidrug resistant
organisms (MDROs)7. Because microbiota perturbation during early life is hypothesized to be
disproportionately damaging272,316, it is imperative to study the lasting effects of antibiotics on
the preterm infant gut microbiota. Prior studies of preterm infants report gut microbiota recovery
concomitant with NICU discharge286,317,318. However, a shortcoming of these studies is their
reliance on exclusively culture based or amplicon sequencing (e.g. 16S rRNA) based analysis,
which are limited in resolution and focus only on taxa present in the microbiota rather than the
65

functions collectively encoded by those taxa. Here, we analyze ~ 1.2 terabases of metagenomic
DNA, culture and sequence 500 bacterial isolates, and functionally select an additional 300
gigabases of metagenomic DNA for expressed antibiotic resistance, to investigate thoroughly
and in high resolution the long-term consequences of antibiotic treatment on the preterm infant
gut microbiota.

2.2 Results
2.2.1 Metagenomics based analysis of effect of antibiotics on the preterm
infant gut microbiota
To understand the lasting effects of early life antibiotics on infant gut bacterial
communities, we whole metagenome shotgun sequenced 444 fecal metagenome samples from 58
infants over the first 21 months of their life (1.18 terabases metagenomic DNA; Supplementary
Fig. 2.3; see Methods). Our cohort included 41 preterm infants sampled while they resided in the
NICU and following discharge to home. One subset of this cohort (n=9) received scant antibiotic
therapy in their neonatal period or subsequently (total duration of antibiotic therapy < 7 days).
The remaining 32 preterm infants received 255 total additional courses of antibiotics over the
first 21 months of life (median (interquartile range (IQR)) 29.5 days (41.6, 68.3 days) antibiotic
therapy). All infants in this cohort were classified as being born very or extremely preterm
(median (IQR) gestational age at birth of 26 weeks (25, 27 weeks)) and had extremely or very
low birth weights (median (IQR) 840 g (770, 960 g)). Additionally, 17 antibiotic-naïve, healthy
early term319 or late preterm320 (median (IQR) gestational age at birth 36 weeks (36, 37 weeks);
hereafter referred to as “near term”) infants of the same chronological age range, sampled
synchronously with the preterm cohort, were included to serve as controls for healthy microbiota
development.
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Table 2.1. Clinical characteristics of infant cohorts analyzed in this study
Preterm Early
Antibiotic
Exposure Only
(N=9)

Birth weight, g, median (IQR)
Gestational age at birth, weeks,
median (IQR)
Gender, M/F
Route of delivery, Csection/vaginal
Antibiotic exposure, n courses
Gentamicin
Ampicillin
Vancomycin
Clindamycin
Meropenem
Cefepime
Cefotaxime
Mupirocin
Trimethoprim-sulfamethoxazole
Ticarcillin-clavulanate
Oxacillin
Cefoxitin
Cefazolin
Amoxicillin
Metronidazole
Penicillin G
Bacterial culture positive, n
Blood
Tracheal
Urine

Preterm Early +
Near Term
Subsequent
Antibiotic-Naïve
Antibiotic
Infants
Exposure
(N=17)
(N=32)
1080 (880, 1270) 830 (698.75, 897.5) 2529 (2359.5, 2966.5)
27 (26, 27)

25 (24, 26)

36 (36,37)

4/5

15/17

6/3

25/7

4/13
15/2

9
9
none
none
none
none
none
none
none
none
none
none
none
none
none
none

74
37
67
16
14
11
10
7
4
3
3
3
2
2
1
1

none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none

0
0
0

22
30
17

0
0
0

We inferred bacterial taxonomic composition from shotgun metagenomic data using
MetaPhlAn 2.0280. Across all infants, Shannon diversity increased during an apparent
developmental phase before stabilizing (Fig. 2.1a). Near term infant microbiota Shannon
diversity increased rapidly in the first month of life before reaching a plateau, while preterm
infant microbiota diversity increased more gradually and with greater variation (Fig. 2.1a). At the
family level, Enterobacteriaceae and Enterococcaceae dominated the preterm infant gut
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microbiota in the first months of life. In contrast, early colonization by Enterobacteriaceae in
near term infants precedes robust colonization with Bifidobaccteriaceae (Fig. 2.1b). Notably,
there is a near absence of Enterococcaceae early in life (<4 months chronological age) in the
near term infants, and a similar absence of Prevotellaceae later (>8 months chronological age) in
preterm infants. In contrast, we observed predicted microbiota functional stability both over time
and between groups (Fig. 2.1c), as inferred by HUMAnN2278.
Low gut microbiota diversity is associated with adverse health outcomes in infancy321-323,
childhood282, and adulthood324. To identify clinical features of our cohort that were associated
with microbiota diversity, we regressed Shannon diversity on clinical variables including
antibiotic treatment (Methods) using a generalized linear mixed model with subject defined as
individual effect to control for repeated samplings. All variables were included in initial
modeling, and a final model was fit by backwards elimination of variables. Following correction
for multiple comparisons, day of life was significantly associated with increased Shannon
diversity (p<0.001), while a recent (within 30 days of sample collection) course of vancomycin
(p<0.001), ampicillin (p<0.001), meropenem (p=0.009), or cefepime (p=0.012) was significantly
associated with decreased species richness (Fig. 2.1d). In this sparse model, 57% of the variance
in Shannon diversity was explained by the fixed effects (day of life and antibiotic treatments)
alone, while an additional 12% of the variance was explained by subject. Across all infants in our
cohort through the first 110 days of life, Shannon diversity of the microbiota was significantly
lower in infants who received >1 course of antibiotics in the prior month (Fig. 2.1e). Thus, recent
antibiotic treatment appears to be a major driver of microbiota diversity early in life.
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Figure 2.1: Clinical variables including antibiotic exposure predict microbiota diversity.
(a) Shannon diversity of all near term (n=17) and preterm (n=41) infants in this study, by month
of life. (b,c) Microbiota species and functional composition of all near term (n=17) and preterm
(n=41) infants in this study, by month. (d) Day of life is significantly associated with an
increased microbial Shannon diversity, while vancomycin, ampicillin, meropenem, or cefepime
treatment within the month prior to sampling is associated with significantly decreased species
richness (***, p<0.001, ** p<0.01, * p<0.05; GLMM with subject as random effect). Oxacillin
was included in the model but its association with diversity was not significant after correction
for multiple comparisons. Error bars indicate s.e. (e) Shannon diversity is significantly lower in
infants who have received >1 course of antibiotic treatment in the past month compared to
infants who had not received antibiotic treatment during that time span (**** p<0.0001, ***,
p<0.001, ** p<0.01, * p<0.05; Wilcoxon with Benjamani-Hochberg correction).

2.2.2 Partial microbiota recovery following NICU discharge
While the taxonomic composition of the preterm infant microbiota clustered by both
gestational age at birth and antibiotic treatment status (Adonis, p<0.001, Bray–Curtis),
chronological age was a major driver of microbiota composition across all infants248,250,286 (Fig.
2.2a). We hypothesized that after early-life antibiotic-induced perturbation7, the gross
composition of the preterm microbiota will converge towards the profile of the microbiota of
age-matched healthy, antibiotic naïve, near term infants within the first 21 months of life, but
that potentially pathological microbiota ‘scars’ from this early-life disruption (e.g., enriched
ARGs and MDROs) persist.
To identify and then quantify the extent of this antibiotic induced perturbation, we used a
random forests algorithm to regress the relative abundances of species present in the microbiota
of infants against their chronological age as previously described251. Because of the
nonparametric assumptions of random forests325, the algorithm detects both linear and nonlinear
relationships between species in the microbiota and age, thus identifying taxa that distinguish
different developmental periods in infancy. By assessing model performance with sequentially
fewer predictors, we determined that 50 was the minimum number of variables required for
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Figure 2.2 Partial architectural recovery of preterm infant gut microbiota following
discharge from NICU. (a) Microbiota composition is distinct between near term infants,
preterm infants with early only antibiotic treatment, and preterm infants with early and
subsequent antibiotic treatment (Bray-Curtis, p<0.001, Adonis), but chronological age is a major
driver of microbiota composition. (b) Fivefold cross-validation indicates that 50 variables are
sufficient for random forests prediction of chronological age of near term infants based on
microbiota composition. Error bars indicate s.e. (c) The 50 most informative predictors to the
random forests model, determined over 100 iterations of the model. These species were included
in a sparse model. Error bars indicate s.e. (d) The sparse random forests model is a good
predictor of near term infant chronological age, but preterm infant chronological age is predicted
to be less than actual age across numerous stages of development. Curves are loess regression fit
to each group. (e) Preterm infant microbiota for age Z-score (MAZ) is significantly lower than
that of near term infants in the first month of life, indicating early microbiota immaturity (**
p<0.01, **** p<0.0001). (f) Preterm infant MAZ is statistically indistinguishable from near term
infant by 12-15 months of life, indicating resolution of microbiota immaturity by this time point.
71

accurate prediction of age (Fig. 2.2b). Hence, we trained a sparse model comprised of the 50
most informative predictors (taxa) on the antibiotic naïve, near term infant subset in order to
model healthy microbiota development, and subsequently refined and validated the model (see
Methods). The top age discriminatory taxa in the gut microbiota of antibiotic naïve, near term
infants were Faecalibacterium prausnitzii, Subdoligranulum sp., Ruminococcus gnavus, and
Oscillobacter sp. (Fig. 2.2c). We used this sparse model to predict the chronological age of an
infant using only the relative abundance of these 50 species. This prediction, or ‘microbiota age,’
provides an approximation of the relative maturity of a microbial community251. We observed a
linear relationship between the chronological and microbiota ages of antibiotic naïve, near term
infants, suggesting that the model accurately predicts near term infant microbiota age. For
preterm infants, however, our model predicted microbiota ages that were younger than
chronological age across several stages of development, indicating that disruption of microbiota
development occurs in these infants. To better quantify the extent of disruption, we computed a
microbiota for age Z-score (MAZ) for each metagenome, as previously described251. Preterm
infants who receive early-only or early-plus-subsequent antibiotic treatment have significantly
lower MAZs than do infants born near term gestation as measured in the first months of life (Fig.
2.2e). However, by months 12-15 of life following discharge from the NICU, the MAZs of
hospitalized preterm infants closely resemble those of healthy, antibiotic naïve, near term infants
(Fig. 2.2f). Thus, despite apparent transient early life delays in the development of the preterm
infant gut microbiota, the bacterial taxonomic composition converges on common structures with
those of healthy, antibiotic naïve, infants within the first 21 months of life (Fig. 2.2d).

2.2.3 Antibiotic resistome of preterm infant gut microbiota
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To characterize the antibiotic resistome encoded in the gut microbiota of our infant
cohort, we first conducted a high throughput functional metagenomic analysis4 of 217 preterm
and near term infant stools, selected to represent the diversity in gestational age at birth,
chronological age, and antibiotic treatment history in our cohort. We constructed 22 functional
metagenomic libraries by pooling metagenomic DNA from 9-10 stools per library, encompassing
396 gigabase pairs (Gb) of metagenomic DNA with an average library size of 18 Gb
(Supplementary Fig. 2.4; see Methods) and an average insert size of 2-3 kilobase pairs (kb). We
selected libraries on sixteen antibiotics relevant to neonatal and pediatric populations
(Supplementary Table 2.2) and recovered resistant transformants for each antibiotic except
meropenem (Supplementary Fig. 2.4). Alarmingly, we found that the infant gut metagenome
encoded transferrable resistance even to antibiotics rarely or never used in neonates, such as
ciprofloxacin and chloramphenicol, and those that represent last lines of defense against
MDROs, such as tigecycline and colistin. Interestingly, only one of eight libraries constructed
from stools of antibiotic naïve, near term infants encoded ciprofloxacin resistance (mediated by
loci other than gyrA or parC), compared to six of fourteen libraries constructed from preterm
infant stools. This observation, viewed in light of the scarce use of ciprofloxacin in neonates269,
suggests that acquired (as opposed to intrinsic) ciprofloxacin resistance occurs naturally in
preterm infant gut bacterial communities, or that organisms resistant to ciprofloxacin may be coselected by other antibiotics to which they are resistant.
We sequenced resistance-conferring inserts and assembled 874 unique, functionally
identified ARGs. The median identity of functionally selected ARGs to sequences in the NCBI
non-redundant protein database (retrieved May 21, 2018) was 94.4%, while their median identity
to the Comprehensive Antibiotic Resistance Database (CARD, version 1.2.1, retrieved January
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Figure 2.3: Preterm infants harbor an enriched gut resistome. (a) Amino acid identity
between all functionally selected ARGs and their top hit in CARD vs their top hit in the NCBI nr
protein database, colored by class of antibiotic used for selection. Notably, ARGs recovered by
fluoroquinolone and polymyxin selection have very low median identity to CARD. (b) The most
commonly predicted hosts of functionally selected ARGs based on highest identity BLAST hit in
the NCBI nr protein database. (c) Gut resistome composition is distinct between near term
infants, preterm infants with early only antibiotic treatment, and preterm infants with early and
subsequent antibiotic treatment (Bray-Curtis, p<0.001, Adonis). (d) Preterm infants had fewer
unique ARGs encoded in their gut metagenomes than near term infants. (* p<0.05, ** p<0.01
Wilcoxon). (e) The cumulative resistome relative abundance was significantly higher in the gut
microbiota of preterm infants with early and subsequent antibiotic treatment compared to both
preterm infants with only early antibiotic treatment and near term infants (* p<0.05, Wilcoxon).
(f) A random forests model trained on near term gut resistome poorly predicts chronological age
of near term infants, suggesting distinct patterns of resistome assembly based on gestational age
at birth and antibiotic treatment status. (g) The programmed assembly of the gut resistome in
preterm infants differs from that of near term infants in prolonged carriage of some ARGs,
delayed acquisition of others, and differences in the relative abundance of ARGs in the gut.
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24, 2018)
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was 32.0% (Fig. 2.3a). Hence, while the resistance determinants discovered in our

functional selections have largely been previously sequenced, in most cases they have not yet
been assigned resistance functions, as we have previously noted7. The predicted sources of
resistance conferring ORFs (determined by best BLAST hit to the NCBI non-redundant protein
database) were predominantly uncultured bacteria or Enterobacteriaceae (Fig. 2.3b). The
identification of Enterobacteriaceae as the likely hosts of ARGs in the infant gut microbiota is
consistent with prior studies7 and current understanding of Enterobacteriaceae as prolific hosts
and traffickers of ARGs327-329. Additionally, the identification of uncultured (189 ORFs) and
unclassified (24 ORFs) bacteria as sources of ARGs highlights the value of functional
metagenomics as a culture- and sequence-unbiased method for characterizing resistomes330.
To extend our resistome analysis to all samples in our cohort, we used ShortBRED235 to
quantify translated ARG abundance in all sequenced metagenomes using a custom database that
included canonical ARGs in CARD as well as the functionally selected ARGs identified here
(see Methods). Resistomes clustered according to gestational age at birth and antibiotic treatment
status (Fig. 2.3c, p<0.001, Adonis). The gut metagenomes of preterm infants encoded fewer
unique ARGs than those of near term infants (p<0.01, Wilcoxon, Fig. 2.3d). However, the
cumulative resistome relative abundance was significantly higher in the gut microbiota of
preterm infants with early-plus-subsequent antibiotic treatment compared to preterm infants with
early-only antibiotic treatment and with antibiotic naïve, near term infants (p<0.05, Wilcoxon,
Fig. 2.3e). There was a weak inverse correlation between alpha diversity and cumulative
resistome burden across all metagenomes (R2=0.09, Supplementary Fig. 2.6a), indicating that
microbiota with an enriched resistome are dominated by a few samples. Indeed, in 41 of the 54
metagenomes with a cumulative resistome of reads per kilobase per million mapped reads
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(RPKM) > 5000, a single species comprised > 50% of microbiota relative abundance. In 25 of
these samples, the dominant species was E. coli (Supplementary Fig. 2.6b). Other dominant
species were Enterococcus faecalis (n=5), Klebsiella pneumoniae (n=2), Staphylococcus
epidermidis (n=2), Enterobacter aerogenes (n=2), Bifidobacterium breve (n=2), Pseudomonas
aeruginosa, Bifidobacterium longum and Citrobacter koseri (n=1, each). Thus, it appears that
extreme prematurity, associated hospitalization, and antibiotic treatment select for one or two
MDROs that dominate the infant gut microbiota rather than enriching for a greater diversity of
resistant organisms and selecting for a diverse resistome.
To define the developmental progression of the infant gastrointestinal resistome over the
first months of life, we regressed the abundance of ARGs (in RPKM) in a subset of antibiotic
naïve, near term infant gut metagenomes (as determined by ShortBRED) against the day of life
for these infants using random forests325. Fivefold cross-validation indicated that 50 predictors
were sufficient for optimal model performance, so we constructed a sparse model using the 50
most informative ARGs. The sparse model was subsequently applied to preterm samples to
predict the apparent ‘resistome age.’ A clear developmental trajectory based on these 50 ARGs
was evident in near term infants (Fig. 2.3g). The developmental trajectory of the preterm infant
gut resistome deviates from that of the antibiotic naïve, near term infants in prolonged carriage of
some ARGs (e.g., oqxA, oqxB, catI, fosA5, cdeA), near absence of others (e.g., abeM), and a
general increase in the normalized abundance of these genes in the gut across all timepoints (Fig.
2.3g). Overall, we found that the model only modestly predicted the chronological age of
preterm infants (R2 = 0.62, Fig. 2.3f), suggesting that there are distinct patterns of resistome
development based on antibiotic treatment status and gestational age at birth.
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Highlighting the potential for lateral ARG exchange within the infant microbiome, 225
contigs (6.4% of all contigs) recovered in functional selections encoded a putative mobile genetic
element (Supplementary Fig. 2.5a-e). Mobile genetic elements were most commonly observed in
tetracycline selections (Supplementary Fig. 2.5f), but were also commonly observed in β-lactam,
chloramphenicol, gentamicin, and ciprofloxacin selections. We observed an enrichment for
mobile genetic elements on amoxicillin/clavulanate (p<0.01, hypergeometric test), tetracycline
(p<0.01, hypergeometric test), and gentamicin (p<0.001, hypergeometric test). The synteny of
functionally selected ARGs with mobile genetic elements provides evidence for a potentially
mobile resistome in the infant gut microbiota.

2.2.4 Persistence of multidrug resistant Enterobacteriaceae in the preterm
infant gut microbiota
Whole metagenome shotgun sequencing is a powerful method for describing gross
microbiota composition and function, but it is less able to elucidate strain level variation. The gut
has been established as an early reservoir of bacteria that cause late onset bloodstream infections
in neonates274 and is dominated by multidrug resistant Proteobacteria7, but the extent to which
these early colonizing strains persist in the infant gut microbiota is not well understood. We
reasoned that early life antibiotic treatment in preterm infants might create a gastrointestinal
niche for such Proteobacteria that is not relinquished even after discharge from the NICU. To
better understand the persistence of specific bacterial strains in the microbiota of infants in our
cohort, we cultured pairs of stools collected 8-10 months apart from 15 infants (nine preterm and
six near term) on a series of selective agars (see Methods). We optimized culture conditions to
isolate opportunistic extraintestinal pathogens known to be highly prevalent and abundant in the
preterm infant gut microbiota as well as those that are frequently multidrug resistant. In total, we
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cultured 530 isolates from these 30 samples. We performed whole genome sequencing,
assembly, and annotation of 277 isolates from the preterm set and 253 isolates from the near
term set.
The species most frequently isolated by this direct antibiotic selection were E. coli
(n=139), K. pneumoniae (n=62), E. faecalis (n=50), Enterobacter cloacae (n=42), E. faecium
(n=22), C. freundii (n=15), and K. oxytoca (n=14). We identified persistence of nearly identical
strains of E. coli, E, cloacae, and K. variicola in samples collected from infants both while in the
NICU and 8-10 months following discharge (Fig. 2.4g). Among the persistent isolates recovered
from infants born prematurely were strains of E. coli ST405 and E. cloacae ST108 (classified by
in silico multilocus sequence typing (MLST)), both of which are high-risk international lineages,
with demonstrated propensity for harboring extended-spectrum β-lactamases (ESBLs) and the
NDM-family carbapenemases331-333. Each of the E. coli strains encoded a TEM-1 β-lactamase as
well as an aac(3)-IId aminoglycoside acetyltransferase with predicted resistance to
aminoglycosides, and each of the E. cloacae strains encoded an AmpC type β-lactamase. The K.
variicola strains each encoded oqxAB, the RND-type multidrug efflux pump334, and the
chromosomal Klebsiella β-lactamase blaOKP-B-1335. The isolation of nearly identical (average
nucleotide identity (ANI) >99.997%) multidrug resistant Enterobacteriaceae from the gut while
infants are in the NICU and then again many months later after discharge provides evidence for
an enduring and transmissible pathological microbiome “scar” associated with preterm birth,
early life hospitalization, and antibiotic treatment.
Because Enterococcus species are highly prevalent and abundant in the preterm infant
gut7, often multidrug resistant336, and cause nosocomial blood stream infections in preterm
infants337, we investigated the resistance and virulence phenotypes of these strains. A particular
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Figure 2.4: Multidrug resistant Enterobacteriaceae lineages persist in preterm infant gut
microbiota. Maximum likelihood core genome phylogenies of E. coli (a), Klebsiella spp. (c),
and E. cloacae (e) isolated from infant stool. Annotations to the right of metadata indicate
timepoints of isolation and sequence type (determined by in silico MLST) for E. coli and E.
cloacae or species for Klebsiella. Persistent isolates are highlighted in red. Average nucleotide
identity heat maps for E. coli (b), Klebsiella spp. (e), and E. cloacae (f) indicate that persistent
isolates are isogenic, i.e., they share >99.997% nucleotide identity. (g) Timeline of isolation of
persistent Enterobacteriaceae from infant stool.
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concern among neonatal populations is vancomycin resistant Enterococci (VRE)338. Of the 15
unique Enterococcus strains we isolated, ten were E. faecalis and five were E. faecium
(Supplementary Fig. 2.7a). Each E. faecalis isolate was susceptible to vancomycin, while two E.
faecium isolates were resistant to vancomycin339. However, no E. faecium strain formed a
biofilm, while four of the E. faecalis strains formed robust biofilms at room temperature and an
additional six formed biofilms at 37˚C (Supplementary Fig. 2.7b). Interestingly, all strains that
formed biofilms were isolated from preterm infant stools. This is consistent with the prevailing
understanding that early colonizers of the preterm infant gut are largely surface adapted strains
that are prevalent in the NICU environment279. Concurringly, E. faecalis that form biofilms,
while susceptible to vancomycin when planktonic, were resistant to this antibiotic when in
biofilms (Supplementary Fig. 2.7c). Thus, despite the apparent tradeoff between vancomycin
resistance and biofilm formation observed among Enterococcus strains, nearly all have evolved
strategies for surviving vancomycin exposure. This finding is disturbing because of the
widespread usage of vancomycin (Table 2.1) and high prevalence of Enterococcus colonization
(Fig. 2.1b) in NICUs.

2.2.5 Persistent metagenomic signature of antibiotic treatment in premature
infants
To understand if there are persistent effects of prematurity, hospitalization, and early life
antibiotic treatment on gut microbial content and function, we sought to identify metagenomic
features that distinguish post-NICU discharge samples in preterm infants from age-matched
samples from antibiotic naïve, near term infants. We used a supervised learning approach to
classify samples as originating from a hospitalized preterm infant (including both early-only and
early-plus-subsequent antibiotic treatment groups) or an antibiotic-naïve near term infant
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Figure 2.5: Enduring damage to the preterm infant gut microbiota. (a)
Support vector machine confusion matrix for classification of gestational age
based on the species, metabolic pathways, and ARGs present in the microbiota
following discharge from the NICU or at matched timepoints in nonhospitalized
near term infants. (b) Twenty predictors most important to classification. A sparse
model trained using only these twenty predictors was highly accurate (96.4%
classification accuracy), a persistent metagenomic signature of preterm birth and
associated hospitalization and antibiotic treatment.
residing at home, based on the relative abundance of bacterial taxa and ARGs in their gut
microbiota. Using a support vector machine, we identified the fifteen most informative features
and constructed a sparse model consisting of only these variables, which correctly classified all
preterm samples and misclassified only two near term samples (96.4% accuracy, Fig. 2.5a). Of
the fifteen variables most important to model performance, six were ARGs and nine were
bacterial taxa (Fig. 2.5b). The ARGs important to classification were the class A β-lactamase
cfxA6340, and three and two genes functionally selected on piperacillin and tetracycline,
respectively. The highest identity BLAST hit of four of the functionally selected ARGs was an
ABC transporter, while the other was a MATE family efflux transporter. The predictive species
were primarily members of the order Clostridiales (Eubacterium rectale, Ruminococcus obeum,
R. lactaris, Dorea formicigenerans, E. ventriosum, E. ramulus, and E. eligens) and Bacteroidales
(Prevotella copri, Barnesiella intestinihominis). Our model identified with high accuracy if a
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preterm infant was hospitalized and received early life antibiotic treatment based on the
taxonomic and functional microbiota composition following discharge from the NICU despite
the apparent recovery observed at a gross architectural level.

2.3 Materials and Methods
2.3.1 Sample and metadata collection
All samples and patient metadata used in this study were collected as part of the Neonatal
Microbiome and Necrotizing Enterocolitis Study (P.I.T., P.I.) or the St. Louis Neonatal
Microbiome Initiative (B.B.W., P.I.) at Washington University in St. Louis School of Medicine
and approved by the Human Research Protection Office (approval numbers 201105492 and
201104267, respectively). Samples were obtained from infants after parents provided informed
consent. We stratified our cohort by antibiotic exposure and gestational age at birth, with a
subset of individuals with early antibiotic exposure only (N=9) with no antibiotic exposure
outside the first week of life, a subset of individuals with early and subsequent antibiotic
exposure (N=32), and a subset of late preterm or early term infants (N=17) who were not
hospitalized and were antibiotic naïve over the first months of life (Table 2.1). All stools
produced were collected and stored as previously described 249,341. In total, 444 samples collected
longitudinally from 58 infants were shotgun sequenced and included in all metagenomic
analysis.

2.3.2 Metagenomic DNA extraction
Metagenomic DNA was extracted from approximately 100 mg of stool samples using the
PowerSoil DNA Isolation Kit (MoBio Laboratories) following the manufacturer’s protocol with
the following modification: samples were lysed by two rounds of two minutes of bead beating at
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2.5k oscillations per minute for 2 minutes followed by 1 minute on ice and 2 additional minutes
of beadbeating using a Mini-Beadbeater-24 (Biospec Products). DNA was quantified using a
Qubit fluorometer dsDNA BR Assay (Invitrogen) and stored at -20˚C.

2.3.3 Metagenomic sequencing library preparation
Metagenomic DNA was diluted to a concentration of 0.5 ng/µL prior to sequencing library
preparation. Libraries were prepared using a Nextera DNA Library Prep Kit (Illumina) following
the modifications described in Baym et al, 2015342. Libraries were purified using the Agencourt
AMPure XP system (Beckman Coulter) and quantified using the Quant-iT PicoGreen dsDNA
assay (Invitrogen). For each sequencing lane, 10 nM of approximately 96 samples were pooled
three independent times. These pools were quantified using the Qubit dsDNA BR Assay and
combined in an equimolar fashion. Samples were submitted for 2×150 bp paired-end sequencing
on an Illumina NextSeq High-Output platform at the Center for Genome Sciences and Systems
Biology at Washington University in St. Louis with a target sequencing depth of 2.5 million
reads per sample.

2.3.4 Rarefaction analysis
To determine the appropriate sequencing depth necessary to fully characterize infant gut
microbiota composition and function, 17 representative metagenomes that were sequenced most
deeply were subsampled at the following read depths: 8000000, 7000000, 6000000, 5000000,
4000000, 3000000, 2000000, 1000000, 100000, and 10000. Subsampled metagenomes were
profiled using MetaPhlAn 2.0280 to determine species richness at each depth.
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2.3.5 Metagenome profiling
Prior to all downstream analysis, Illumina paired-end reads were binned by index sequence.
Adapter and index sequences were trimmed and sequences were quality filtered using
Trimmomatic v0.36343 using the following parameters: java -Xms2048m -Xmx2048m -jar
trimmomatic-0.33.jar

PE

-phred33

ILLUMINACLIP:

NexteraPE-PE.fa:2:30:10:1:true

SLIDINGWINDOW:6:10 LEADING:13 TRAILING:13 MINLEN:36. Relative abundance of
species was calculated using MetaPhlAn 2.0204 (repository tag 2.2.0). Relative abundance tables
were merged using the merge_metaphlan_tables.py script. Abundance of metabolic pathways
was determined using HUMAnN2. Raw count values were normalized for sequencing depth,
collapsed by ontology, and tables were merged using the humann2_renorm_table,
humann2_regroup_table, and humann2_join_tables utility scripts278.

2.3.6 Construction of metagenomic libraries from infant gut samples for
functional selection
Approximately 5 µg purified extracted total metagenomic DNA was used as starting material for
metagenomic library construction. To create small-insert metagenomic libraries, DNA was
sheared to a target size of 3,000bp using the Covaris E210 sonicator following manufacturer’s
recommended

settings

(http://covarisinc.com/wp-content/uploads/pn_400069.pdf).

Sheared

DNA was concentrated by QIAquick PCR Purification Kit (Qiagen) and eluted in 30 μl
nuclease-free H2O. Then the purified DNA was size-selected by using BluePippin instrument
(Sage Science) to a range of 1000-6000 bp DNA fragment through a premade 0.75% Pippin gel
cassette. Size selected DNA was then end-repaired using the End-It DNA End Repair kit
(Epicentre) with the following protocol:
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(1) Mix the following in a 50 μl reaction volume: 30 μl of purified DNA, 5 μl dNTP mix (2.5
mM), 5 μl 10X End-Repair buffer, 1 μl End-Repair Enzyme Mix and 4 μl nuclease-free
H2O.
(2) Mix gently and incubate at room temperature for 45 min.
(3) Heat-inactivate the reaction at 70°C for 15 min.
End-repaired DNA was then purified using the QIAquick PCR purification kit (Qiagen) and
quantified using the Qubit fluorometer BR assay kit (Life Technologies) and ligated into the
pZE21-MCS-1 vector at the HincII site. The pZE21 vector was linearized at the HINCII site
using inverse PCR with PFX DNA polymerase (Life Technologies):
(1) Mix the following in a 50 μl reaction volume: 10 μl of 10X PFX reaction buffer, 1.5 μl of
10 mM dNTP mix (New England Biolabs), 1 μl of 50 mM MgSO4, 5 μl of PFX enhancer
solution, 1 μl of 100 pg μl 21 circular pZE21, 0.4 μl of PFX DNA polymerase, 0.75 μl
forward primer (5’ GAC GGT ATC GAT AAG CTT GAT 3’), 0.75 μl reverse primer (5’
GAC CTC GAG GGG GGG 3’) and 29.6 μl of nuclease free H2O to a final volume of 50
μl.
(2) PCR cycle temperature as follows: 95°C for 5 min, then 35 cycles of [95°C for 45 s, 55°C
for 45 s, 72°C for 2.5 min], then 72°C for 5 min.
Linearized pZE21 was size-selected (~2,200bp) on a 1% low melting point agarose gel (0.5X
TBE) stained with GelGreen dye (Biotium) and purified by QIAquick Gel Extraction Kit
(Qiagen). Pure vector was dephosphorylated using calf intestinal alkaline phosphatase (CIP, New
England BioLabs) by adding 1/10th reaction volume of CIP, 1/10th reaction volume of New
England BioLabs Buffer 3, and nuclease-free H2O to the vector elute and incubating at 37°C
overnight before heat inactivation from 15 min at 70°C. End-repaired metagenomic DNA and
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linearized vector were ligated together using the Fast-Link Ligation Kit (Epicentre) at a 5:1 ratio
of insert:vector using the following protocol:
(1) Mix the following in a 15 μl reaction volume: 1.5 μl 10X Fast-Link buffer, 0.75 μl ATP
(10 mM), 1 μl FastLink DNA ligase (2 U/μl), 5:1 ratio of metagenomic DNA to vector,
and nuclease-free H2O to final reaction volume.
(2) Incubate at room temperature overnight.
(3) Heat inactivate for 15 min at 70°C.
After heat inactivation, ligation reactions were dialyzed for 30 min using a 0.025 um cellulose
membrane (Millipore catalogue number VSWP09025) and the full reaction volume used for
transformation by electroporation into 25 μl E. coli MegaX (Invitrogen) according to the
manufacturer’s recommendations. Cells were recovered in 1 ml Recovery Medium (Invitrogen)
at 37°C for one hour. Libraries were titered by plating out 0.1 μl and 0.01 μl of recovered cells
onto Luria–Bertani (LB) agar plates containing 50 μg/ml kanamycin. For each library, insert size
distribution was estimated by gel electrophoresis of PCR products obtained by amplifying the
insert from 36 randomly picked clones using primers flanking the HincII site of the multiple
cloning site of the pZE21 MCS1 vector (which contains a selectable marker for kanamycin
resistance). The average insert size across all libraries was determined to be 3 kb, and library size
estimates were calculated by multiplying the average PCR-based insert size by the number of
titered colony forming units (CFUs) after transformation recovery. The rest of the recovered cells
were inoculated into 50 ml of LB containing 50 μg/ml kanamycin and grown overnight. The
overnight culture was frozen with 15% glycerol and stored at -80°C for subsequent screening.
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2.3.7 Functional selections for antibiotic resistance
Each metagenomic library was selected for resistance to each of 16 antibiotics (at concentrations
listed in Supplementary Table 2.2 plus 50 μg/ml kanamycin for plasmid library maintenance)
was performed using LB agar. Of note, as our library host, E. coli, is intrinsically resistant to
vancomycin, we are unable to functionally screen for loci conferring resistance to this antibiotic.
Further, the use of kanamycin as the selective marker for the metagenomic plasmid library
results in low-level cross-resistance with other aminoglycoside antibiotics, resulting in a higher
required minimum inhibitory concentration for gentamicin. For each metagenomic library, the
number of cells plated on each antibiotic selection represented 10x the number of unique CFUs
in the library, as determined by titers during library creation. Depending on the titer of live cells
following library amplification and storage, the appropriate volume of freezer stocks were either
diluted to 100 μl using MH broth + 50 μg/ml kanamycin or centrifuged and reconstituted in this
volume for plating. After plating (using sterile glass beads), antibiotic selections were incubated
at 37°C for 18 hours to allow the growth of clones containing an antibiotic resistance conferring
DNA insert. Of the 352 antibiotic selections performed, 296 yielded antibiotic-resistant E. coli
transformants (Supplementary Fig. 2.4). After overnight growth, all colonies from a single
antibiotic plate (library by antibiotic selection) were collected by adding 750 μl of 15% LBglycerol to the plate and scraping with an L-shaped cell scraper to gently remove colonies from
the agar. The slurry was then collected and this process was repeated a second time for a total
volume of 1.5 mL to ensure that all colonies were removed from the plate. The bacterial cells
were then stored at -80°C before PCR amplification of antibiotic-resistant metagenomic
fragments and Illumina library creation.

87

2.3.8 Amplification and sequencing of functionally selected fragments
Freezer stocks of antibiotic-resistant transformants were thawed and 300 μl of cells pelleted by
centrifugation at 13,000 revolutions per minute (r.p.m.) for two minutes and gently washed with
1 mL of nuclease-free H2O. Cells were subsequently pelleted a second time and re-suspended in
30 μl of nuclease-free H2O. Re-suspensions were then frozen at -20°C for one hour and thawed
to promote cell lysis. The thawed re-suspension was pelleted by centrifugation at 13,000 r.p.m.
for two minutes and the resulting supernatant was used as template for amplification of
resistance-conferring DNA fragments by PCR with Taq DNA polymerase (New England
BioLabs):
(1) Mix the following for a 25 μl reaction volume: 2.5 μl of template, 2.5 μl of ThermoPol
reaction buffer (New England BioLabs), 0.5 μl of 10 mM deoxynucleotide triphosphates
(dNTPs, New England Biolabs), 0.5 μl of Taq polymerase (5 U/μl), 3 μl of a custom
primer mix, and 16 μl of nuclease-free H2O.
(2) PCR cycle temperature as follows: 94°C for 10 min, then 25 cycles of [94°C for 45 s,
55°C for 45 s, 72°C for 5.5 min], then 72°C for 10 min.
The custom primer mix consisted of three forward and three reverse primers, each targeting the
sequence immediately flanking the HincII site in the pZE21 MCS1 vector, and staggered by one
base pair. The staggered primer mix ensured diverse nucleotide composition during early
Illumina sequencing cycles and contained the following primer volumes (from a 10 mM stock) in
a single PCR reaction: (primer F1, CCGAATTCATTAAAGAGGAGAAAG, 0.5 μl); (primer F2,
CGAATT

CATTAAAGAGGAGAAAGG,

GAATTCATTAAAGAGGAGAAAGGTAC,

0.5

GATATCAAGCTTATCGATACCGTC,

0.21
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μl);

0.5

μl);
μl);

(primer
(primer
(primer

F3,
R1,
R2,

CGATATCAAGCTTATCGATACCG,

0.43

μl);

(primer

R3,

TCGATATCAAGCTTATCGATACC, 0.86 μl). The amplified metagenomic inserts were then
cleaned using the Qiagen QIAquick PCR purification kit and quantified using the Qubit
fluorometer HS assay kit (Life Technologies).
For amplified metagenomic inserts from each antibiotic selection, elution buffer was added to
PCR template for a final volume of 200 μl and sonicated in a half-skirted 96-well plate on a
Covaris E210 sonicator with the following setting: duty cycle, 10%; intensity, 5; cycles per burst,
200; sonication time, 600s. Following sonication, sheared DNA was purified and concentrated
using the MinElute PCR Purification kit (Qiagen) and eluted in 20 μl of pre-warmed nucleasefree H2O. In the first step of library preparation, purified sheared DNA was end-repaired:
(1) Mix the following for a 25 μl reaction volume: 20 μl of elute, 2.5 μl T4 DNA ligase
buffer with 10 mM ATP (10X, New England BioLabs), 1 μl dNTPs (1 mM, New
England BioLabs), 0.5 μl T4 polymerase (3 U/μl, New England BioLabs), 0.5 μl T4 PNK
(10 U/μl, New England BioLabs), and 0.5 μl Taq Polymerase (5 U/μl, New England
BioLabs).
(2) Incubate the reaction at 25°C for 30 min followed by 20 min at 75°C.
Next, to each end-repaired sample, 5 μl of 1 μM pre-annealed, barcoded sequencing adapters
were added (adapters were thawed on ice). Barcoded adapters consisted of a unique 7-bp
oligonucleotide sequence specific to each antibiotic selection, facilitating the de-multiplexing of
mixed-sample sequencing runs. Forward and reverse sequencing adapters were stored in TES
buffer (10 mM Tris, 1 mM EDTA, 50 mM NaCl, pH 8.0) and annealed by heating the 1 μM
mixture to 95°C followed by a slow cool (0.1°C per second) to a final holding temperature of
4°C. After the addition of barcoded adapters, samples were incubated at 16°C for 40 min and
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then for 10 min at 65°C. Before size-selection, 10 μl each of adapted-ligated samples were
combined into pools of 12 and concentrated by elution through a MinElute PCR Purification Kit
(Qiagen), eluting in 14 μl of elution buffer (10 mM Tris-Cl, pH 8.5). The pooled, adaptor-ligated,
sheared DNA was then size-selected to a target range of 300-400 bp on a 2% agarose gel in 0.5X
TBE, stained with GelGreen dye (Biotium) and extracted using a MinElute Gel Extraction Kit
(Qiagen). The purified DNA was enriched using the following protocol:
(1) Mix the following for a 25 μl reaction volume: 2 μl of purified DNA, 12.5 μl 2X Phusion
HF Master Mix (New England BioLabs), 1 μl of 10 mM Illumina PCR Primer Mix (5’AAT GAT ACG GCG ACC ACC GAG ATC-3’ and 5’-CAAGCAGA A GAC GGC
ATA CGA GAT-3’), and 9.5 μl of nuclease-free H2O.
(2) PCR cycle as follows: 98°C for 30 s, then 18 cycles of [98°C for 10s, 65°C for 30 s, 72°C
for 30s], then 72°C for 5 min.
Amplified DNA was measured using the Qubit fluorometer HS assay kit (Life Technologies) and
10 nM of each sample were pooled for sequencing. Subsequently, samples were submitted for
paired-end 101-bp sequencing using the Illumina Next Seq platform at the DNA Sequencing and
Innovation Lab at the Edison Center for Genome Sciences and Systems Biology, Washington
University in St Louis, USA). In total, three sequence runs were performed at 10 pM
concentration per lane.

2.3.9 Assembly and annotation of functionally selected fragments
Illumina paired-end sequence reads were binned by barcode (exact match required), such that
independent selections were assembled and annotated in parallel. Assembly of the resistanceconferring DNA fragments from each selection was achieved using PARFuMS 344 (Parallel
Annotation and Reassembly of Functional Metagenomic Selections), a tool developed
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specifically for the high-throughput assembly and annotation of functional metagenomic
selections.
Open reading frames (ORFs) were predicted in assembled contigs using MetaGeneMark345
and annotated by searching amino acid sequences against an ARG specific profile hidden
Markov model (pHMM) database, Resfams346, with HMMER3347. MetaGeneMark was run using
default gene-finding parameters while hmmscan (HMMER3) was run with the option --cut_ga as
implemented in the script annotate_functional_selections.py. Selections were excluded from
analysis if (a) more than 200 contigs were assembled or (b) the number of contigs assembled
exceeded the number of colonies on the selection plate by a factor of ten. Further, assembled
contigs less than 500 bp were discarded. Proteins were classified as resistance determinants using
the following hierarchical scheme: If a contig encoded a protein with a 100% amino acid identity
hit to the CARD database326, it was considered the causative resistance determinant on that
contig. Next, if a contig encoded a protein with a significant hit to a Resfams pHMM using
profile specific gathering thresholds, it was considered the causative resistance determinant on
that contig. In absence of a high scoring hit to the CARD or Resfams databases, contigs were
manually curated to identify plausible resistance determinants on an antibiotic specific basis.
Using these criteria, 1184 of the 5658 unique predicted proteins (20.9%) were classified as
resistance determinants.
The percent identity of all resistance determinants were determined using BlastP 116 query
against both the NCBI non-redundant protein database (retrieved May 21, 2018) and the
CARD326 database (version 1.2.1, retrieved January 24, 2018). Once the top local alignment was
identified with BlastP, it was used for a global alignment using the Needleman-Wunsch
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algorithm as implemented in the needle program of EMBOSS348 version 6.6.0 as previously
described7.
Putative mobile genetic elements were identified on functionally selected based on string
matches to one of the following keywords in Pfam and TIGRfam annotations: ‘transposase’,
‘transposon’, ‘conjugative’, ‘integrase’, ‘integron’, ‘recombinase’, ‘conjugal’, ‘mobilization’,
‘recombination’, or ‘plasmid’.

2.3.10 Bacterial isolation from infant stools
Approximately 50 mg of frozen stool was resuspended in 1 mL Tryptic Soy Broth (TSB) and
incubated with shaking at 37˚C for four hours. 50 µL of culture was streaked for isolation using
the four quadrant method on each of the following agars: Bile Esculin Agar, ESBL Agar,
MacConkey Agar, MacConkey Agar+cefotaxime, MacConkey Agar+ciprofloxacin, and Blood
Agar (Hardy Diagnostics catalog numbers G12, G321, G35, G121, G258, A10, respectively).
Plates were incubated for 18-24 hours at 37˚C. Four colonies of each distinct morphology on
each plate were substreaked onto blood agar and incubated for 18-24 hours at 37˚C. Following
confirmation of morphology, a 1 mL TSB was inoculated with a single colony and grown
overnight at 37˚C with shaking. Overnight cultures were frozen in 15% glycerol in TSB.

2.3.11 Genomic DNA isolation
1.5 mL TSB was inoculated from isolate glycerol stocks and grown overnight at 37˚C with
shaking. DNA was extracted using the BiOstic Bacteremia DNA Isolation Kit (MoBio
Laboratories) following manufacturer’s protocols. Genomic DNA was quantified using a Qubit
fluorometer dsDNA BR Assay (Invitrogen) and stored at -20˚C.
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2.3.12 Isolate sequencing library preparation
Isolate sequencing libraries were prepared in the same manner as described for metagenomic
sequencing libraries, following the protocol described in Baym et al., 2015. For each sequencing
lane, 10 nM of approximately 300 samples were pooled three independent times. These pools
were quantified using the Qubit dsDNA BR Assay and combined in an equimolar fashion.
Samples were submitted for 2×150 bp paired-end sequencing on an Illumina NextSeq HighOutput platform at the Center for Genome Sciences and Systems Biology at Washington
University in St. Louis with a target sequencing depth of 1 million paired end reads per sample.

2.3.13 Assembly of isolate genomes
Prior to all downstream analysis, Illumina paired end reads were binned by index sequence.
Adapter and index sequences were trimmed using Trimmomatic v0.36343 using the following
parameters:

java

-Xms2048m

-Xmx2048m

-jar

trimmomatic-0.33.jar

PE

-phred33

ILLUMINACLIP: NexteraPE-PE.fa:2:30:10:1:true. Contaminating human reads were removed
using DeconSeq349 and unpaired reads were discarded. Reads were assembled using SPAdes350
with the following parameters: spades.py -k 21,33,55,77 –careful. Contigs less than 500 bp were
excluded from further analysis. Assembly quality was assessed using QUAST351. Average
coverage across the assembly was calculated by mapping raw reads to contigs using bbmap
(https://jgi.doe.gov/data-and-tools/bbtools/).

2.3.14 Isolate genomic analysis
A total of 406 assemblies had an N50 greater than 50,000 and fewer than 500 total contigs longer
than 1000 bp, and were included in further analysis. Genomes were annotated using Prokka352
with default parameters. Multilocus sequence types were determined using in silico MLST
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(https://github.com/tseemann/mlst). Species assignments were determined by querying
assemblies against a RefSeq sketch using Mash identifying RefSeq hit with the minimum Mash
distance353. Assemblies were binned by species according to Mash designation. For each of the
seven most commonly occurring species, pangenome analysis was performed using Roary, with
core genome alignments created with PRANK354. An outgroup assembly of the same genus but
different species was downloaded from NCBI and included in each pangenome analysis
(Supplementary Table 2.1). Maximum likelihood core genome phylogenies were constructed
using RAXML under the GTRGAMMA model with 1000 bootstraps and maximum likelihood
optimization initialized from a random starting tree.

2.3.15 Enterococcus biofilm formation assay
Mid-log phase cultures in freshly-prepared tryptic soy broth containing 0.5% glucose (TSBG)
were diluted to OD 0.1. 200ul of the diluted culture was added in quadruplicate to 96 well
polystyrene plates and incubated at room temperature or 37˚C without shaking. After 24 hours of
growth, wells were decanted, washed three times with sterile PBS, and fixed for 30 minutes with
200 µl Bouin’s solution. Fixative was removed by washing three times with sterile PBS, then
wells were stained with 0.1% crystal violet for 30 minutes. Excess stain was removed by
washing three times with sterile PBS, the stain was solubilized in 200ul ethanol, and absorbance
read at 590nm. E. faecalis strains TX5682 (biofilm negative) and TX82 (biofilm positive) were
used as controls355.

2.3.16 Enterococcus vancomycin susceptibility testing
Isolates identified as Enterococcus were phenotyped for vancomycin resistance using microbroth
dilution according to the CLSI guidelines339.
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ATCC29212 (vancomycin susceptible) and

ATCC51299 (vancomycin-resistant) were included in all assays as controls. Isolates were grown
to mid-log phase, diluted in culture media to 1×106 CFU/ml, and used to inoculate plates
containing vancomycin ranging from 128-2ug/ml. After 24 hours of static growth at 37˚C,
optical density was read at 600 nm and MIC was determined by scoring by eye for turbidity.
Vancomycin resistance of biofilms was assayed after establishing biofilms as above. After 24
hours of static growth at 37˚C, planktonic cells were removed by washing three times with sterile
water, and then 200 µl of TSBG containing 5 mg/ml, 5 µg/ml, or no vancomycin, and the plates
incubated at 37˚C for an additional 24 hours. After washing planktonic cells three times with
sterile water, 200 µl sterile water was added to each well and the viability of the cells in the
biofilm was assessed using an XTT Cell Viability Kit (Cell Signaling Technology, #9095)
according to manufacturer’s protocols, reading absorbance at 450nm 60 minutes after addition of
reagents.

2.3.17 Microbiota age regression using random forests
Random forests was used to regress the relative abundances of all species predicted by
MetaPhlAn2 in infant stool samples against their chronological age using the R package
“randomForest”356 as previously described251.

The default parameters were used with the

following exceptions: ntree=10,000, importance=TRUE. Fivefold cross-validation was
performed using the rfcv function over 100 iterations to estimate the minimum number of
features needed to accurately predict microbiota age. The features most important for prediction
were identified over 100 iterations of the importance function, and a sparse model consisting of
the 50 most important features was constructed and trained on a set of nine antibiotic naïve near
term infants randomly selected from the larger near term infant set. This model was validated in
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the remaining eight antibiotic naïve near term infants, and then applied preterm infants to predict
microbiota age. Microbiota for age Z-score was computed as previously described251.

2.3.18 Classification of post-discharge samples
A single sample from each individual was selected (the final post-discharge sample collected
from each preterm infant and a roughly age matched sample from each near term infant). All
metagenomic data (species and ARG abundances, centered and scaled) were initially used as
input for a support vector machine as implemented in the R package e1071. Feature importance
was determined by computing the elementwise absolute value of the matrix of weights by the
matrix of support vectors357. A sparse model was subsequently constructed consisting of only the
fifteen most important features.

2.4 Discussion
By combining metagenomic sequencing, selective and differential stool culture paired
with isolate sequencing, functional metagenomics, and machine learning, we demonstrate for the
first time persistent and potentially pathological metagenomic signatures of early life antibiotic
treatment and hospitalization in preterm infants. This is manifest in an enriched gut resistome
and persistent carriage of multidrug resistant Enterobacteriaceae, despite apparent recovery at
the gross taxonomic level. Our work highlights the need to integrate high resolution and culturebased approaches for deeply interrogating the gut microbiota to reveal metagenomic signatures
of microbiota perturbation. These complementary methods provide the first evidence of a
persistent metagenomic signature of early life antibiotic treatment in the dynamic microbial
community housed in the infant gut. This provides compelling evidence for an underappreciated
lasting effect of preterm birth and associated hospitalization and antibiotic treatment on the
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microbiome, which may play a role in chronic pathologies associated with prematurity for which
the etiology is unclear. From a clinical standpoint, our findings emphasize a necessity for
alternatives to broad-spectrum antimicrobial therapy for managing infection in the NICU. While
it is possible that the metagenomic scars we identified are implicated in sequelae of preterm birth
such as neurodevelopmental 358-360, metabolic 361,362, cardiac 363,364, and respiratory 365,366 defects,
further experiments with model systems including gnotobiotic animals are needed to establish a
link between these persistent dysbioses and lasting pathologies.
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2.6 Supplementary Figures

Supplementary Fig. 2.1. Rarefaction curve of species identified by Metaphlan by sequencing
depth. Rarefaction curve for the number of unique species identified by subsampled sequencing
depth. Black bar indicates median sequencing depth for all samples, gray shading indicates one
standard deviation.
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Supplementary Fig. 2.2. Temporal changes in relative abundance of top eight classes by group.
The changes in relative abundance of the eight most abundant classes of bacteria in the gut
microbiota of all infants over time. Curves are loess regression fit to the data. Shading indicates
95% confidence interval.
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Supplementary Fig. 2.3. Timeline of samples and antibiotic treatments for infants in this study.
Sampling timeline for near term (top) and preterm (bottom) infants included in this study.
Periods of antibiotic treatment are indicated by colored bars.
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Supplementary Fig. 2.4. Functional selections of 22 metagenomic libraries constructed from
infant stool. Heatmap of resistance phenotypes observed in functional metagenomic selections.
Library size and source (term or preterm infant) is indicated to the left of heatmap.
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Supplementary Fig. 2.5. Synteny of functionally selected ARGs with mobile genetic elements.
Putative mobile genetic elements were identified syntenic to ARGs recovered from tetracycline
(A), gentamicin (B), chloramphenicol (C), cefoxitin (D), and piperacillin (E) selections. (F)
mobile genetic elements were most commonly identified on tetracycline selections.
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Supplementary Fig. 2.6. Microbiota with enriched resistome are low in diversity and dominated
by Enterobacteriaceae. (A) There is a negative correlation between cumulative relative resistome
and alpha diversity (R2=0.092). (B) Composition of the microbiota in samples with a resistome
relative abundance > 5000 RPKM. Samples are low in diversity and dominated by a few
organisms. In 41 out of 54 samples (76%), a single species comprises >50% of the microbiota.
These organisms are most commonly E. coli, Enterococcus faecalis, Klebsiella pneumoniae,
Staphylococcus epidermidis, Enterobacter aerogenes, and Bifidobacterium breve.
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Supplementary Fig. 2.7. Genomic and phenotypic heterogeneity in Enterococcus isolated from
infant stool. (A) Maximum likelihood core genome phylogeny of Enterococcus strains isolated
from infant gut microbiota. Persistent strains are highlighted in red. Annotations indicate time
point and species. (B) Biofilm formation phenotypes of E. faecalis and E. faecium strains at 37˚C
and at room temperature. (C) Viability of Enterococcus strains in biofilms following
vancomycin treatment.
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Supplementary Table 2.1. Assemblies used as outgroups for maximum likelihood phylogenies
Species

Count Outgroup to include

Outgroup assembly
accession

Escherichia coli

30

Escherichia fergusonii ATCC 35469

ASM2622v1

Enterococcus spp.

19

Lactococcus garvieae ATCC 49156

ASM26992v1

Enterobacter
cloacae

11

Enterobacter asburiae ATCC 35953

ASM152171v1

Klebsiella spp.

21

Salmonella enterica subsp. enterica serovar
Typhi str. CT18

ASM19599v1

106

Supplementary Table 2.2. Antibiotic concentrations used for functional selections
Antibiotic

Abbreviation

Screening
Concentration - µg/ml

Amoxicillin

AX

16

Amoxicillin +
Clavulanate
Ampicillin

AXCL

16-8

AP

64

Aztreonam

AZ

8

Cefepime

CP

8

Cefoxitin

CX

64

Ceftazidime

CZ

16

Chloramphenicol

CH

8

Ciprofloxacin

CI

0.5

Colistin

COL

8

Gentamicin

GE

16

Meropenem

ME

16

Penicillin G

PE

128

Piperacillin

PI

16

Tetracycline

TE

8

Tigecycline

TG

2
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Chapter 3: Tetracycline resistance by
inactivation across environmental,
commensal, and pathogenic microbes
3.1 Introduction
3.1.1 Abstract
Many antibiotic resistance genes have their evolutionary origins in benign environmental
microbes. Identification of environmental antibiotic resistance genes that are not yet widespread
in the clinical setting can allow for the proactive mitigation of the threat posed by these genes.
Tetracycline resistance by antibiotic inactivation (e.g. by Tet(X)), has been identified in
numerous environmental microbes, but occurrences in pathogens or clinical isolates have thus far
been limited. Here, we identify putative genes encoding tetracycline resistance by inactivation
across diverse human associated and environmental metagenomes by antibiotic selection of
metagenomic libraries. We find that identified genes formed two distinct clades by microbial
habitat of origin, and that resistance phenotypes were similarly correlated. Each of the genes
isolated from the human gut encode resistance to next generation tetracycline antibiotics
including eravacycline and omadacycline (recently approved for human use). We report a
comprehensive biochemical and structural characterization of one of these enzymes, TE_7F_3.
Further, we identify TE_7F_3 in a clinical Pseudomonas aeruginosa isolate, indicating that this
family of genes has already disseminated to pathogens of serious clinical concern. Lastly, we
show that highlight the need for further surveillance of this family of emerging resistance
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determinants and provide the foundation for an inhibition based strategy for countering this
resistance.

3.1.2 Introduction
Benign environmental microbes are ancient and diverse reservoirs of antibiotic resistance
genes, and are the likely evolutionary progenitors of most clinical resistance15,20,25,58. Nonpathogenic bacteria from habitats as varied as soils and healthy human guts have recently
exchanged multidrug-resistance cassettes with globally distributed human pathogens4. With
widespread antibiotic use in the clinical and agricultural settings, there is strong selective
pressure for pathogens to acquire resistance genes with novel activities and substrate specificities
from environmental resistomes93,367. The discovery and characterization of environmental
resistance genes with novel activities before they are acquired by and widely disseminated into
pathogens can help lessen their potential clinical impact, as well as improve fundamental
understanding of the ecology, evolution, and transmission of resistance genes across habitats25,94.
Further, understanding the evolutionary origins, genetic contexts, and molecular mechanisms of
antibiotic resistance is critical to devising strategies to curb the spread of resistant organisms and
their antibiotic resistance genes, and for sustainable development of new strategies for
countering infection.
Since their discovery from extracts of Streptomyces aureofaciens in 1948, the
tetracyclines have become one of the most widely used classes of antibiotics in agriculture,
aquaculture, and the clinic due to their broad antimicrobial spectrum, oral availability, and low
cost368,369. Extensive use over the past seven decades has selected for the expansion of
tetracycline resistance in environmental microorganisms21, human and animal commensals370,
and among bacterial pathogens371. Tetracycline use is particularly prevalent in agriculture, with
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tetracyclines comprising 66% of total therapeutic antibiotic use in livestock372. Widespread
anthropogenic use has resulted in detectable ng/uL to µg/L quantities of tetracyclines in livestock
manure and wastewater373, with tetracycline concentration directly correlating with changes in
microbial community composition and increase in antibiotic resistance374. In human pathogens,
tetracycline resistance is typically acquired via horizontal gene transfer and occurs almost
exclusively by ribosomal protection or antibiotic efflux368,371. This distinguishes tetracycline
resistance from the primary enzymatic inactivation mechanisms observed against other naturalproduct antibiotics26,375. Both common tetracycline resistance mechanisms have their
evolutionary origins in the environment, but are now found widely distributed in many
commensal and pathogenic bacteria25,94,376.
The rise in tetracycline resistance has been partially countered by the development of
synthetic and semisynthetic next-generation tetracyclines368. The first generation natural product
antibiotics, including chlortetracycline (1948), oxytetracycline (1951), and tetracycline (1953),
were followed by the semisynthetic second generation tetracyclines, including doxycycline
(1967) and minocycline (1971), and third generation tetracyclines such as tigecycline (2005),
eravacycline (2018) and omadacycline (2018)377. As a result, the tetracyclines are still widely
used in agriculture and medicine378. Tetracyclines remain the frontline therapies for a range of
indications, including Rickettsia, Mycoplasma pneumoniae, Borrelia recurrentis, Yersinia pestis,
Vibrio cholera, Clostridium species, Chlamydia species, Neisseria species, and Bacillus
anthracis369,379. Next-generation tetracyclines represent a promising option for treating
recalcitrant infections caused by carbapenem non-susceptible Acinetobacter baumannii380,
extended spectrum β-lactamase or carbapenemase producing Enterobacteriaceae381, ventilator
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associated pneumonia382, and complicated urinary tract infections and complicated intraabdominal infections due to a range of bacterial pathogens383.
Regrettably, modification of tetracycline’s napthacene scaffold is not a sustainable
strategy for countering resistance, as clinical resistance arises soon after, or even prior to, the
approval of next-generation antibiotics for clinical use. For example, while tigecycline is
unaffected by efflux and ribosomal protection139,384, tigecycline is vulnerable to oxidative
inactivation by Tet(X)385. Until recently, Tet(X) was the only known enzyme capable of
providing both tetracycline and tigecycline resistance, identified exclusively in non-pathogenic
bacteria. In 2013, however, tet(X) was identified in pathogens for the first time. Eleven isolates
from the Enterobacteriaceae, Comamonadaceae, and Pseudomonadaceae families from clinical
urine specimens in a hospital in Sierra Leone tested positive for tet(X)138, and tet(X) has now
been reported in four out of six ESKAPE pathogens137,138,386. The discovery of a tetracyclineinactivating gene in nosocomial pathogens foreshadows the increasing clinical resistance to nextgeneration tetracycline antibiotics and emphasizes the immediate importance of studying this
emerging mode of tetracycline resistance by enzymatic inactivation.
In 2015, we reported a family of tetracycline inactivating enzymes from tetracycline
selections of soil metagenomes and a previously uncharacterized homolog from the human
pathogen Legionella longbeachae29 . These genes were annotated as FAD-dependent
oxidoreductases and were unable to be identified as resistance genes based on sequence alone.
Our in vitro characterizations indicated that they were mechanistically distinct from Tet(X)387,
consistent with their low amino acid identity to all known tet(x) genes388. Flavoenzymes are an
abundant and diverse enzyme family, and display a proclivity for HGT and gene duplication,
allowing them to spread between species and acquire novel functionality with relative ease389.
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Thus, these genes are likely candidates for dissemination to the clinic, potentially compromising
new tetracycline derivatives and motivating surveillance of the prevalence and abundance of this
gene family across microbial habitats.
Understanding the current prevalence and distribution of resistance mechanisms across
habitats and anticipating when, where, and how further resistance might spread or evolve upon
imposition of antibiotic selective pressure is an important component of addressing antibiotic
resistance. To this end, we sought to characterize the tetracycline resistome across diverse
environmental and human associated metagenomes. We find that genes that encode tetracyclineinactivating enzymes are widespread in diverse microbial communities but cluster by habitat of
origin, and that resistance phenotypes also correlate with microbial habitat. Furthermore, we
describe TE_7F_3, a tetracycline resistance gene recovered from a human gut metagenome that
confers resistance to omadacycline and eravacycline, recently approved next-generation
tetracyclines. We identify TE_7F_3 in a clinical isolate of Pseudomonas aeruginosa from a
cystic fibrosis patient in a tertiary care hospital in Pakistan, signaling the clinical arrival of
tetracycline resistance by inactivation, but show that inhibition of this enzyme with
anhydrotetracycline or analogues can prevent tetracycline degradation and rescue antibiotic
efficacy.
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3.2 Results
3.2.1 Ecology of tetracycline inactivation across habitats
In order to understand better the prevalence of tetracycline inactivation as a resistance
mechanism across habitats, we conducted a retrospective screen of our 744 Gb of functional
metagenomic libraries that had previously been selected on tetracycline and tigecycline
3,4,7,23,58,103

[GenBank

accession

numbers:

JX009202-JX009380,

KJ691878-KJ696532,

KU605810-KU608292, KF626669-KF630360, KX125104-KX128902, KU543693-KU549046].
In addition to the 10 tetracycline inactivating genes from soil metagenomes that had previously
been described29, we discovered an additional 69 potential tetracycline inactivating enzymes
based on growth in the presence of a tetracycline or tigecycline selective agent and annotation as
an FAD-dependent oxidoreductase (Fig. 3.1a). We found that these genes formed two distinct

Figure 3.1: Diversity in tetracycline inactivating enzyme sequence corresponds to microbial
habitat of origin. (a) Seventy tetracycline inactivators were identified from tetracycline and
tigecycline selections of diverse metagenomic libraries. Genes selected for further analysis are
indicated by gray dots at branch tips. (b) A phylogeny of the 70 genes selected for further
analysis reveals that genes cluster by microbial habitat of origin. Genes from soil metagenomes
are shown with red branches, and genes from gut metagenomes are shown with blue branches.
(c) Percent amino acid identity heatmap indicates greater relative sequence diversity in the soil
derived set compared to the gut derived set, but low identity between the two sets.
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clades that were correlated with habitat of origin (Fig. 3.1b). There was greater sequence
diversity within the soil-derived subset (mean ± s.d. percent amino acid identity 66.48% ±
9.37%) compared to the gut-derived subset (mean ± s.d. percent amino acid identity 91.42% ±
4.72%), but very low identity between the two habitats (mean ± s.d. percent amino acid identity
20.81% ± 1.45%, Fig. 3.1c).
We selected ten genes from this set (nine human gut derived and one soil derived) for
further analysis and cloned them into E. coli DH10β. We performed antimicrobial susceptibility
testing using the broth microdilution method for these constructs as well as the ten previously
reported

tetracycline

inactivators29

against

11

tetracycline

compounds

as

well

as

anhydrotetracycline. All but one of these computationally predicted tetracycline inactivators had
a bona fide resistance function when subcloned into E. coli. We found that resistance
phenotypes, like genotypes, were highly correlated to habitat of origin (Fig. 3.2). While all gutderived tetracycline inactivators were capable of conferring high-level resistance to tigecycline,
minocycline, eravacycline, and omadacycline, soil-derived enzymes were all susceptible or
intermediate to these drugs. Thus, resistance to next-generation tetracyclines mediates functional
clustering between the soil-derived and gut-derived genes and discriminates between habitat of
origin.

3.2.2 TE_7F_3 confers resistance to next-generation tetracyclines via
inactivation
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Each of the gut-derived tetracycline inactivators encoded resistance to every tetracycline
currently approved for use in the clinic, including minocycline, tigecycline, eravacycline, and
omadacycline. Tigecycline was approved for human use in 2005, and is an antibiotic of last
resort

for

recalcitrant

infections

including

those

caused

by

carbapenem

resistant

Enterobacteriaceae134,381. Eravacycline was approved in August 2018 for treatment of complex
intra-abdominal infections, and omadacycline was approved in October 2018 for treatment of
community acquired bacterial pneumonia and acute skin and skin structure infections. Reports of
resistance to eravacycline and omadacycline have to date been limited. Eravacycline resistance

Figure 3.2: Phenotypic profiles of heterologously expressed tetracycline inactivating
enzymes correlate with habitat of origin. Antimicrobial susceptibility testing was performed
by microbroth dilution on a subset of predicted tetracycline inactivators. We observed broad
high-level resistance to tetracyclines within this class. Resistance phenotypes clustered by
microbial habitat of origin, with resistance to next-generation tetracyclines (e.g. minocycline,
tigecycline, eravacycline, omadacycline) discriminating between habitats.
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in Klebsiella pneumoniae has been attributed to overexpression of the OqxAB and MacAB
efflux pumps390, and nonsusceptibility (MIC 4 µg/mL) has been observed in Escherichia coli
DH10β overexpressing tet(X). The recent clinical approval of these drugs and the limited reports
of resistance motivate further study of this mode of resistance. To understand better the
mechanistic basis of resistance to next-generation tetracyclines by these resistance determinants,
we selected one of these genes, TE_7F_3, for further analysis. We found that media conditioned
by E. coli expressing TE_7F_3 could support the growth of a susceptible E. coli strain, indicating
that the mechanism of resistance is drug inactivation.
In vitro reactions containing purified TE_7F_3, NADPH, and tigecycline, eravacycline,
or omadacycline exhibited a time dependent decrease in absorbance between 360 nm and 400 nm
(Supplementary Fig. 3.1a-c). This is consistent with enzymatic disruption of tetracycline’s βdiketone chromophore, as has previously been described for enzymatic modification of
tetracycline29. To understand the biochemical basis of next-generation tetracycline (Fig. 3.3d)
modification by TE_7F_3, we determined kinetic parameters of enzymatic activity by
monitoring in vitro reaction progress using absorbance at 400 nm. For comparison, we
determined kinetic parameters of Tet(X) mediated inactivation of tigecycline and eravacycline in
a similar manner. The catalytic efficacy of TE_7F_3 was five times greater than that of Tet(X)
for degradation of eravacycline (kcat/KM values of 0.068 ± 0.017 and 0.013 ± 0.002 µM-1min-1,
respectively), and eight times greater for degradation of tigecycline (kcat/KM values of 0.072 ±
0.009 and 0.009 ± 0.001 µM-1min-1, respectively; Fig. 3.3a-b). The difference in catalytic
efficacy is largely mediated by more rapid substrate turnover by TE_7F_3 compared to Tet(X),
as KM values are of similar magnitude across all pairwise enzyme-substrate combinations, but
TE_7F_3 kcat values are an order of magnitude greater compared to Tet(X) (Fig. 3.3c). When
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Figure 3.3: Biochemical basis for tetracycline inactivation by TE_7F_3. Michaelis-Menten
kinetics of tetracycline destructase-mediated degradation of next-generation tetracyclines. (a)
Michaelis-Menten plot of Tet(X) degradation of tigecycline and eravacycline. (b) MichaelisMenten plot of TE_7F_3 (Tet(3)) degradation of next-generation tetracyclines. (c) Apparent Km,
kcat, and catalytic efficiencies for the tetracycline destructase-mediated degradation of
tigecycline, eravacycline, and omadacycline. (d) Next-generation tetracycline antibiotics
tigecycline, eravacycline, and omadacycline. Error bars represent standard deviation for three
independent trials. All data points possess error bars, though some are not visible at the plotted
scale.
enzymatic reactions were analyzed by liquid chromatography-mass spectrometry, we observed
that the primary product of omadacycline, tigecycline, and eravacycline degradation is consistent
with monohydroxylation (Supplementary Fig. 3.1d-f). For each next-generation tetracycline
substrate, there was a time dependent decrease in the relative extracted ion counts of the
tetracycline substrate (m/z for [M+H]+ equal to 586, 557, 559 for tigecycline, eravacycline, and
omadacycline, respectively), and a corresponding increase in the relative extracted ion counts of
the monooxygenated product (m/z for [M+H]+ equal to 602, 573, 575 for tigecycline,
eravacycline, and omadacycline, respectively).
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3.2.3 TE_7F_3 confers resistance in clinical P. aeruginosa isolate
While functional metagenomics is a powerful method for identifying resistance genes in a
sequence and culture unbiased manner, it is poorly equipped to associate specific resistance
determinants with their native hosts. Thus, we sought to identify homologues of our set of
functionally validated resistance genes in sequenced clinical isolates. We identified Pa-3, a
Pseudomonas aeruginosa strain isolated from a 45-year-old male cystic fibrosis patient’s
tracheal aspirate in an ICU in a tertiary care hospital in Pakistan in December 2016. This strain
was predicted to encode a 97% ID tet(X) homologue by BLAST, which we identified as having
100% nucleotide identity to TE_7F_3. We conducted antimicrobial susceptibility testing on this
strain using disk diffusion for a panel of clinical antibiotics. This isolate was resistant to all
antibiotics tested with the exception of piperacillin/tazobactam, a β-lactam/β-lactamase inhibitor
combination, and colistin (Table 3.1). The isolate was positive by carbapenem inactivation assay,
indicating that it encodes a functional carbapenemase. Multidrug resistant P. aeruginosa are
designated a serious clinical threat by CDC, and acquisition of resistance to next-generation
tetracyclines would further exacerbate this hazard.
In addition to antimicrobial susceptibility testing by disk diffusion, we performed broth
microdilution for a subset of tetracycline antibiotics for which disks are not yet commercially
available against Pa-3 (the strain encoding TE_7F_3), Pa-3 (another clinical isolate from the
same collection which did not encode TE_7F_3), and the P. aeruginosa type strain ATCC
27853. Each P. aeruginosa isolate phenotyped displayed at least moderate resistance to
tigecycline, eravacycline, and omadacycline, even in the absence of a putative tetracycline
inactivator. This is likely due to drug efflux as low-level OprM mediated tigecycline resistance
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Table 3.1: Zone of clearance (mm) and phenotypic resistance determination for clinical
Pseudomonas aeruginosa isolate bearing TE_7F_3. Blank interpretation indicates that no
interpretive criteria have been established.
Antibiotic
Delafloxacin

Kirby-Bauer (mm)
6

Interpretation
Resistant

Ceftazidime

6

Resistant

Cefepime

6

Resistant

Meropenem

6

Resistant

Imipenem

6

Resistant

Piperacillin/Tazobactam

24

Sensitive

Ceftolozane/Tazobactam

6

Resistant

Ceftazidime/Avibactam

6

Resistant

Ciprofloxacin

6

Resistant

Levofloxacin

6

Resistant

Gentamicin

6

Resistant

Amikacin

6

Resistant

Trimethoprim/Sulfamethoxazole

6

Fosfomicin

12

Resistant

Colistin

13

Sensitive

Aztreonam

17

Intermediate

Doxycycline

6

Minocycline

6

Tigecycline

6

Nitrofurantoin

6

Carbapenem inactivation assay

14

Positive

in P. aeruginosa PAO1 has been previously reported391. Although tigecycline, eravacycline, and
omadacycline breakpoints do not yet exist for P. aeruginosa, Pa-3 was 4-8 fold more resistant to
these drugs than Pa-8 and ATCC 27853. To our knowledge, this is the first description of
resistance to either eravacycline or omadacycline via enzymatic inactivation in a clinical isolate,
although we anticipate clinical deployment of these antibiotics will lead to selection for and
expansion of this mode of resistance in both the hospital and community settings. Media
conditioned by Pa-3 could support the growth of susceptible E. coli, while media conditioned by
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27853 or Pa-8 could not, confirming that the mechanism of resistance in Pa-3 but not Pa-8 or
27853 involves antibiotic inactivation. The resistance phenotype was not transferable to wild
type E. coli via transformation of bulk plasmid purification from Pa-3, so it is unlikely that
TE_7F_3 is plasmidic. Nonetheless, clinical use of next generation tetracyclines may select for
dissemination of this strain. Furthermore, Pseudomonas has a highly plastic genome and undergo
horizontal gene transfer at rates greater than observed for other genera392, so even
chromosomally encoded genes are possible threats for transfer beyond this strain. Lastly, we
observed that TE_7F_3 was syntenic with putative rolling circle transposases (Pfam:PF04986
per Prodigal annotation, see Methods), suggesting that they may be poised for horizontal
transfer4,393.

3.2.4 Anhydrotetracycline analogues rescue tetracycline efficacy against
resistant strains
We have previously shown that anhydrotetracycline is an inhibitor of tetracycline
inactivating enzymes in vitro, and that this inhibition is sufficient to rescue tetracycline efficacy
against E. coli resistant via heterologous expression of a tetracycline inactivator294. We reasoned
that this strategy might likewise prove useful to prevent degradation of next-generation
tetracyclines by TE_7F_3. To this end, we conducted in vitro inhibition assays with purified
TE_7F_3, all necessary cofactors, a next-generation tetracycline substrate, and an
anhydrotetracycline inhibitor (see Methods). Reaction progress was monitored by measuring
absorbance at 400 nm. In addition to parent anhydrotetracycline, we conducted assays using
anhydrodemeclocycline as an inhibitor. We found that anhydrotetracycline inhibited TE_7F_3
degradation of tigecycline, eravacycline, and omadacycline at the micromolar level (IC 50s of
1.06 ± 0.108 µM, 6.89 ± 0.655 µM, and 2.37 ± 0.510 µM, respectively). Anhydrodemeclocycline
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Figure 3.4: Anhydrotetracycline inhibits inactivation of next-generation tetracyclines by
TE_7F_3. Anhydrotetracycline and analogues inhibit enzymatic inactivation of tetracycline and
next-generation tetracyclines. (a) In vitro, anhydrotetracycline, anhydrochlortetracycline, and
anhydrodemeclocycline
inhibit
Tet(X)
modification
of
tigecycline.
Likewise,
anhydrotetracycline and anhydrodemeclocycline inhibit in vitro enzymatic modification of
tigecycline (b), eravacycline (c), and omadacycline (d) by TE_7F_3. (e) Anhydrodemeclocycline
at subinhibitory concentrations can partially rescue tetracycline, tigecycline, eravacycline, and
omadacycline efficacy against Pseudomonas aeruginosa Pa-3 and E. coli DH10β heterologously
expressing TE_7F_3.

was an even more potent inhibitor of TE_7F_3 degradation of these next-generation substrates,
with IC50s of 0.262 ± 0.035 µM, 2.75 ± 0.256 µM, and 0.309 ± 0.036 µM, respectively (Fig.
3.4a-c). We reason based on the predicted structural similarity to previously published cocrystal
structures of Tet(50) (PDB ID: 5TUF) with anhydrotetracycline that the mechanism of inhibition
likely occurs similarly294. Specifically, anhydrotetracycline or analogue binds slightly offset from
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the active site and inhibits degradation of tetracycline or analogue by both competing for
substrate binding and sterically restricting dynamics of the FAD cofactor critical for catalysis.
In order to extend our in vitro studies, we sought to determine whether
anhydrotetracycline or anhydrodemeclocycline could restore the activity of next-generation
tetracyclines against Pa-3, the clinical P. aeuruginosa isolate that encodes TE_7F_3. 32 µg/mL
anhydrotetracycline caused a two- to four-fold increase in sensitivity of Pa-3 to tigecycline,
eravacycline, or omadacycline (Fig 4d). In the same way, 8 µg/mL anhydrodemeclocycline was
sufficient to cause a fourfold increase in sensitivity to tetracycline and a twofold increase in
sensitivity to tigecycline, eravacycline, or omadacycline. Thus, this strategy has promise for
restoring the efficacy of tetracycline antibiotics, including next-generation tetracyclines, against
bacteria that resist tetracycline through inactivation.

3.3 Materials and Methods
3.3.1 Identification of candidate tetracycline inactivators in sequenced
functional selections
In order to identify additional tetracycline inactivators, we queried previously sequenced
functional selections of human gut, animal gut, latrine, and soil metagenomes3,4,7,23,58,103
[GenBank accession numbers:
KU608292,

JX009202-JX009380, KJ691878-KJ696532, KU605810-

KF626669-KF630360,

KX125104-KX128902,

KU543693-KU549046].

Functionally selected contigs were annotated using Resfams122 as previously described3, and
annotations were queried for putative tetracycline inactivating function based on string matches
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to one of the following keywords in Pfam and TIGRfam annotations: “FAD dependent
oxidoreductase”, “oxidoreductase”, “FAD binding domain”.

3.3.2 Construction of maximum likelihood phylogenies
A multiple sequence alignment of predicted tetracycline inactivating enzymes was created with
MAFFT using the L-INS-i method394. A maximum likelihood phylogeny was then constructed
using RAxML with GAMMA model of rate heterogeneity and JTT empirical base frequencies
with 100 bootstraps395. Trees were visualized and decorated with metadata using iTol 396.

3.3.3 Subcloning predicted tetracycline inactivators from metagenomic source
Specific predicted tetracycline inactivators were selected for subcloning for downstream
phenotypic analysis if they met each of the following criteria: (1) the open reading frame
contained a start codon; (2) the open reading frame contained a stop codon; and (3) the open
reading frame was greater than 1000 base pairs but less than 1500 base pairs. Tet(47-56) and
Tet(X) had previously been subcloned29. Additional predicted tetracycline inactivators were
amplified from their initial metagenomic source using Phusion Hi-Fidelity Polymerase
(ThermoFisher) and primers as specified in Supplemental Table 3.1. Amplicons were ligated into
pZE21 at the KpnI/HindIII sites using Fast-Link DNA Ligase (Lucigen) and transformed into E.
coli MegaX DH10β cells (Invitrogen) via electroporation. The orientation and sequence of all
inserts was confirmed by Sanger sequencing prior to phenotypic analyses.

3.3.4 Antimicrobial susceptibility testing by microbroth dilution
Antibiotic susceptibility testing was performed in E. coli MegaX cells (Invitrogen) bearing the
pZE21 expression vector with the tetracycline inactivating gene of interest. Minimum inhibitory
concentrations were determined according to Clinical and Laboratory Standards Institute (CLSI)
123

procedures 339 using Mueller-Hinton broth with 50 µg/mL kanamycin and a range of tetracycline
antibiotic concentrations profiled via absorbance measurements at 600nm (OD600) at 45 minute
intervals using the Synergy H1 microplate reader (Biotek Instruments, Inc) for 48 hours at 37ºC
and scored by eye following 20 hours of growth at 37ºC.

3.3.5 Pseudomonas aeruginosa genomic DNA isolation
1.5 mL TSB was inoculated from isolate glycerol stocks and grown overnight at 37˚C with
shaking. DNA was extracted using the BiOstic Bacteremia DNA Isolation Kit (MoBio
Laboratories) following manufacturer’s protocols. Genomic DNA was quantified using a Qubit
fluorometer dsDNA BR Assay (Invitrogen) and stored at -20˚C.

3.3.6 Pseudomonas aeruginosa isolate sequencing library preparation
Genomic DNA was diluted to a concentration of 0.5 ng/µL prior to sequencing library
preparation. Libraries were prepared using a Nextera DNA Library Prep Kit (Illumina) following
the modifications described in Baym et al, 2015342. Libraries were purified using the Agencourt
AMPure XP system (Beckman Coulter) and quantified using the Quant-iT PicoGreen dsDNA
assay (Invitrogen). For each sequencing lane, 10 nM of approximately 300 samples were pooled
three independent times. These pools were quantified using the Qubit dsDNA BR Assay and
combined in an equimolar fashion. Samples were submitted for 2×150 bp paired-end sequencing
on an Illumina NextSeq High-Output platform at the Center for Genome Sciences and Systems
Biology at Washington University in St. Louis with a target sequencing depth of 1 million reads
per sample.
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3.3.7 Assembly and annotation of Psuedomonas aeruginosa genome
Prior to all downstream analysis, Illumina paired end reads were binned by index sequence.
Adapter and index sequences were trimmed using Trimmomatic v0.36343 using the following
parameters:

java

-Xms2048m

-Xmx2048m

-jar

trimmomatic-0.33.jar

PE

-phred33

ILLUMINACLIP: NexteraPE-PE.fa:2:30:10:1:true. Contaminating human reads were removed
using DeconSeq349 and unpaired reads were discarded. Reads were assembled using SPAdes350
with the following parameters: spades.py -k 21,33,55,77 –careful. Contigs less than 500 bp were
excluded from further analysis. Assembly quality was assessed using QUAST351. Average
coverage across the assembly was calculated by mapping raw reads to contigs using bbmap
(https://jgi.doe.gov/data-and-tools/bbtools/)397. Genomes were annotated using Prokka352 with
default parameters.

3.3.8 Antimicrobial susceptibility testing for Pseudomonas aeruginosa
Susceptibility testing was performed using the Kirby-Bauer disk diffusion method on MuellerHinton agar (Hardy Diagnostics) in accordance with CLSI standards. Pseudomonas aeruginosa
ATCC 27853 was used as a quality control.

3.3.9 Cloning, expression and purification of tetracycline-inactivating enzymes
All genes encoding tetracycline-inactivating enzymes were cloned into the pET28b(+) vector
(Novagen) at BamHI and NdeI restriction sites. Constructs were transformed into BL21-Star
(DE3) competent cells (Life Technologies). Cells harboring the plasmid were grown at 37ºC in
LB medium containing a final concentration of 0.03 mg/mL kanamycin. Once cells reached an
OD600 of 0.6, cells were cooled to 15 ºC and induced with 1 mM IPTG overnight. After this
period, cells were harvested by centrifugation at 4000 rpm for 10 min at 4 ºC. Cell pellets were
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suspended in 10 mL of 50 mM Tris (pH 8.0), 100 mM NaCl, 10 mM imidazole (pH 8.0), 1 mM
PMSF, and 5 mM BME per 1 liter of LB medium and stored at -80ºC.
Cells were thawed in the presence of 0.25 mg/mL lysozyme and disrupted using sonication on
ice for 60 seconds. The cell extract was obtained by centrifugation at 13,000 rpm for 30 min at 4
ºC and was applied onto nickel rapid run agarose beads (Goldbio) equilibrated with wash buffer
(50 mM Tris (pH 8.0), 150 mM NaCl, 20 mM imidazole (pH 8.0), and 5 mM BME). The wash
buffer was used to wash the nickel column three times with five column volumes. After washing,
protein was eluted with five column volumes of elution buffer (wash buffer with 300 mM
imidazole). The protein sample was further purified by gel chromatography using a HiLoad
16/600 Superdex 200pg column (GE Healthcare) equilibrated with 10 mM Tris (pH 8.0), 150
mM NaCl, 5 mM dithioerythritol (DTT). The fractions containing the protein of interest were
pooled and concentrated using a 30K MWCO Amicon centrifugal filter (Millipore).

3.3.10 In vitro tetracycline inactivation assays
Reactions were prepared in 100 mM TAPS buffer with 100 µM substrate, 14.4 µM enzyme, and
an NADPH regenerating system consisting of the following components (final concentrations):
glucose-6-phosphate (40mM), NADP+ (4mM), MgCl2 (1mM), and glucose-6-phosphate
dehydrogenase (4U/ml). The regeneration system was incubated at 37ºC for 30 minutes to
generate NADPH before use in reactions. Reactions were sampled at various timepoints, and
quenched in four volumes of an acidic quencher consisting of equal parts acetonitrile and 0.25 M
HCl.
Products generated from enzymatic inactivation of both tetracycline and chlortetracycline were
separated by reverse phase HPLC using a Phenomenex Luna C18 column (5µm, 110 Å,
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2×50mm) and 0.1% trifluoroacetic acid in water (A) and acetonitrile (B) as mobile phase.
Injections of 25µl sample volume were eluted using a linear gradient from 25%B to 75%B over
14 minutes at a flow rate of 1ml/min.

3.3.11 Kinetic characterization of tetracycline inactivation
The optimal enzyme concentration for steady-state kinetics assays was determined by varying
the concentration of enzyme while keeping chlortetracycline and NADPH concentration
constant. 0.4 μM enzyme was found to give linear slopes for all concentrations of substrate
tested, and was used as the enzyme concentration for all kinetics experiments.
Reactions were prepared in 100 mM TAPS buffer at pH 8.5 with 0-160 µM substrate, 1.6 mM
NADPH, and 0.4 µM enzyme. UV-visible spectroscopy measurements were taken in triplicate at
400nm wavelength light with a Cary 60 UV/Vis system (Agilent) for 10 minutes at room
temperature. Initial reaction velocities were determined by linear regression using the Agilent
Cary WinUV Software, and fitted to the Michaelis-Menten equation:

using GraphPad Prism 6.

3.3.12 LC-MS characterization of chlortetracycline degradation products
Reactions were prepared in 100 mM phosphates buffer at pH 8.5 with 1mM CTC, 0.5 mM
NADPH, 5 mM MgCl2 and 0.4 µM Tet(55). After 10 minutes, the reaction was centrifuge
filtered for 10 minutes using a Millipore Amicon Ultracel (3 kDa MW cutoff) to remove enzyme.
Prior to centrifugation, filters were triply rinsed with phosphate buffer to remove excess glycerol.
The filtrate was collected and analyzed by LC-MS using an Agilent 6130 single quadrupole
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instrument with G1313 autosampler, G1315 diode array detector, and 1200 series solvent
module. Reaction products were separated using a Phenomenex Gemini C18 column, 50 × 2 mm
(5 µm) with guard column cassette was used with a linear gradient of 0% acetonitrile + 0.1%
formic acid to 95% acetonitrile + 0.1% formic acid over 14 min at a flow rate of 0.5 mL/min
prior to analysis by electrospray ionization.

3.3.13 In vitro characterization of anhydrotetracycline inhibition
IC50 values were determined for TE_7F_3 by measuring the initial velocity of tetracycline
degradation

in

the

presence

of

varying

concentrations

of

anhydrotetracycline

or

anhydrodemeclocycline. The concentrations of tetracycline and NADPH were kept constant at
25 μM and 500 μM, respectively. Assays were prepared by combining all components except for
enzyme and equilibrating to 25°C for five minutes. After the addition of enzyme, absorbance at
400 nm was measured for five minutes. All measurements were taken in triplicate. The final
concentrations for assay components were 100 mM TAPS buffer (pH 8.5), 25 μM tetracycline,
500 μM NADPH, 16 mM MgCl2, 0.4 μM enzyme, and 0.05 – 150 μM inhibitor. IC50 values were
determined by plotting the log of anhydrotetracycline concentration against v0 in GraphPad
Prism 6.

3.4 Discussion
Our results indicate that tetracycline inactivation is a resistance mechanism that is
widespread in environmental and human associated metagenomes. We describe two distinct
clades of tetracycline resistance genes, and demonstrate that genotypes and resistance
phenotypes are correlated with microbial habitat of origin. Amongst the gut-derived enzymes
reported herein, we also describe the first report of resistance by inactivation to eravacycline and
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omadacycline (recently approved for human use) in a clinical isolate. We identify TE_7F_3 in a
clinical isolate of Pseudomonas aeruginosa, indicating that this mechanism of resistance has
already disseminated to the clinical setting. Lastly, we show that inhibition of TE_7F_3 by
anhydrotetracycline and derivatives may be a promising strategy for restoring efficacy of next
generation tetracyclines in the face of high-level tetracycline resistance. The results presented
herein motivate continued surveillance of tetracycline resistance by inactivation in environmental
and clinical settings. Similarly, this work underscores the value in proactive screening of
antimicrobial agents in the pipeline for resistance determinants present in diverse microbial
communities such that strategies to minimize their eventual clinical impact can be explored.
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3.6 Supplementary Figures

Supplementary Figure 3.1: TE_7F_3 inactivates next-generation tetracyclines by
monooxygenation. In vitro reactions containing purified TE_7F_3 (Tet(3)), NADPH, and
tigecycline (a), omadacycline (b), or eravacycline (c) were assayed by absorbance scans taken at
one minute intervals. The rainbow pattern depicts a spectral change over time. Decrease in
absorbance over time from 360 nm to 400 nm indicates enzymatic disruption of the characteristic
tetracycline β-diketone chromophore. In the case of tigecycline (d), omadacycline (e), and
eravacycline (f), the product of enzymatic modification is consistent with monooxygenation.
Plots show the relative extracted ion counts of the parent tetracycline (blue curves; m/z for
[M+H]+ equal to 586, 557, 559, respectively ) or the monooxygenated product (orange curves;
m/z for [M+H]+ equal to 602, 573, 575, respectively).
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Supplementary Table 3.1: Primers used in this study
Primer sequence (5'  3')

Designed specificity

ATGACTTTGCTAAAAAATAAAAAAATTA
TTATAGATTCATTAGTTTTTGGAATGA
ATGAATTTACTAAACAATAAAAAAGTTACA
TTATAGATTCATTAGTTTTTGGAATGA
ATGACAATGCGAATAGATACAGACA
TTATACATTTAACAATTGCTGAAACG
ATGACTTTGCTAAAAAATAAAAAAATT
TTATAGATTCATTAGTTTTTGGAATGA
ATGACAATGCGAATAGATACAGACA
TTATACATTTAACAATTGCTGAAACG
ATGACAATGCGAATAGATACAGACA
TTATACATTTAACAATTGCTGAAACG
ATGACTTTACTAAAACATAAAAAAATTACA
TTATAGATTCATTAGTTTTTGGAATGA
ATGACTAGCGATAAGAACCCT
TCATTCGTATTCTGGTAGCG

TE_7F_Contig_3 (452_1588)
TE_7F_Contig_3 (452_1588)
TG_0402_Contig_27 (425_1561)
TG_0402_Contig_27 (425_1561)
TE_0402_Contig_1789 (2156_3322)
TE_0402_Contig_1789 (2156_3322)
TE_0402_Contig_1211 (2189_3325)
TE_0402_Contig_1211 (2189_3325)
TG_0402_Contig_45 (861_2027)
TG_0402_Contig_45 (861_2027)
TG_0401_3a_Contig_236 (181_1347)
TG_0401_3a_Contig_236 (181_1347)
TE_6F_Contig_7 (1101_2237)
TE_6F_Contig_7 (1101_2237)
S08_TE.2:1046-1630 Contig:2
S08_TE.2:1046-1630 Contig:2
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Chapter 4: Plasticity, dynamics, and
inhibition of emerging tetracycline-resistance
enzymes

4.1 Introduction
4.1.1 Abstract
While tetracyclines are an important class of antibiotics in agriculture and the clinic, their
efficacy is threatened by increasing resistance. Resistance to tetracyclines can occur through
efflux, ribosomal protection, or enzymatic inactivation. Surprisingly, tetracycline enzymatic
inactivation has remained largely unexplored despite providing the distinct advantage of
antibiotic clearance. The tetracycline destructases are a recently-discovered family of
tetracycline-inactivating flavoenzymes from pathogens and soil metagenomes with a high
potential for broad dissemination. Here, we show tetracycline destructases accommodate
tetracycline-class antibiotics in diverse and novel orientations for catalysis, and antibiotic
binding drives unprecedented structural dynamics facilitating tetracycline inactivation. We
identify a key inhibitor binding mode that locks the flavin adenine dinucleotide cofactor in an
inactive state, functionally rescuing tetracycline activity. Our results reveal the potential of a
novel tetracycline/tetracycline destructase inhibitor combination therapy strategy to overcome
resistance by enzymatic inactivation and restore the use of an important class of antibiotics.
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4.1.2 Introduction
Antibiotics revolutionized the treatment of infectious diseases, enabling significant
reductions in deaths due to infection over the past 80 years. However, the prolific anthropogenic
use of these life-saving chemotherapeutics in the clinic and agriculture has also selected for a
steady increase in antibiotic resistance in both benign and pathogenic bacteria21. Regrettably,
increasing antibiotic resistance has been accompanied by a decrease in development and
regulatory approval of new antibiotics157, threatening the end of the modern antibiotic era. The
likely origin of virtually all clinical antibiotic resistance genes are environmental microbial
communities, which harbor ancient and diverse resistomes4,15,20,58,94,398,399. Indeed, environmental
reservoirs have been identified for a number of recently-emerged and rapidly-disseminating
resistance genes representing urgent clinical threats (e.g. plasmid-borne and chromosomallyacquired carbapenem88, colistin75, and quinolone93 resistance genes). This motivates the need to
better understand resistance mechanisms of environmental origin before they are widespread in
the clinic and ultimately guide new drug discovery and therapeutic strategies that mitigate
emerging mechanisms of resistance.
Despite growing resistance, the tetracyclines remain among the most widely used
antibiotics in clinical and agricultural settings368. Indeed, tetracyclines ranked in the top three
antibiotics in both clinical prescriptions in the United States in 2010 (representing 15% of all
antibiotic prescriptions) and in global sales for animal use in 2009 ($500 million in sales)400.
Furthermore, next-generation derivatives are currently fueling a tetracycline renaissance, with
the 2005 clinical approval of tigecycline134 and ongoing late-stage clinical trials of eravacycline
and omadacycline139,140 justifying urgent interrogation of emerging and novel tetracycline
resistance mechanisms. Previously, tetracycline resistance was thought to occur almost
134

exclusively by two mechanisms: ribosomal protection or antibiotic efflux368,371. However, an
alternate mechanism – enzymatic inactivation – has been documented in benign and pathogenic
bacteria, such as the enzyme Tet(X)28,100,136,385,401-405. We recently identified a new family of
tetracycline-inactivating enzymes through functional metagenomic selections for tetracycline
resistance from 18 grassland and agricultural soils58. We showed that these nine proteins, Tet(4755), were able to enzymatically inactivate tetracycline, resulting in 16-64 fold increases in
minimum inhibitory concentration (MIC)406 when expressed in E. coli.
Here, we pursued a multi-pronged structural, in vitro enzymatic, and bacterial phenotypic
investigation of the emerging tetracycline destructases. We show that a recently identified
tetracycline destructase confers tetracycline resistance to a known soil-derived human pathogen.
We hypothesized that structural characteristics of tetracycline-inactivating enzymes would reveal
useful information about their unique activity profiles and lead to the rational design of
inhibitors, similar to the widely employed β-lactamase inhibitors110. Discerning the structural and
mechanistic details of conformational or transitional states in target proteins has been crucial for
the rational design of successful inhibitors in a number of cases, as exemplified by inhibitors of
HIV-1 protease407 and mechanistic inhibitors of glycosyltransferases that involve significant
conformational movement in the active site408. Through structure-function analyses of four
tetracycline destructases alone and in complex with tetracycline-class ligands, we present the
molecular basis for unexpected structural dynamics in tetracycline destructases driven by
antibiotic binding. These unprecedented changes provide a novel mechanism for inhibition that
has the potential to synergistically restore tetracycline activity and rescue an important class of
antibiotics.
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4.2 Results
4.2.1 Tetracycline inactivation by Legionella longbeachae
The tetracycline destructase family was initially discovered by functional metagenomic
selection for tetracycline resistance from soil samples58. We observed that the soil-derived
human pathogen Legionella longbeachae, the causative agent of Pontiac Fever and Legionnaires’
Disease409,410 encodes a homolog to the tetracycline destructases, termed tet(56). Like the other
tetracycline destructases, Tet(56) is able to inactivate tetracycline in vitro and expression of
tet(56) in E. coli confers high-level tetracycline resistance406. To confirm that tet(56) is a
functional resistance determinant in L. longbeachae, we deleted the gene and examined the strain
for changes in drug sensitivity. Deletion of the chromosomally-encoded tet(56) resulted in an
increase in tetracycline sensitivity to L. longbeachae (Fig. 4.1). Moreover, overexpression of

Figure 4.1: Dose-response curve showing the effect of tetracycline on
growth of Legionella strains. Deletion of tet(56) from L. longbeachae causes
an increase in tetracycline sensitivity. Complementation with a plasmid
containing the tet(56) insert rescues the tetracycline resistance phenotype
compared to strains bearing the empty-vector control. Furthermore, introduction
of the complementing vector into L. pneumophila, which lacks a tet(56)
homolog, results in an increase in tetracycline resistance. Data are represented
as mean ± s.d. of three technical replicates.
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tet(56) in the L. longbeachae Δtet(56) strain resulted in increased tetracycline resistance to levels
even higher than the wild type L. longbeachae strain containing vector. Finally, expression of
tet(56) in L. pneumophila, a Legionella strain lacking a tetracycline destructase homolog, also
dramatically increased the level of tetracycline resistance of the strain. These results demonstrate
that tetracycline destructases are already functional in a known human pathogen and their
introduction into a related pathogen would lead to increased antibiotic resistance.

4.2.2 Tet(50,51,55,56) crystal structures reveal a conserved domain
architecture and a dynamic substrate loading channel
We began our structural analysis by solving the X-ray crystal structures of four tetracyclineinactivating enzymes: Tet(50), Tet(51), Tet(55), and Tet(56) (Fig. 4.2a and Supplementary Fig.
4. 1a-e). Although only sharing ~24% amino acid identity with the previously crystallized Tet(X)
and requiring initial structure determination via experimental phasing (Supplementary Table
4.1), Tet(50,51,55,56) and Tet(X) exhibit a similar overall architecture. Each possesses a flavin
adenine dinucleotide (FAD)-binding Rossmann-type fold domain, a tetracycline-binding domain,
and a C-terminal -helix that bridges the two domains (Fig. 4.2a-d). Surprisingly, each of the
new structures revealed an unexpected second -helix at the C-terminus (Fig. 4.2a-c) that is not
present in Tet(X) (Fig. 4.2d) and could not be predicted based on their primary sequences.
Comparisons to co-crystal structures of Tet(X) in complex with either chlortetracycline [PDB
2Y6R] or iodtetracycline [PDB 2Y6Q]385 reveal that this helical extension comes in close
proximity to the tetracycline binding site (Fig. 4.2d), contributing to the formation of a substrateloading channel. In the Tet(50) crystal structure, we observed two distinct monomers in the
asymmetric unit. In Tet(50) monomer A (Fig. 4.2b), this substrate-loading channel is blocked by
a flexible loop (Fig. 4.2e,f), whereas in Tet(50) monomer B (Fig. 4.2c), the channel is open,
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Figure 4.2: Crystal structures of Tet(50), Tet(51), Tet(55), and Tet(56) reveal a conserved
architecture, structural changes that enable substrate loading channel accessibility, and
two conformations of the FAD cofactor. (a) Overlay of the Tet(50) monomer A, Tet(50)
monomer B, Tet(51), Tet(55), and Tet(56) crystal structures. The FAD-binding domain
(salmon), the tetracycline-binding domain (pale green), the first (cyan) and second (deep teal) Cterminal α-helixes, and FAD molecules (orange) are shown. (b) Cartoon depiction of Tet(50)
monomer A. (c) Cartoon depiction of Tet(50) monomer B. (d) A previously published crystal
structure of Tet(X) with chlortetracycline (yellow) bound – PDB ID 2Y6R. Tet(X) does not
possess the second C-terminal α-helix. (e) Surface representation of Tet(50) monomer A reveals
that the substrate-loading channel is closed. Rotated 180º along the y-axis compared to b. (f)
Zoomed in view of the closed substrate-loading channel in Tet(50) monomer A. (g) Surface
representation of Tet(50) monomer B reveals that the substrate-loading channel is open. Rotated
180º along the y-axis compared to c. (h) Zoomed in view of the open substrate-loading channel
in Tet(50) monomer B. (i) Surface representation of Tet(X) reveals that absence of the second Cterminal α-helix results in a wide-open substrate-binding site. Rotated 180º along the y-axis
compared to d. (j) Zoomed in view of the wide open substrate-binding site in Tet(X). (k) The
FAD cofactor adopts the IN conformation in Tet(50) monomer A, characterized by a 12.3 Å
distance between the C8M and C2B atoms of the FAD molecule. (l) In Tet(50) monomer A,
FAD is IN and the substrate-loading channel is closed. (m) The FAD cofactor adopts the OUT
conformation in Tet(50) monomer B, characterized by a 5.2 Å distance between the C8M and
C2B atoms of the FAD molecule. (n) In Tet(50) monomer B, FAD is OUT, and the channel is
open. (o) The IN conformation of FAD allows for substrate catalysis. The OUT conformation of
FAD allows for regeneration of the reduced FAD for the next round of catalysis. The green area
indicates the substrate-binding site. The pink area indicates the putative NADPH binding site.
allowing tetracycline to access the substrate-binding site (Fig. 4.2g,h). The absence of the
second -helix in Tet(X) results in a widely exposed entrance to the substrate-binding site (Fig.
4.2i,j), which likely contributes to alternate substrate specificity of this enzyme.

4.2.3 Two FAD conformations are linked to the accessibility of the substrate
loading channel
Tetracycline destructases are flavoenzymes that utilize an FAD cofactor to degrade their
substrate411,412. These enzymes bind FAD in two distinct conformations that are important for
catalysis413. Both conformations are captured by the structures presented here (Supplementary
Fig. 4.1f-j). Tet(50) monomer A, which has a closed substrate-loading channel, bound FAD in an
IN conformation (Fig. 4.2k,l). In this conformation the reactive isoalloxazine moiety of the FAD
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is stretched away from the adenosine moiety and into the substrate-binding site. This allows
reaction with molecular oxygen to produce an FAD-hydroperoxide intermediate that is in close
proximity to the tetracycline substrate (the C4a of FAD is ~5.9 Å away from the C11a substrate
hydroxylation site in Tet(X)), allowing for hydroxylation and subsequent spontaneous
degradation of the tetracycline substrate (Fig. 4.2o)414. After catalysis, FAD flips away from the
substrate-binding site, adopting the OUT conformation. Tet(50) monomer B, which has an open
substrate-loading channel, binds FAD in an OUT conformation where the isoalloxazine moiety is
bent towards the adenosine and away from the substrate-binding site (Fig. 4.2m,n). This
conformational change allows for products to be released through the open channel and positions
the oxidized FAD for reduction by NADPH in a distinct NADPH binding site during cofactor
regeneration (Fig. 4.2o and Fig. 4.3a)414. After reduction, FAD is poised to flip back to the IN
conformation for the next round of catalysis upon substrate binding. Our observation of FAD in
both IN and OUT conformations imply that FAD exists in an equilibrium between the two states
in the absence of substrate binding.

4.2.4 Chlortetracycline binds to Tet(50) in an unprecedented mode, driving
FAD conversion and substrate loading channel closure
Since accessibility of the substrate-loading channel appeared to be dependent on the
conformation of FAD in the Tet(50) crystal structures, we soaked Tet(50) with various
tetracycline compounds. Surprisingly, chlortetracycline binds to Tet(50) in a ~180° rotated
orientation compared to the orientation in which chlortetracycline and other tetracycline
substrates (e.g. iodtetracycline, minocycline, tigecycline) bind Tet(X)385,415 (Fig. 4.3a-d and
Supplementary Fig. 4.2). Tetracycline compounds have a four-ring system (labeled A-D (Figure
3a,c), and have a distinctive three-dimensional architecture with a significant bend between rings
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A and B, allowing for unambiguous modeling into the electron density. In the
Tet(X)+chlortetracycline structure, the chlortetracycline D-ring with the attached chlorine faces
away from the substrate-binding site and towards bulk solvent (Fig. 4.3c,d). This places the C11a
substrate hydroxylation site of ring C proximal to FAD. In the Tet(50)+chlortetracycline
structure, the D-ring chlorine now faces FAD with the dimethylamine group of the A-ring
making van der Waals contacts with Phe-95 from the flexible loop, Val-348 from the first Cterminal -helix, and Ile-371 from the second C-terminal -helix (Fig. 4.3a,b). Surprisingly, this
new orientation positions C11a of chlortetracycline away from C4a of FAD.
We observed a second notable characteristic when comparing the structures of Tet(50) in
the presence or absence of chlortetracycline. In the absence of chlortetracycline, Tet(50)
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Figure 4.3: Crystal structure of Tet(50) in complex with chlortetracycline reveals an
unexpected mode of binding to the tetracycline-binding site that drives substrate loading
channel closure and FAD conversion. (a) Chlortetracycline binds to the active site of Tet(50)
in a ~180º rotated orientation relative to Tet(X)+chlortetracycline such that the D-ring of
chlortetracycline is proximal to FAD in the IN conformation (orange). A model of FAD OUT
(grey) is overlaid as found in the Tet(50) monomer B in the absence of chlortetracycline (see Fig.
4.2m and 4.2n). (b) The rotated orientation of chlortetracycline in the Tet(50)+chlortetracycline
structure is supported by van der Waals contacts provided by Val-348 (cyan) and Ile371 (deep
teal) from the two C-terminal α-helices in Tet(50) to the dimethylamine group of the A-ring of
chlortetracycline. Additionally, Phe-95 from the flexible loop makes contacts with the
dimethylamine group and closes off the substrate-binding site. (c) Tet(X) with chlortetracycline
bound with D-ring distal to FAD in the IN conformation. The substrate-binding site is widely
exposed to bulk solvent. (d) Residue Met-375 from the first C-terminal α-helix in Tet(X) (cyan)
makes van der Waals contacts to the D-ring of chlortetracycline. A second C-terminal helix (red
dashed circle, colored in deep teal) does not exist in Tet(X), and substrate can potentially enter
from various possible directions. (e) Surface representation of Tet(50)+chlortetracycline
monomer A reveals the substrate-loading channel is closed. (f) The substrate-loading channel is
also closed in Tet(50)+chlortetracycline monomer B. (g) In Tet(50)+chlortetracycline monomer
A, FAD is IN, the loop is closed, and no chlortetracycline is bound. (h) In
Tet(50)+chlortetracycline monomer B, FAD is IN, the loop is closed, and chlortetracycline is
bound. (i) While the substrate-loading channel is open in Tet(50) monomer B, with FAD OUT,
in the absence of chlortetracycline (grey), the flexible loop containing Phe-95 closes over the
channel in Tet(50)+chlortetracycline monomer B, with FAD now IN.
monomer A had FAD in an IN conformation with a closed channel (Fig. 4.2e,f,k,l) and monomer
B had FAD in an OUT conformation with an open channel (Fig. 4.2g,h,m,n). However, in the
presence of chlortetracycline, we only detected bound chlortetracycline in monomer B, which
now had FAD in an IN conformation and a closed channel (Fig. 4.3e-h). Thus, substrate binding
to Tet(50) monomer B induced a conformational switch from FAD OUT to FAD IN and loop
closure (Fig. 4.3h,i).

4.2.5 Tetracycline destructases degrade chlortetracycline despite the novel
binding mode
Due to the unanticipated orientation of chlortetracycline binding, we examined whether
the tetracycline destructases could degrade chlortetracycline. Enzymatic reactions were analyzed
at several time points by reverse-phase high-performance liquid chromatography (HPLC). We
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observed the time- and enzyme-dependent degradation of chlortetracycline by Tet(50) and
Tet(X) (Fig. 4.4a). Kinetic parameters of enzymatic inactivation were determined by monitoring
in vitro reaction progress using absorbance at 400 nm. The catalytic efficiency of Tet(50) was
five times higher than that of Tet(X) (kcat/KM values of 0.55 and 0.11 µM-1min-1, respectively)
(Supplementary Table 4.2). This increased efficiency is primarily due to increased turnover as
the apparent KM values are comparable between Tet(50) (6.3±2.0 µM) and Tet(X) (7.9±2.7 µM)
in spite of different substrate binding orientations. Tet(55) and Tet(56) also degraded
chlortetracycline in vitro with 4-fold and 15-fold greater efficiency than Tet(X), respectively
(Supplementary Table 4.2). Furthermore, tet(50,51,55,56,X) each confer chlortetracycline
resistance when expressed in E. coli at levels 16-32 fold greater than the vector-only control
(Supplementary Table 4.3). As a result, despite employing a distinct mode of substrate binding,
Tet(50,51,55,56) are able to degrade chlortetracycline more efficiently than Tet(X).
Tetracycline inactivation by Tet(X) occurs via catalysis at C11a resulting in a product of
m/z 461406. Because chlortetracycline binds Tet(50) in an alternative mode that positions C11a
far away from the reactive flavin peroxide moiety, we sought to characterize the degradation
product to establish substrate hydroxylation. Enzymatic reactions were analyzed by liquid
chromatography-mass spectrometry (Supplementary Fig. 4.6), and found to convert
chlortetracycline (m/z 479) to an oxidation product with an m/z of 467. This is in contrast to the
m/z 461 monooxygenation product observed for tetracycline406, consistent with an alternate
binding mode for chlortetracycline. To further characterize this product, reactions were subjected
to high resolution mass spectrometry. Reactions with each enzyme assayed (Tet(50,55,56))
yielded a primary product with an exact m/z of 467.12 (Supplementary Fig. 4.7). In the
alternative binding mode, the nonplanarity of the chlortetracycline substrate positions the
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Figure 4.4: Chlortetracycline is degraded by tetracycline destructases despite the unusual
binding mode. (a) HPLC chromatograms show the time and enzyme dependent consumption of
chlortetracycline. (b) High-resolution MS-MS analysis of the tetracycline destructase reaction
with chlortetracycline supports clean conversion to the m/z 467 oxidation product. MS-MS
spectrum of the m/z 467 ion from the Tet(55) reaction with proposed fragmentation pathway.
The closest reactive carbons to C4a of the FAD cofactor are C3 (c) and C1 (d) of the
chlortetracycline A ring, both of which are closer than C11a (e), the hydroxylation site observed
in Tet(X) mediated chlortetracycline degradation. (f) Two proposed mechanisms for degradation
of chlortetracycline, consistent with MS and crystallographic data. Addition of the C4a flavin
peroxide to C3 generates intermediate 1, which can undergo epoxide formation to give an
equilibrating mixture of intermediates 2 and 3. Intermediate 3 can also be generated via
intermediate 4 arising from direct attack of the C4a flavin peroxide on carbonyl C1. Intermediate
3 can rearrange to cycloheptanone intermediate 5. Fragmentation will give intermediate 6 via
loss of carbon monoxide followed by ring contraction resulting in formation of product 7 with
m/z 467 for [M+H]+.
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reactive A-ring C3 in closest proximity to the flavin cofactor. Notably, the C3 is 6.1 Å (Fig. 4.4c)
and the C1 carbonyl is 7.4 Å (Fig. 4.4d) from the C4a of the flavin cofactor. These distances are
similar to C11a of chlortetracycline and C4a of FAD in the Tet(X)+chlortetracycline structure 385,
and well within the C4a-reactive atom distances observed for flavin monooxygenases416. The
C11a in the Tet(50)+chlortetracycline, on the other hand, is on the opposite side of the molecule
and 7.9 Å away (Fig. 4.4e). Accordingly, we propose a mechanism in which the flavin peroxide
can attack C3 of the chlortetracycline A ring, yielding intermediate 1 (Fig. 4.4f). Spontaneous
epoxide formation gives intermediates 2 and 3, which rearranges to a cycloheptanone
intermediate 5 via Baeyer-Villiger ring expansion. Expulsion of carbon monoxide yields
intermediate 6, and ring contraction yields oxidation product 7, with an m/z of 467. Alternatively,
intermediate 3 can be formed by flavin peroxide attack of C1 of the chlortetracycline A ring, via
intermediate 4, and then similarly continuing through products 5-7. The final product 7 is
consistent with the fragmentation pattern observed in tandem mass spectrometry (Fig. 4.4b).
Similar oxidative cascades proceeding through Baeyer-Villiger reactions have been observed in
the biosynthesis of the cyclic type II polyketide mithramycin by the flavin monooxygenase
MtmOIV417. The discovery of alternative substrate binding modes and characterization of
degradation products demonstrates the plasticity of tetracycline destructases for adapting
flavoenzyme-mediated degradation chemistries to achieve resistance in the presence of diverse
tetracycline scaffolds.
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Figure 4.5: Anhydrotetracycline binds to the active site of Tet(50), trapping FAD in the
unproductive OUT conformation. (a) Anhydrotetracycline binds the active site of Tet(50) and
traps the FAD cofactor in the unproductive OUT conformation (orange) in monomer B. The IN
conformation of FAD from monomer A is superimposed in grey for comparison, and sterically
clashes with the D-ring hydroxyl of anhydrotetracycline. (b) Surface representation of
Tet(50)+anhydrotetracycline reveals that the substrate-loading channel remains open, which
corresponds to FAD locked in the OUT conformation. (c) In Tet(50)+anhydrotetracycline
monomer B, FAD is OUT, the loop is open, and anhydrotetracycline is bound (not shown: in
monomer A, FAD is IN, the loop is closed, no anhydrotetracycline is bound). (d) Residue Thr207 in Tet(50) makes van der Waals interactions with the planar 6-methyl group of
anhydrotetracycline (aTC) (yellow) in the bound orientation, but would sterically clash with the
6-methyl and 6-hydroxyl groups that branch from the C ring of tetracycline or chlortetracycline
if bound in a flipped orientation.

4.2.6 Anhydrotetracycline is a mechanistic and competitive inhibitor that
locks the FAD in an unproductive conformation
Due to the global dissemination of the β-lactamases, nearly all β-lactam antibiotics are
co-developed with β-lactamase inhibitors110, an approach that has successfully prolonged their
clinical utility. We reasoned that a similar strategy might be useful to counteract tetracycline
resistance by inactivation, and therefore sought to identify small molecule inhibitors of these
enzymes. Previously, we observed that anhydrotetracycline, a key biosynthetic precursor418 and
degradation product419 of tetracycline with poor antibiotic activity was not degraded by Tet(4756)406. Nonetheless, it is known to be an effector of tetracycline producers and tetracyclineresistant bacteria by inducing expression of energetically expensive tetracycline efflux pumps,
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permitting tetracycline producers to survive and selecting against tetracycline resistance112.
Based on the structural similarity to tetracycline and the intimate role that anhydrotetracycline
plays in tetracycline biology, we hypothesized that anhydrotetracycline represents an
evolutionarily-privileged

chemical

lead

for

inhibitor

design.

We obtained a co-crystal structure of Tet(50) with anhydrotetracycline bound, and
observed two unique features in comparison to our Tet(50)+chlortetracycline and the earlier
Tet(X)+chlortetracycline structures. First, anhydrotetracycline binds to Tet(50) in a flipped
orientation and in a position distinct from where chlortetracycline binds (Fig. 4.5a-c and
Supplementary Fig. 4.3-4). The unique binding mode for anhydrotetracycline is enabled by the
lack of a 6-hydroxyl group of ring C present in tetracycline or chlortetracycline (Fig. 4.5a).
Without this substitution at the 6 position, the tetracycline gains additional aromatic stabilization.
The resultant planar structure allows the 6-methyl group to make van der Waals interactions with
a conserved Thr/Ser at residue position 207 in Tet(47-56) (Fig. 4.5d and Supplementary Fig. 4.45). Thr-207 would cause a steric clash with the 6-methyl and 6-hydroxyl groups of ring C in
tetracycline or chlortetracycline, explaining the distinct binding modes.
The second interesting feature is that when anhydrotetracycline was bound, FAD was in
the OUT conformation and the substrate-loading channel was open (Fig. 4.5b,c). The unique
binding location of anhydrotetracycline locks the isoalloxazine moiety of FAD away from the
substrate-binding site and sterically blocks the transition to the FAD IN conformation observed
in the Tet(50)+chlortetracycline monomer B. This unexpected binding mode establishes a novel
mechanism for inhibitors that stabilize the inactive OUT conformation of the FAD cofactor in
flavoenzymes and prevents transition to the necessary FAD IN conformation for catalysis.
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Therefore, anhydrotetracycline is a mechanistic inhibitor of the tetracycline destructases that also
competitively blocks substrate binding.

4.2.7 Anhydrotetracycline inhibits tetracycline destructases and functionally
rescues tetracycline
We examined the effect of anhydrotetracycline on tetracycline destructase activity in
vitro. We performed in vitro enzymatic reactions in the presence or absence of
anhydrotetracycline followed by HPLC. For clinical relevance, we first focused on Tet(56), the
tetracycline destructase from pathogenic L. longbeachae. We observed the Tet(56)-dependent
degradation of 0.1 mM tetracycline over time, as demonstrated by the decrease in the tetracycline
peak (Fig. 4.6a). However, in the presence of 1 mM anhydrotetracycline, the tetracycline peak
does not change, indicating that tetracycline is not degraded (Fig. 4.6b). Similar results were
observed for Tet(50,51,55,X) (Supplementary Fig. 4.8, Supplementary Table 4.4). We also
monitored enzymatic inactivation of tetracycline using absorbance at 400 nm in the presence of a
range of anhydrotetracycline concentrations. Anhydrotetracycline inhibited Tet(50,55,56) with
IC50 values of 83.2±1.2 µM, 25.6±1.2 µM, and 37.1±1.1 µM, respectively (Fig. 4.6c). Thus,
anhydrotetracycline prevents the enzyme-dependent degradation of tetracycline. Together with
our structural data, this indicates a common mechanism of inhibition for tetracycline-inactivating
enzymes, and establishes anhydrotetracycline as a lead compound that presents a flexible starting
point for generating tetracycline destructase inhibitors with improved activity420. This inhibition
strategy that stabilizes inactive cofactor states is widely applicable to the larger superfamily of
flavoenzymes and offers new avenues for inhibiting any member of this superfamily, many of
which have been implicated in human disease and represent promising targets for
hypercholesterolemia and antifungal drugs421.
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Figure 4.6: Anhydrotetracycline prevents enzymatic tetracycline degradation, functionally
rescuing tetracycline antibiotic activity. (a) Tetracycline (TC) is degraded by Tet(56) in vitro
HPLC chromatograms show in vitro reactions with UV detection at 363 nm and separation on a
C18 column. (b) TC degradation is attenuated by the addition of an excess of aTC. (c) Dosedependent inhibition of Tet(50,51,56) activity by anhydrotetracycline. Velocity is determined by
measuring tetracycline consumption via change in absorbance at 400 nm. Data are represented as
mean ± s.d. of three technical replicates. (d) Dose-response curve showing effect of aTC on
sensitivity of Tet(56)-expressing E. coli to TC in liquid culture. Data are represented as mean ±
s.e.m. of three technical replicates. (e) TC and aTC synergistically inhibit growth of E. coli
expressing Tet(56), FICI = 0.1875. Points show minimum inhibitory concentrations of two drugs
in combination. Dashed line indicates the theoretical concentration of additive drug interaction.
Data represented as mean ± s.e.m. of three technical replicates.

4.2.8 The novel inhibition mechanism restores tetracycline activity against
tetracycline destructase-expressing bacteria
Our

data

suggest

that

a

tetracycline/tetracycline-destructase-inhibitor

(e.g.

anhydrotetracycline) combination therapy strategy could potentially be employed to rescue
antibiotic activity of tetracyclines against bacteria that encode tetracycline-inactivating enzymes.
Tet(X) and Tet(56) are of particular interest due to their clinical significance. tet(X) has been
recently identified in a number of human pathogens, including 11 nosocomial uropathogens from
Sierra Leone138 and 12 Acinetobacter baumannii isolates from a hospital in China137. We also
showed that tet(56) is present and functional in L. longbeachae406 – a pathogen responsible for
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causing Pontiac Fever and Legionnaires’ Disease409,410. Accordingly, we tested whether
anhydrotetracycline rescues tetracycline efficacy against E. coli expressing tet(56). Two µg/mL
anhydrotetracycline caused a greater than 5-fold change in sensitivity of E. coli expressing
tet(56) to tetracycline in liquid culture, as indicated by a change in IC50 from 47.4 to 8.27 µg/mL
(Fig. 4.6d). Further, anhydrotetracycline and tetracycline acted synergistically to inhibit growth
of E. coli expressing Tet(50,51,55,56), with fractional inhibitory concentration indices (FICI) of
0.625, 0.5, 0.375 and 0.1875, respectively (Fig. 4.6e and Supplementary Fig. 4.9). Although
anhydrotetracycline is not degraded by Tet(47-56), it is slowly degraded by Tet(X)406. However,
anhydrotetracycline still was able to prevent tetracycline degradation by Tet(X) in vitro
(Supplementary Fig. 4.8). Our proof of concept experiment, taken together with our structural
and in vitro data, reveals that a co-administration strategy based on inhibition of tetracyclineinactivating enzymes could be effective for the treatment of tetracycline-resistant bacterial
infections.

4.3 Materials and Methods
4.3.1 Legionella plasmid construction
The Tet(56) deletion plasmid, pJB7204, was constructed by amplifying 2 kb of DNA
upstream and downstream of the Tet(56) ORF using primers JVP2913/JVP2910 and
JVP2911/JVP2912 and Legionella longbeachae chromosomal DNA. The PCR products were
digested with SalI/NotI and NotI/SacI, respectively, and ligated into SalI/SacI-digested suicide
vector pSR47S422. The ligated product was transformed into EC100D::Δpir and selected on LB
plates containing 20 µg/ml kanamycin.

The Tet(56) complementing clone, pJB7207, was

constructed by amplifying the Tet(56) ORF using primers JVP2921/JVP2922 and Legionella
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longbeachae chromosomal DNA. The PCR product was digested with BamHI/SalI and cloned
into BamHI/SalI-digested expression vector pJB1625 (Supplementary Table 4.5).

4.3.2 Legionella strain construction
The Tet(56) deletion strain, JV8858, was constructed by a traditional loop-in/loop-out
strategy.

Briefly, the wild type Legionella longbeachae strain JV595 was transformed by

electroporation with the ΔTet(56) suicide plasmid pJB7204 and integrants were selected on CYE
plates423 containing 30 µg/ml kanamycin. Resolution of the merodiploid was obtained on CYE
plates containing sucrose. Strains were then electroporated with the vector pJB1625 or the
Tet(56) complementing clone pJB7207 and transformants were selected on CYE plates
containing 5 µg/ml chloramphenicol.

4.3.3 Tetracycline inactivation in Legionella
Antibiotic susceptibility testing was performed using L. longbeachae wild type and
deletion strains and L. pneumophila424, bearing either the vector pJB1625425 or the Tet(56)
complementing clone pJB7207. Minimum inhibitory concentrations were determined according
to Clinical and Laboratory Standards Institute (CLSI) procedures with the following
modifications. Results are representative of three independent experiments. The strains were
initially grown as a patch on CYE plates containing chloramphenicol for 2 days at 37 degrees.
The bacteria were swabbed into distilled water, washed one time, and resuspended at an 600 nm
absorbance (OD600) of 1 (~1E9 CFU/ml). The culture was diluted 200 fold into 10 mL of
buffered AYE media containing 2 µg/ml chloramphenicol and a range of tetracycline but lacking
supplemental iron, as iron can interfere with tetracycline activity. The cultures were grown for
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48 hours at 37ºC on a roller drum and the absorbances (OD600) were periodically measured using
a Genesys 20 Spectrophotometer.

4.3.4 Cloning, expression and purification of tetracycline-inactivating enzymes
All genes encoding tetracycline-inactivating enzymes were cloned into the pET28b(+)
vector (Novagen) at BamHI and NdeI restriction sites. Constructs were transformed into BL21Star (DE3) competent cells (Life Technologies). Cells harboring the plasmid were grown at 37ºC
in LB medium containing a final concentration of 0.03 mg/mL kanamycin. Once cells reached an
OD600 of 0.6, cells were cooled to 15 ºC and induced with 1 mM IPTG overnight. After this
period, cells were harvested by centrifugation at 4000 rpm for 10 min at 4 ºC. Cell pellets were
suspended in 10 mL of 50 mM Tris (pH 8.0), 100 mM NaCl, 10 mM imidazole (pH 8.0), 1 mM
PMSF, and 5 mM BME per 1 liter of LB medium and stored at -80ºC.
Cells were thawed in the presence of 0.25 mg/mL lysozyme and disrupted using
sonication on ice for 60 seconds. The cell extract was obtained by centrifugation at 13,000 rpm
for 30 min at 4 ºC and was applied onto nickel rapid run agarose beads (Goldbio) equilibrated
with wash buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 20 mM imidazole (pH 8.0), and 5 mM
BME). The wash buffer was used to wash the nickel column three times with five column
volumes. After washing, protein was eluted with five column volumes of elution buffer (wash
buffer with 300 mM imidazole). The protein sample was further purified by gel chromatography
using a HiLoad 16/600 Superdex 200pg column (GE Healthcare) equilibrated with 10 mM Tris
(pH 8.0), 150 mM NaCl, 5 mM dithioerythritol (DTT). The fractions containing the protein of
interest were pooled and concentrated using a 30K MWCO Amicon centrifugal filter (Millipore).
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4.3.5 Tet(55) selenomethionine-labelling
For selenomethionine-labelled Tet(55) (Se-Met Tet(55)), cells were grown in 1 L of
SelenoMetTM Medium supplemented with SelenoMet Nutrient Mix (Molecular Dimensions
Limited). Once cells reached an OD600 of 0.6, feedback inhibition amino acid mix (0.1 g of
lysine, threonine, phenylalanine; 0.05 g of leucine, isoleucine, valine; 0.05 g of L(+)
selenomethionine (ACROS Organics 259960025)) was added and the cells were shaken for 15
minutes at 15 ºC. After 15 minutes, cells were induced at 15 ºC with 1 mM IPTG overnight. All
other purification conditions were the same as for the native tetracycline-inactivating enzymes.

4.3.6 Crystallization, data collection, and structure determination
For crystallization, Se-Met Tet(55) was concentrated to 25 mg/mL. Crystals were
obtained by vapor diffusion using hanging drops equilibrated at 18 °C. Se-Met Tet(55)
crystallized in 0.1 M Tris-HCl (8.5) and 20-25% PEG 3000. Se-Met Tet(55) crystals were
harvested directly from the growth condition and flash-frozen under liquid nitrogen.
Native Tet(55) was concentrated to 50 mg/mL and crystallized in 0.1 M Tris-HCl (8.5)
and 25-27% PEG 4000. Native Tet(55) crystals were harvested directly from the growth
condition and flash-frozen. Tet(50) was concentrated to 35 mg/mL and crystallized in 0.1 M
MES (pH 6.0-6.5), 1.6-2.0 M ammonium sulfate, 2-10% 1,4-Dioxane. Crystals were harvested
directly from the growth condition and flash-frozen. For co-crystal structures, Tet(50) was
concentrated to 17 mg/mL, and Tet(50) crystals were soaked with mother liquor plus 5 mM
chlortetracycline or 4mM anhydrotetracycline for 30 minutes before flash-freezing. Tet(51) was
concentrated to 13 mg/mL and crystallized in 0.1 M MES (pH 6.0) and 10% PEG 6000. Crystals
were cryo-protected with 0.1 M MES (pH 6.0), 10% PEG 6000, and 30% glycerol before flashfreezing. Tet(56) was concentrated to 38 mg/mL and crystallized in 0.1 M tri-sodium citrate (pH
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5.6), 10% PEG 4000, 10% isopropanol. Tet(56) crystals were cryo-protected in 0.1 M tri-sodium
citrate (pH 5.6), 10% PEG 4000, 10% isopropanol, and 20% glycerol before flash-freezing.
The crystal structure of Tet(55) was solved by seleno-methionine labeling and singlewavelength anomalous dispersion (SAD) (Supplementary Table 4.1), as molecular replacement
using the previously published Tet(X) structures was unsuccessful. The inability to solve the
structure by molecular replacement demonstrates that tetracycline-inactivating enzymes are
structurally diverse and multiple structures are required to capture the diversity within the family.
X-ray data for selenomethionine-labelled Tet(55) were collected from a single crystal using a
wavelength of 0.976289 Å at synchrotron beamline 4.2.2 of the Advanced Light Source in
Berkeley, CA. All other native data sets were collected at a wavelength of 1 Å. Data were
collected on the CMOS detector and were processed with XDS426. Structure solution for Se-Met
Tet(55) was performed using PHENIX AutoSol. Thirteen selenium sites were found, which gave
a figure of merit of 0.370. The resulting Tet(55) model was refined against the native Tet(55)
data set. R and Rfree flags were imported from the Se-Met Tet(55) mtz file using UNIQUEIFY
within the CCP4 package427. Tet(50,51,56) structures were solved my PHENIX AutoMR using
an ensemble of three domains of Tet(55) (domain 1 = aa1-70, aa100-172, aa276-319; domain 2=
aa71-99, 173-275; domain 3= aa320-387). Structure solution for the Tet(50) chlortetracycline
and anhydrotetracycline structures were performed by refinement with the apo Tet(50) structure,
from which the R and Rfree flags were imported using UNIQUEIFY.
Subsequent iterated manual building/rebuilding and refinement of models were
performed using Coot428 and PHENIX429, respectively. The structure validation server
MolProbity430 was used to monitor refinement of the models. All final refined models have
favorable crystallographic refinement statistics, as provided in Supplementary Table 4.1. Figures
154

were generated and rendered in PyMOL Molecular Graphics System, Version 0.99rc6,
Schrödinger, LLC.

4.3.7 In vitro tetracycline and chlortetracycline inactivation assays
Reactions were prepared in 100 mM TAPS buffer with 100 µM substrate, 14.4 µM
enzyme, and an NADPH regenerating system consisting of the following components (final
concentrations): glucose-6-phosphate (40mM), NADP+ (4mM), MgCl2 (1mM), and glucose-6phosphate dehydrogenase (4U/ml). The regeneration system was incubated at 37ºC for 30
minutes to generate NADPH before use in reactions. Reactions were sampled at various
timepoints, and quenched in four volumes of an acidic quencher consisting of equal parts
acetonitrile and 0.25 M HCl.
Products generated from enzymatic inactivation of both tetracycline and chlortetracycline
were separated by reverse phase HPLC using a Phenomenex Luna C18 column (5µm, 110 Å,
2×50mm) and 0.1% trifluoroacetic acid in water (A) and acetonitrile (B) as mobile phase.
Injections of 25µl sample volume were eluted using a linear gradient from 25%B to 75%B over
14 minutes at a flow rate of 1ml/min.
Chlortetracycline reactions analyzed by high resolution tandem mass spectrometry were
sampled at 75 minutes. The quenched samples were diluted 6X with 50% methanol in 0.1%
formic acid and run on the Q-Exactive Orbitrap by direct infusion using the Advion Triversa
nanomate. The data were acquired with resolution of 140,000. The MS scan was acquired from
m/z 300 – 550. MS/MS spectra were acquired on the m/z 467.12 compounds.
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4.3.8 Tetracycline inactivation in E. coli
Antibiotic susceptibility testing was performed in E. coli MegaX cells (Invitrogen)
bearing the pZE21 expression vector with the tetracycline inactivating gene of interest.
Minimum inhibitory concentrations were determined according to Clinical and Laboratory
Standards Institute (CLSI) procedures339 using Mueller-Hinton broth with 50 µg/mL kanamycin
and a range of chlortetracycline concentrations profiled via absorbance measurements at 600nm
(OD600) at 45 minute intervals using the Synergy H1 microplate reader (Biotek Instruments, Inc)
for 48 hours at 37ºC.

4.3.9 Kinetic
inactivation

characterization

of

tetracycline

and

chlortetracycline

The optimal enzyme concentration for steady-state kinetics assays was determined by
varying the concentration of enzyme while keeping chlortetracycline and NADPH concentration
constant. 0.4 μM enzyme was found to give linear slopes for all concentrations of substrate
tested, and was used as the enzyme concentration for all kinetics experiments.
Reactions were prepared in 100 mM TAPS buffer at pH 8.5 with 0-160 µM substrate, 1.6
mM NADPH, and 0.4 µM enzyme. UV-visible spectroscopy measurements were taken in
triplicate at 400nm wavelength light with a Cary 60 UV/Vis system (Agilent) for 10 minutes at
room temperature. Initial reaction velocities were determined by linear regression using the
Agilent Cary WinUV Software, and fitted to the Michaelis-Menten equation:

using GraphPad Prism 6.
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4.3.10 LC-MS characterization of chlortetracycline degradation products
Reactions were prepared in 100 mM phosphates buffer at pH 8.5 with 1mM CTC, 0.5
mM NADPH, 5 mM MgCl2 and 0.4 µM Tet(55). After 10 minutes, the reaction was centrifuge
filtered for 10 minutes using a Millipore Amicon Ultracel (3 kDa MW cutoff) to remove enzyme.
Prior to centrifugation, filters were triply rinsed with phosphate buffer to remove excess glycerol.
The filtrate was collected and analyzed by LC-MS using an Agilent 6130 single quadrupole
instrument with G1313 autosampler, G1315 diode array detector, and 1200 series solvent
module. Reaction products were separated using a Phenomenex Gemini C18 column, 50 × 2 mm
(5 µm) with guard column cassette was used with a linear gradient of 0% acetonitrile + 0.1%
formic acid to 95% acetonitrile + 0.1% formic acid over 14 min at a flow rate of 0.5 mL/min
prior to analysis by electrospray ionization.

4.3.11 In vitro characterization of anhydrotetracycline inhibition
IC50 values were determined for Tet(50), Tet(55), and Tet(56) by measuring the initial
velocity of tetracycline degradation in the presence of varying concentrations of
anhydrotetracycline. The concentrations of tetracycline and NADPH were kept constant at 25
μM and 500 μM, respectively. Assays were prepared by combining all components except for
enzyme and equilibrating to 25°C for five minutes. After the addition of enzyme, absorbance at
400 nm was measured for five minutes. All measurements were taken in triplicate. The final
concentrations for assay components were 100 mM TAPS buffer (pH 8.5), 25 μM tetracycline,
500 μM NADPH, 16 mM MgCl2, 0.4 μM enzyme, and 0.05 – 150 μM anhydrotetracycline. A
control assay using no anhydrotetracycline was assigned a concentration of 1.0×10-15 μM for
analysis. A second control using no enzyme and 100 μM anhydrotetracycline was assigned a
concentration of 1.0×1015 μM to simulate full inhibition of enzyme. IC50 values were determined
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by plotting the log of anhydrotetracycline concentration against v0 in GraphPad Prism 6.
Functional Tet(51) expressed poorly, so Tet(51) was omitted from these and other in vitro
experiments.

4.3.12 Checkerboard synergy assay
Tetracycline (1024 µg/mL) and anhydrotetracycline (256 µg/mL) were dissolved in
cation-adjusted Mueller-Hinton broth supplemented with 50 ug/mL kanamycin. A twofold
dilution series of each drug was made independently across 8 rows of a 96 well master plate
before 100 uL of each drug dilution series were combined into a 96 well culture plate (Costar),
with rows included for no-drug and no-inocula controls. A sterile 96-pin replicator (Scinomix)
was used to inoculate plates with ~1 uL of E. coli MegaX (Invitrogen) expressing a tetracycline
inactivating enzyme, diluted to OD600 0.1 using. Plates were sealed with Breathe-Easy
membranes (Sigma-Aldrich) and incubated at 37˚C with shaking at 220 rpm. Endpoint growth
was determined by OD600 at 20 and 36 hours of growth using a Synergy H1 plate reader
(BioTek, Inc.). Three independent replicates were performed for each strain on separate days.
Synergy of anhydrotetracycline and tetracycline combinations was determined using the
fractional inhibitory concentration index (FICI) method431,

where FICI>1 indicates antagonism, FICI = 1 indicates additivity, and FICI <1 indicates
synergy. The efficacy of the drug combination was also evaluated in the L. longbeacheae
background, but synergy was not observed.
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4.4 Discussion
The widespread anthropogenic use of tetracycline antibiotics motivates the immediate
study of emerging mechanisms of tetracycline resistance, such as enzymatic inactivation. Our
data provide unprecedented insight into the dynamics of tetracycline-inactivating enzymes and
reveal a novel mode of inhibition. Substrates like chlortetracycline are loaded into enzymes in
the FAD OUT conformation through the substrate-loading channel (Supplementary Fig. 4.10a),
which is open as a flexible loop is pulled away from the channel. Upon substrate binding, the
enzyme converts to FAD IN, the channel closes, and catalysis can occur due to the proximity of
FAD to the substrate. Mechanistic inhibitors like anhydrotetracycline also enter the enzyme
through the same channel but bind at a distinct site (Supplementary Fig. 4.10b). Binding of
inhibitor in this location sterically blocks FAD conversion to the IN conformation and prevents
subsequent substrate binding and catalysis. Our model predicts that compounds that either bind
with higher affinity to the inhibitor binding pocket, or that concomitantly bind to the inhibitor
and substrate-binding sites will provide enhanced inhibition for the control of tetracycline
resistance. This novel mechanism of inhibition is not only applicable to preventing antibiotic
resistance, but is highly relevant to additional FAD dependent enzymes that comprise the
flavoenzyme superfamily and are of clinical interest421.
The rise in resistance to early-generation tetracyclines has spurred the development of
next-generation derivatives, including tigecycline (approved for human use in 2005)134, and
eravacycline and omadacycline (currently in late-stage clinical trials)139,140. These newer drugs
are designed to evade resistance by efflux or ribosomal protection, but they are largely untested
against tetracycline-inactivating enzymes. Alarmingly, tigecycline was found to be vulnerable to
oxidative inactivation by Tet(X)385, which was recently identified for the first time in numerous
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pathogens of high clinical concern137,138. These challenges highlight the immediate importance of
studying mechanisms of emerging tetracycline resistance, such as those described here that
expand substrate scope.
Tetracycline resistance by enzymatic inactivation has thus far been rarely documented
compared to resistance by efflux or ribosomal protection. Growing evidence, however, indicates
that enzymatic tetracycline inactivation is a widespread feature in soil microbial communities 406,
and is a recently observed emerging threat in human pathogens137,138,386. Flavoenzymes display a
proclivity for horizontal gene transfer and gene duplication, bestowing the potential to spread
between bacteria and acquire novel functions389. Interestingly, the contigs on which tet(47-55)
were discovered also contained mobility elements and other resistance genes58,406, suggesting
that their original genomic context may be as part of a multidrug resistance cassette or mobile
genetic element. This indicates that tetracycline-inactivating enzymes pose a threat for facile
acquisition by additional human pathogens. Indeed, we show that tet(56) is present and
functional in the human pathogen L. longbeachae, and tet(X) has now been reported in four out
of six ESKAPE pathogens137,138,386, demonstrating the urgency of this threat. Our results reveal
the structural basis for plasticity and dynamics in substrate binding in these enzymes. We
propose a novel combination therapy strategy to retain tetracycline efficacy against bacteria that
harbor tetracycline-inactivating resistance genes. Our results provide the structural and
biochemical foundation to counter the alarming emergence of tetracycline resistance via
enzymatic inactivation.
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4.6 Supplementary Figures

Supplementary Figure 4.1: Overall structures and FAD conformation states of
Tet(50,51,55,56)
Crystal structures of (a) Tet(50) monomer A, (b) Tet(50) monomer B, (c) Tet(51), (d) Tet(55),
and (e) Tet(56).
(f) In Tet(50) monomer A, FAD is bound non-covalently in the IN conformation, characterized
by a 12.3 Å distance between the C8M and C2B atoms of the FAD molecule.
(g) In Tet(50) monomer B, FAD is bound in the OUT conformation (5.2 Å between the C8M and
C2B atoms).
(h) In Tet(51), FAD is bound in the OUT conformation (4.5 Å between the C8M and C2B
atoms).
(i) In Tet(55), no electron density for ordered FAD is observed.
(j) In Tet(56), FAD is bound in the OUT conformation (5.2 Å between the C8M and C2B
atoms).
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Supplementary Figure 4.2: Tetracycline compounds have a distinctive three-dimensional
architecture with a significant bend between rings A and B, allowing for unambiguous
modeling into the electron density
(a) The Fo - Fc map (contoured at 2.0) before modeling of chlortetracycline.
(b) The 2Fo - Fc map (contoured at 1.0) after modeling of chlortetracycline.
(c)The Fo - Fc map (contoured at 2.0) before modeling of anhydrotetracycline.
(d)The 2Fo - Fc map (contoured at 1.0) after modeling of anhydrotetracycline.
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Supplementary Figure 4.3: Multiple sequence alignment of Tet(47-56). Tetracycline
destructases have high levels of sequence similarity in the residues important for binding of
anhydrotetracycline (aTC, orange) or chlortetracycline (CTC, pink). Conserved FAD binding
motif is boxed in blue.
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Supplementary Figure 4.4: Anhydrotetracycline prevents enzymatic degradation of
tetracycline
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Supplementary Figure 4.5: Anhydrotetracycline restores tetracycline efficacy against E.
coli expressing tet(50,51,55,56),
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Supplementary Figure 4.6: Anhydrotetracycline synergizes with tetracycline to kill E. coli
expressing tet(50,51,55,56) but not tet(X)
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Supplementary Figure 4.7: Model for binding dynamics, substrate plasticity, and inhibition
of tetracycline-inactivating enzymes
(a) Substrate (e.g. chlortetracycline) can enter and bind the active site of a tetracycline
destructase, resulting in a conformational switch from FAD OUT (grey) to FAD IN (orange) and
closure of the substrate site.
(b) A mechanistic inhibitor (e.g. anhydrotetracycline) enters and binds the active site, but
sterically prevents the FAD cofactor from switching from the OUT to IN conformation and
thereby preventing catalysis. Further, it can act synergistically to competitively prevent substrate
from binding.
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Supplementary Table 4.1: Data collection and refinement statistics

Data
collection
Space group
Cell
dimensions
a, b, c (Å)
 (º)

Tet(55)
Native

Tet(55)
SeMet

Tet(50)

Tet(51)

Tet(56)

Tet(50) +
chlortetracyc
line

Tet(50) +
anhydrotetrac
ycline

P21212

P21212

P212121

P21

P21212

P212121

P212121

64.74,
124.43,
45.73
90, 90,
90

65.14,
123.98,
45.75
90, 90,
90

50.94,
107.61,
152.48
90, 90, 90

83.49,
81.69,
127.31
90,
96.790,
90

76.49,
114.02,
94.81
90, 90, 90

51.10,
107.22,
152.63
90, 90, 90

50.99,
107.37,
152.79
90, 90, 90

1.000029

1.000028

1.000032

1.000031

1.000031

20 - 2.10
(2.20 - 2.10)

20 - 1.85
(1.95 1.85)
9.7%
(79.7%)
11.93
(1.90)
99.8%
(69.7%)
99.7
(99.6)
3.77
(3.67)

20 - 3.30
(3.30 3.20)
13.2%
(119.2%)
10.76
(1.16)
99.6%
(48.7%)
98.5
(94.0)
3.60
(3.22)

20 - 1.75
(1.85 - 1.75)

20 - 2.25
(2.35 - 2.25)

8.6%
(86.5%)
19.31 (2.35)

11.5%
(68.7%)
13.57 (2.37)

99.9%
(76.4%)
98.7 (98.1)

99.7%
(88.0%)
98.6 (92.7)

7.42 (7.37)

4.93 (4.92)

Wavelength

1.018211

Resolution (Å)

20 - 2.00
(2.102.00)
11.0%
(96.4%)
16.14
(2.24)
99.9%
(70.5%)
99.7
(98.8)
7.17
(6.85)

Rmeas
I/I
CC1/2
Completeness
(%)
Redundancy

Refinement
Resolution (Å)
No. reflections
Rwork/ Rfree
No. atoms
Protein
Ligand/ion
Water
B-factors
Protein
Ligand/ion
Water
R.m.s
deviations
Bond
lengths (Å)
Bond angles
(º)

Peak
0.97628
9
20 - 1.90
(2.00 1.90)
6.4%
(59.7%)
17.45
(2.57)
99.9%
(79.5%)
99.6
(98.0)
3.79
(3.59)

10.8%
(71.6%)
15.07 (2.47)
99.8%
(83.1%)
98.1 (99.3)
5.70 (5.55)

20 - 2.00
25,629
19.25/
23.86

20 - 2.10
48,794
22.66/26.21

20 - 1.85
144,460
16.77/
19.58

20 - 3.30
12,803
23.96/
29.55

20 - 1.75
84,325
17.80/
21.90

20 - 2.25
39,793
20.73/
25.39

3,284
5
187

6,641
136
376

13,095
256
942

5,819
116
0

6,733
181
444

6,697
182
337

30.24
28.36
30.51

29.97
36.23
39.75

27.94
17.78
32.00

97.42
82.54

23.42
29.83
26.88

30.66
39.44
28.79

0.005

0.003

0.011

0.002

0.011

0.005

0.797

0.547

1.186

0.645

1.273

0.789
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Supplementary Table 4.2: Kinetic parameters for Tet(50,55,56,X)
Tetracycline

Chlortetracycline

KM (µM)

Vmax (s-1)

kcat/KM (µM-1s-1) KM (µM)

Vmax (s-1)

kcat/KM (µM-1s-1)

Tet(50)

16.84 ± 3.555

0.02852 ±
0.001555

0.004234

6.298 ± 2.035

0.02302 ±
0.001634

0.009138

Tet(55)

4.562 ± 1.684

0.01233 ±
0.0009667

0.006757

6.001 ± 1.315

0.0194 ±
0.0002397

0.008082

Tet(56)

7.665 ± 1.630

0.0425 ±
0.002051

0.013862

3.654 ± 1.080

0.04389 ±
0.002619

0.030029

Tet(X)

10.77 ± 2.613

0.00448 ±
0.0002618

0.00104

7.878 ± 2.668

0.00598 ±
0.0004613

0.001898
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Supplementary Table 4.3: Relevant strains, plasmid, and primers employed in this study
Strains, Plasmids, Primers

Reference or source

Strains
Lp02

Legionella pneumophila Philadelphia I

424

JV595

Legionella longbeachae

ATCC 33462

JV8858

Legionella longbeachae ∆tet(56)

This study

JV8861

JV595 + pJB7207

This study

JV8864

JV595 + pJB1625

This study

JV8868

JV8858 + pJB7207

This study

JV8870

JV8858 + pJB1625

This study

JV8874

Lp02 + pJB7207

This study

JV8876

Lp02 + pJB1625

This study

pSR47S

Suicide plasmid R6K suicide vector (KanR sacB)

422

pJB1625

Complementing vector (CmR version of pJB908)

425

pJB7204

∆tet(56) suicide plasmid

This study

pJB7207

tet(56) complementing clone

This study

Plasmids

Primers
JVP2910

GCAGCGGCCGCGCCAATGACGAGAATTTTGATATTTTTAGAC

JVP2911

GCAGCGGCCGCCAATTTCGAATGGGATTACCTTACCTC

JVP2912

GCAGAGCTCGCTTAATGATATCAAGATTAATACAATTCCAATCC

JVP2913

GCAGTCGACGCTCAATTGTATGTTCGTTATGAAGATGGG

JVP2921

CCAGGATCCTAAGAGGAGAAATTAACTATGTCTAAAAATATCAAAATTCTCGTC

JVP2922

CCAGTCGACGTCCACTATGATGATTCATATTGAGG
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Chapter 5: Conclusions
5.1 The effects of early life antibiotic therapy on the preterm
infant gut microbiota and resistome
A reservoir of antibiotic resistance genes of critical interest lies in human associated
microbes, encompassing both benign or commensal organisms and pathogens. The human gut
hosts a diverse commensal microbial community, whose collective genomes (the microbiome)
encode an arsenal of functions, including vital activities that modulate host health and
physiology as well as antibiotic resistance genes295. During the first years of life, the infant gut
microbiota plays crucial roles in pathogen exclusion, nutrient acquisition, and immune system
maturation295,432. Microbiota development can be altered by factors including gestational age at
birth, delivery and feeding modes, and antibiotic exposure7,432,433. Perturbation of the gut
microbiota during early infancy may be disproportionately damaging272,316, and has been linked
to a variety of morbidities such as metabolic and immune disorders263,264,295,298. This is
particularly relevant for preterm infants, who almost all receive antibiotics in the first days of
life249,272,316.
The infant gut microbiota is shaped by both prenatal and postnatal factors246,247.
Following birth, the infant gut microbiota undergoes a patterned maturation process248-250.
Perturbation of the gut microbiota during this key developmental window can have lasting
effects on host physiology and disease risk254-259. One of the most common perturbations during
this period, antibiotic therapy258,260, can substantially alter the gut microbiota and infant
physiology255,261-266. Antibiotic-induced gut microbiota dysbioses in this population are linked to
the pathogenesis of necrotizing enterocolitis270-272, late onset sepsis273,274, and other adverse
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health outcomes275. While these correlations exist, the underlying etiologies remain unclear,
motivating the study of microbiota development in the context of antibiotic therapy in this
vulnerable population276.
During early-life hospitalization in the NICU, the preterm infant gut microbiota is
characterized by an extensive antibiotic resistome and a high relative proportion of MDROs,
which are further enriched following antibiotic exposure7. However, the persistence of these
microbiome disruptions is unclear. To this end, I conducted a longitudinal sequencing and
culture based interrogation of the preterm infant gut microbiota compared to age-matched,
antibiotic naïve near term infant controls to quantify the effects of early life antibiotic therapy on
microbiota and resistome development over the first twenty months of life. Using random
forests, I trained a model of healthy microbiota development in the absence of early life
hospitalization and antibiotic treatment. I applied this model to preterm infants in my cohort and
identified acute but transient microbiota immaturity that resolves concomitant with discharge
from the NICU. By sequencing isolates cultured from infant stools at multiple timepoints, I
identified prolonged and persistent carriage of multidrug resistant Enterobacteriaceae in the gut
microbiota of preterm infants. This suggests that these potentially pathogenic strains establish a
gastrointestinal niche while infants are hospitalized, and retain that niche following discharge to
home. In order to characterize the gut resident resistome of the infants in my cohort, I used
functional metagenomics to assay 320 Gb of metagenomic DNA for resistance function in high
throughput. I assembled and annotated 874 unique antibiotic resistance genes from these
microbiota. After computing the relative abundance of these genes across all microbiota in my
cohort, I identified a persistently enriched resistome as well as perturbed patterns of resistome
assembly in the gut microbiota of preterm infants over the twenty months of life. Lastly, to
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synthesize my findings on enduring effects of early life antibiotic treatment on the preterm infant
gut microbiota, I used a support vector machine to classify post-discharge samples as originating
from an antibiotic treated preterm infant or an antibiotic naïve near term infant based on the
metagenomic features present in the stool. I was able to classify with high accuracy the group to
which a stool belonged despite inability to distinguish these stools based on species composition
alone. This provides evidence of a persistent metagenomic signature of early life antibiotic
treatment in preterm infants that lasts beyond discharge from the NICU and may play a role in
long-term adverse health outcomes in preterm infants for which the etiology is currently unclear.
This work has the potential to improve antibiotic stewardship in NICU settings, as well as
inform antibiotic treatment strategies in neonatal settings such that infections are appropriately
treated while microbiota diversity is spared. My results underscore the need for narrow spectrum
alternative to the antibiotic regimens currently used widely in neonatal medicine. While it is
possible that the persistent metagenomic signatures of early life antibiotic treatment which I
identified play a role in the long term neurological, metabolic, and immune pathologies from
which preterm infants suffer, further experiments using model systems including gnotobiotic
animals are required to substantiate this link. Additional future work in this space could

5.2 Emergence of tetracycline resistance by inactivation
across habitats
Tetracycline resistance is typically acquired via horizontal gene transfer and occurs
almost exclusively by ribosomal protection or antibiotic efflux368,371. A third mechanism,
enzymatic inactivation of tetracycline, is rarely observed, with Tet(X) being the only previously
characterized example28,401,434. Both common tetracycline resistance mechanisms have their
evolutionary origins in the environment25,94,376, but are now widely distributed in many
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commensal and pathogenic bacteria4,23,122. Tetracycline antibiotics have been widely used in
clinical, agricultural, and industrial settings for the past seven decades, and medicinal chemists
and pharmaceutical companies continue to revisit the tetracycline scaffold as a source for new
antibiotics. These new developments include tigecycline (approved for human use in 2005)134,
eravacycline383 (approved for human use in 2018), and omadacycline (currently in late stage
clinical trials)140.
We recently discovered a novel family of ten tetracycline inactivating enzymes from
functional selection of grassland and agricultural soil metagenomes58,406. The set included a
functionally validated but previously unknown tetracycline destructase homolog from the human
pathogen Legionella longbeachae. These genes were annotated as flavin adenine dinucleotide
(FAD) dependent oxidoreductases. The tetracycline destructases confer high-level resistance
against tetracycline and oxytetracycline when heterologously expressed in E. coli, and degrade
tetracycline in vitro with a dependence on time, enzyme, and reduced nicotinamide adenine
dinucleotide phosphate (NADPH). Furthermore, tetracycline inactivation by the tetracycline
destructases proceeds via diverse mechanisms, producing decay products not seen in tetracycline
inactivation by Tet(X)28,387,406. The tetracycline destructases are likely candidates for
dissemination to the clinic and expansion of substrate tolerance, potentially compromising nextgeneration tetracyclines139 and motivating deep mechanistic analysis of their activities and
surveillance of their prevalence across microbial habitats.
This work has importantly identified tetracycline resistance by inactivation as a
mechanism of resistance that is more widespread in commensal, environmental, and pathogenic
organisms than had previously been appreciated. By elucidating the mechanism of action of
these enzymes prior to their broad clinical dissemination, we were able to devise rationally an
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inhibitor-based strategy to counter the action of these resistance genes. I described
anhydrotetracycline, and inhibitor that blocks tetracycline degradation by tetracycline
inactivating enzymes in vitro and is sufficient to restore tetracycline efficacy in the face of
resistant bacteria which encode a tetracycline inactivator. Using biochemistry and structural
biology, we revealed a twofold mode of inhibition in which anhydrotetracycline both competes
with tetracycline for binding in the active site and restricts critical dynamics of the FAD cofactor,
thus halting the catalytic cycle. Should tetracycline resistance by inactivation expand to become
a dominant mechanism of resistance to tetracycline antibiotics, coadministration of
anhydrotetracycline and tetracycline (or derivatives thereof) is a promising method for
circumventing this resistance threat. Additionally, and more broadly, this work has established
and expanded a paradigm in which surveillance of environmental resistance threats allows for
proactive development of strategies to mitigate the eventual threat posed by clinical emergence
of said resistance threat. In the face of increasing antibiotic resistance and decreasing antibiotic
development, this model holds promise as a means for preemptive and sustainable development
of novel approaches to address resistance threats before they are endemic.
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